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GeneRaL InTRoDUCTIon
1

PsyChoLoGICaL weLL-beInG In ChRonIC MeDICaL ILLness
In the last decades, the relationship between psychological well-being and chronic medical illness 
is increasingly recognized [1]. Mood disturbances such as depression are generally found to have 
a higher prevalence in patients with medical illness compared to healthy controls [1]. Published 
prevalence rates of depressive disorders among a variety of medical illnesses range from 10% 
up to 30% [2] or above [3], whereas in general practice attendees across Europe (including also 
patients with chronic medical conditions), the reported mean prevalence of major depression 
was 8.5% for men and 13.9% for women [4]. Other studies [5] have reported a 41% increased risk 
of having a recent psychiatric disorder (anxiety, depression, substance abuse) in patients with 
medical conditions. Depression in patients with medical illnesses was found to be associated 
with emotional suffering, increased symptom burden, additive functional impairment, greater 
health care utilization and health care costs, and increased comorbidity and mortality [6].
There is evidence that suggests that the pathway between mood disturbances and physical 
health is bidirectional. In addition to an increased risk for depression after being diagnosed 
with for instance diabetes or coronary heart disease, in large epidemiologic studies depression 
was found to be a risk factor for the development of these diseases as well [1,6,7]. Furthermore, 
depression might have a direct pathophysiological effect on inflammatory and metabolic 
factors, the hypothalamic pituitary axis, and autonomic nervous system [8-11], increasing the 
risk for complications and worse disease outcome. Besides this, depression might aversively 
affect memory, energy, and executive function, leading to behavioural processes with negative 
effects on the course of chronic medical illnesses. For instance, poor adherence to self-care 
and medical treatment regimens, a reduced likelihood of adapting health-promoting behaviors 
(e.g., exercise, smoking cessation), and greater social isolation, were found to be associated 
with depression [2,12-14].
Also in rheumatoid arthritis (RA), a chronic disease characterized by inflammation of 
joints, prevalences of depression are high and range from 13% to 20% [15,16]. Moreover, in RA, 
evidence was found that long-term patterns of depression were associated with worse function 
and perceptions of poor health, even after controlling for disease-related factors, physical 
limitations, and medication [17]. These findings endorse the necessity to pay attention also to 
psychological well-being in rheumatic diseases. 
Systemic sclerosis (SSc), also known as scleroderma, is a rheumatic disease with serious 
consequences in many patients. As of now, no cure is available for SSc, and treatment focuses 
on symptom reduction. Increasing quality of life is an important goal in the treatment of patients 
with SSc, leaving room for non-pharmacological treatment options, including psychological 
therapies. Recently, the number of studies into psychological well-being and the impact on 
SSc patient’s quality of life has increased substantially [18]. However, research is still needed 
on several understudied disease-related stressors and their interaction with other aspects of 
behavioural health. This thesis aims to contribute to this important gap of knowledge, through 
studies into the assessment and treatment of psychological well-being in SSc and into disease-
specific factors related to psychological well-being, such as changes in appearance and a 
decreased life expectancy. The studies described in this thesis focus on the assessment of 
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Systemic 
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depressive symptoms, quality of life, and fear of disease progression. Furthermore, we assessed 
the extent to which patients use health care services and started to develop and test psycho-
educational and psychological interventions. This thesis does not take into account potential 
other sources of stress that are of importance to patients with SSc and might be related to 
psychological well-being. These stressors include for instance, sexual dysfunction, pruritis and 
problems accessing health care [18]. 
When studying psychological well-being and its associated factors, some generally 
accepted moderators of psychological well-being should be taken into account to explain 
individual differences in the impact of the disease on psychological well-being, such as coping, 
cognitive appraisal, and social support. Cognitive appraisal refers to the process by which a 
person categorizes a situation and its aspects in relation to whether it is potentially threatening 
or not [19,20]. Coping could be defined as “cognitive and behavioural efforts to manage specific 
external and/or internal demands that are appraised as taxing or exceeding the resources of 
the person” [20]. Social support refers to “the nature of the interactions occurring in social 
relationships, especially how these are evaluated by the person as to their supportiveness” [20]. 
Figure 1 describes a conceptual model for the factors that might be related to psychological 
well-being in SSc and displays which domains are taken into account in this thesis. 
sysTeMIC sCLeRosIs
Systemic sclerosis (SSc) or scleroderma is a rare chronic disease of connective tissue. The 
name scleroderma derives from the Greek words skleros (hard) and derma (skin) and reflects 
one of the most characteristic symptoms of the disease; fibrosis of the skin due to increased 
production and deposits of collagen [21]. In addition to the skin, internal organs might become 
affected by the disease, leading to pulmonary fibrosis and dysfunction of lungs, kidneys, and 
the gastrointestinal tract. Raynaud’s phenomenon in hands or feet is reported in 95% of patients 
with SSc, leading to tissue ischemia and digital ulcers [22]. 
Figure 1: Conceptual model of possible factors influencing the relation of systemic sclerosis and 
psychological well-being. 
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With an estimated prevalence in the Netherlands of 8.9 per 100,000 adults and an 
estimated incidence of 0.77 per 100,000 [23], SSc is less common than most other rheumatic 
diseases. However, the mortality rate in SSc is amongst the highest [24] with standardized 
mortality rates of 1.5 to 7.2 [25]. Although the clinical manifestations of SSc vary widely across 
individuals, the disease is associated with a significant reduction in life expectancy (median 
survival time from diagnosis is approximately 11 years), in particular for patients with pulmonary 
fibrosis, pulmonary arterial hypertension, and cardiac involvement [25,26]. Usually, two clinical 
subtypes are recognized based on the extent of skin involvement; limited cutaneous SSc, with 
skin involvement distal to the elbows and knees, with or without face involvement and diffuse 
cutaneous SSc, with skin involvement proximal to the elbows and knees, and the trunk also [27]. 
The rate of onset of SSc is the highest between the ages of 30 - 50 years, and women contract 
the disease 4 - 5 times more often than men [24]. 
Patients with SSc report substantial disability and impairments in physical functioning, 
which increases over time [28]. Due to impairments in physical functioning, patients experience 
difficulties with personal care, household chores, work and leisure activities [29-32]. A study 
including thirty patients from Sweden [31] found that mobility problems of the hands, in particular 
finger flexion and extension, were common and associated with problems performing activities 
of daily living. A recent study [33] showed that the most frequently reported symptoms, which 
were also the most likely to have significant impact on daily activities, were fatigue, Raynaud’s 
phenomenon, stiff hands, joint pain, and difficulty sleeping. A systematic review of the literature 
[34] found that, in addition to impairments in physical quality of life, also mental quality of life 
was substantially impaired in patients with SSc. 
PsyChoLoGICaL weLL-beInG In sysTeMIC sCLeRosIs
A systematic review of studies on depression in SSc found that rates of depressive symptoms 
above cut-off scores for potential clinical significance on self-report questionnaires range from 
36 – 65%, depending on the questionnaire and cut-off used [35]. In cross-sectional studies, 
a diversity of sociodemographic variables (e.g., unmarried, less education), disease-related 
factors (e.g., pain, breathing problems, gastrointestinal symptoms) and psychosocial factors 
(e.g., personality, coping, social support) were found to be associated with depressive symptom 
scores [36-40]. As yet, no longitudinal studies into depressive symptoms in SSc were published, 
although there are currently studies being conducted in various countries, including Canada 
[41] and the Netherlands [42] that will begin to address this important knowledge gap. 
Disfigurement in visible and socially relevant areas of the body (e.g., hands, neck, face, 
mouth) is a central feature of SSc [43]. Patients rate disfigurement as a significant source of 
stress, and studies have reported that particularly women have diminished appearance self-
esteem and higher levels of body image dissatisfaction [43-47]. Existing studies have shown 
that significant skin changes in the hands and face are associated with greater body image 
dissatisfaction. Lower self-rated attractiveness and higher fear of negative evaluation were 
found to be associated with symptoms of depression and anxiety and poorer psychosocial 
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Figure 2: A) Raynaud’s phenomenon; B) Digital ulcer; C) Impaired hand function; D) Skin tightness of the mouth 1
A B
C D
functioning. A recent study [48] including 489 patients with SSc showed that the extent of skin 
involvement, in particular skin involvement in the face, were associated with dissatisfaction 
with appearance and social discomfort. Also, younger patients and patients with telangiectasias 
(small dilated blood vessels near the surface of the skin or mucous membranes) in the upper 
body and face reported greater social discomfort, and patients with more severe hand 
contractures were less satisfied with their appearance. 
1 Pictures published with approval of person involved
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In addition to appearance related stress, patients with SSc have reported uncertainty about 
the future, fear of disease progression, dependency on others, and fear of becoming physically 
disabled as important stressors in previous studies assessing patients’ perspectives on the disease 
[46,49-52]. However, although concerns about the future are often expressed by patients with 
SSc, this has as yet received little attention in the published literature. Fear of disease progression 
has been defined as “a reactive, consciously perceived fear that develops from a serious, potential 
life-threatening or disabling disease or its treatment” [53]. Since SSc is a highly unpredictable 
disease with serious consequences in most patients, disease progression is a realistic threat to 
them. However, if patients get overwhelmed by their concerns about the future, this may have 
an impact on their current quality of life. In the latter case, concerns about the future, although 
based in reality, become dysfunctional and might need attention from health care professionals. 
The experience of disease symptoms such as fatigue and pain, involves both physical as 
well as psychological processes. There is extensive data that suggest that having a comorbid 
psychiatric disorder such as anxiety and depression interferes with the adaptation process 
to fatigue and pain [54], leading to heightened awareness and focus on these symptoms. 
Moreover, psychological therapies were found to be effective in reducing pain and fatigue 
through altering coping and/or cognitions [55-57]. Therefore, health psychologists generally 
focus on these symptoms as well. Studies have reported that fatigue is present in approximately 
75% of SSc patients [33,58]. Fatigue scores from SSc patients were similar to scores from patients 
with other rheumatic diseases and cancer patients currently undergoing treatment, and higher 
than scores from general population samples and cancer patients in remission [59]. Persistent 
fatigue from chronic illness involves ongoing exhaustion that is disproportionate to exertion 
and not alleviated by rest [60]. In patients with SSc, more fatigue was found to be associated with 
worse physical function, even after controlling for education level, disease subtype, pain, sleep 
quality, and depressive symptoms [61]. In another study, fatigue was associated with the number 
of medical comorbidities, breathing problems, gastrointestinal symptoms, depression, and pain, 
as well as smoking, which may be related to breathing problems and other medical issues [62].
Pain is reported in 60 – 83% of patients with SSc [33,51,58,63,64], and pain severity is 
comparable to levels found in other chronic pain conditions and rheumatic diseases [63,65,66]. 
Pain in the rheumatic diseases is associated with higher rates of physician visits, greater 
disability, and reduced health related quality of life [67,68]. Improved pain management is 
an important priority for many patients with rheumatic diseases [69]. There are, however, 
relatively few studies on pain in SSc, and the complex etiology of pain in SSc remains unclear. 
Patients described multiple sources of pain [33,51], including joint and musculoskeletal pain, 
skin pain, pain associated with Raynaud’s phenomenon, gastrointestinal and digestive pain, and 
pain in distal extremities (tightness, calcinosis, and ulcers). In addition to depressive symptoms, 
factors that have been found to be independently associated with pain in multivariate analyses 
were more skin involvement, patient-reported leg swelling and joint tenderness, severe 
Raynaud’s phenomenon symptoms, active ulcers, moderate to severe synovitis, gastrointestinal 
symptoms, and painful comorbid conditions [64,70]. Patients with diffuse SSc reported only 
slightly higher pain severity than patients with limited disease [64].
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Because of the great potential of psychological and behavioural health research to improve 
psychological well-being and quality of life, especially in the absence of a cure, developments in 
these domains are warranted for patients with SSc. To improve patient-centered care, accurate 
measurement of outcomes important to patients is crucial. However, in SSc there is a lack of studies 
assessing the psychometric properties of health-related patient-reported outcome measures.
assessMenT
Health-related patient-reported outcome (HR-PRO) measures are designed to assess patient 
health, well-being, and response to treatment based on patient perspectives. HR-PRO measures 
could reflect complex constructs, such as health-related quality of life, or narrower constructs, 
such as pain, fatigue or depressive symptoms that are important for assessing health status in 
patients with rheumatic diseases [71-74]. In rheumatoid arthritis, several studies have shown 
that HR-PROs are at least as sensitive to treatment effects as clinically determined outcomes 
and physician-reported outcomes. Furthermore, HR-PRO measures were found to be even 
less susceptible to placebo effects [75-77]. HR-PRO measures are also important when changes 
in clinical measurements may not translate into detectable changes for patients or when 
treatments do not focus directly on disease-related outcomes, but on patients’ experiences 
of symptoms or quality of life, like in psychological therapies. In chronic diseases, quality of 
life is as important to many patients as survival. As a result, HR-PRO measures are now widely 
accepted as primary outcomes in rheumatology and are generally included in consensus-based 
core sets of measures to be used in clinical trials [78-81].
The increased recognition of HR-PRO measures in research and clinical practice, has 
also led to efforts to document and improve operationalization of HR-PRO measures. In the 
rheumatic diseases, OMERACT (Outcome Measures in Rheumatology [82]) has delineated a set 
of standards by which measures can be evaluated, including the truth or validity, discrimination, 
and feasibility of measures. There is relatively little research, however, on HR-PRO measures 
related to quality of life and psychological well-being in SSc. 
A contemporary issue in the use of HR-PROs is the interpretation of changes in scores. In the 
evaluation of the effectiveness of treatments, it is important to determine the clinical significance 
of change scores, and which changes in outcomes could be interpreted as “meaningful 
improvements” to patients and clinicians. A minimal important difference (MID) could be defined 
as “the smallest difference in score in the domain of interest which patients perceive as beneficial 
and which would mandate, in the absence of troublesome side effects and excessive cost, a 
change in the patient’s (health care) management” [83]. There is no “gold standard” methodology 
of estimating MIDs and a variety of methods is used, including the patient rating of change (global 
transition items), clinical anchors, standard error of measurement and effect size. For a particular 
HR-PRO measure, MIDs may vary by population and context and they may depend on the clinical 
context and decision at hand, the baseline from which the patient starts, and whether they are 
improving or deteriorating [84,85]. Thus, for the interpretation of research findings and treatment 
effects, MIDs for HR-PRO measures should be established in patients with SSc.
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Another concern in the use of HR-PRO measures is the cross-cultural validity of instruments. 
Cross-cultural validity refers to the degree to which outcome measures generate scores that are 
equivalent or invariant across linguistic or cultural groups, meaning that individuals from different 
groups with equal levels of an outcome of interest (e.g., fatigue), should obtain similar scores on 
the measure and respond similarly to individual items of the measure. This is because differences 
in the meaning of items due to translation or cultural differences in item interpretation can lead 
to responses that differ across groups even when levels of the outcome being measured are 
similar. Measurement differences between translated questionnaires can be a serious threat to 
the validity of cross-cultural comparisons, because when measures are not equivalent metrically, 
it is not possible to determine if any observed differences between groups reflect real differences 
or are a consequence of measurement artefacts due to linguistic or cultural differences [86]. 
Therefore, cross-cultural validity should be established if HR-PROs are to be pooled among 
or used to compare results between patients from different cultural or linguistic groups [87]. 
However, there are only few examples in which measurement equivalence for HR-PRO measures 
in patient groups were assessed, none of them including patients with SSc. On the other hand, 
efforts to improve treatment of patients with SSc trials are routinely conducted in multicenter 
trials, involving patients from multiple countries and measures translated into multiple 
languages, for instance by The Scleroderma Clinical Trials Consortium [88] and the EULAR 
Scleroderma Trials and Research group [89]. In addition, The Scleroderma Patient-centered 
Intervention Network (SPIN) was recently established, to develop and test psychosocial and 
rehabilitation interventions in patients from across Europe and North America [90]. 
TreaTmenT
Despite the recent advances in the treatment for some of the manifestations of SSc, currently 
there are no cures or true disease modifying agents for a majority of SSc complications [91]. 
Additionally, delays in diagnosis, problems accessing health care, and managing health care 
needs were found to be important sources of stress for patients with SSc [18].
Recent studies in Canada and Hungary showed, that treatment of SSc involves multiple 
health care providers [92-94]. The rheumatologist (70 - 90%) and general practitioner(≈ 80%) 
were the most frequently visited physicians. In addition, also the pulmonologist (40 - 67%), 
gastroenterologist (32 - 44%), cardiologist (22 - 51%), and dermatologist (21 - 42%) were often 
involved in the care of many patients, as was the physical therapist (31 - 46%). Factors associated 
with higher physician use were a higher income, more skin involvement, more comorbidities, 
and lower physical health status. The annual number of visits to medical specialists ranges 
from  3.8 to 7.1, with the most visits to the general practitioner. The extent to which health 
professionals other than physical therapists, such as nurses and psychologists, are involved in 
the care of patients with SSc have not received much attention in the published literature, while 
the care for patients with SSc might profit from the involvement of these disciplines as well. 
Recently, 18 SSc experts from Europe, the USA and Japan, two SSc patients from the Federation 
of the European Scleroderma Associations (FESCA) developed evidence-based, consensus-derived 
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recommendations for the treatment of SSc [91]. However, due to a lack of evidence on psychological, 
educational, physical- and occupational therapy interventions, no recommendations could be 
made for or against these types of interventions [91]. In particular, there are no evidence-based 
interventions for patients with SSc to manage symptoms of fatigue, depression, and other quality of 
life outcomes, despite evidence from other chronic diseases that these symptoms can be reduced 
with pharmacological and non-pharmacological approaches [e.g., 95-98]. 
For instance, in RA, psycho-education interventions were found to be effective in reducing pain, 
physical disability, and psychological distress, although in general effect sizes were small [97]. The 
term “psycho-education” encompasses a diversity of intervention formats in terms of its content (e.g., 
education, relaxation, skills training), method (e.g., brochures, group sessions, minimal contact), and 
set-up (e.g., number of sessions), making it hard to come to a conclusion on the optimal format when 
developing these interventions. In addition to psycho-education, cognitive-behavioural therapy 
was found to be moderately effective in reducing psychological distress in patients with rheumatic 
diseases, especially if patients were selected on high levels of psychological distress at baseline 
[e.g., 99,100]. To optimize treatment effects, it has been suggested that interventions should be 
tailored to specific patient physical and psychological characteristics [101]. This might be particularly 
important in diseases with a heterogeneous manifestation, such as SSc.
Studies into the needs and preferences in patients with SSc regarding the delivery of health 
care services and information provision have revealed high needs with respect to medical 
issues, such as information on medical treatment options and test results. Also, patients 
reported unmet needs in the psychological domain, including coping with anxiety and stress, 
fear of the future, coping with disease symptoms and fatigue, feeling down, and changes in 
appearance [49,50]. As yet, however, there are only a few published interventions to address 
these needs [102-104], and effectiveness was evaluated in small numbers of patients only. Given 
the various problems faced by patients with SSc, and the high unmet health care needs, the 
development and evaluation of behavioural and educational interventions in SSc is warranted.
Objectives and Outline Of the thesis
Although the knowledge regarding psychological well-being in patients with SSc is increasing, 
as yet much is still unknown about contributing factors, behavioural and educational treatment 
options, and psychometric properties of HR-PRO measures. The studies described in this thesis were 
designed with the overarching aim to improve the assessment of HR-PROs, and to develop and test 
non-pharmacological interventions for patients with SSc, as is reflected in the two parts of this thesis. 
In part I, psychological well-being and its assessment was studied. First, depressive symptoms 
and associated sociodemographic, disease-related, and psychosocial factors were assessed 
(Chapter 2). Studying factors that are associated with depressive symptoms provides us with 
insight into factors that health care providers should pay attention to when treating patients, as 
well as variables that might be useful to target in the treatment of depressive symptoms in SSc. 
In addition, the psychometric properties of a variety of HR-PRO measures related to 
psychological well-being in SSc were assessed. Chapter 3 describes a validation study of the 
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Dutch translation of the Fear of Progression Questionnaire-Short Form. Since fear of disease 
progression and uncertainty regarding the future were found to be important stressors in patients 
with SSc, a valid questionnaire to assess fear of progression is warranted. In Chapter 4, the cross-
language measurement equivalence of the Center for Epidemiologic Studies Depression Scale 
was assessed for English-speaking Canadian and Dutch patients. In SSc, since results are often 
pooled across nations and languages, it is important to assess the measurement equivalence of 
HR-PRO measures. Chapter 5 describes the comparison of the EQ-5D and SF-6D utility measures 
in patients with SSc. Self-administered utility measures, designed to assess value of health in a 
single summary measure, are increasingly used in economic evaluations of treatments and policy-
making. However, yet little is known about the psychometric properties of utility measures in SSc.
Part II of this thesis focuses on the treatment of patients with SSc. In Chapter 6, health 
care utilization and patients’ perspectives on the quality of health care are described. Systemic 
sclerosis is a complex disease that often needs multidisciplinary treatment. Knowledge on 
health care utilization of patients is scarce and was not yet comprehensively assessed in any 
Western European country. Chapter 7 describes the content and pre-post assessment of a 
psycho-educational group programme, designed to address patient health care demands. In 
Chapter 8, a case study is presented to illustrate an individually tailored intervention targeting 
depressive symptoms and fear of progression in a patient with SSc. In the final chapter of this 
thesis (Chapter 9), a summary and discussion of the results of the present thesis are described, 
including recommendations for future research and practice. 
RefeRences
1. Evans DL, Charney DS, Lewis L, Golden RN, 
Gorman JM, Krishnan KR, et al. Mood disorders 
in the medically ill: scientific review and 
recommendations. Biol Psychiatry 2005;58:175-
89.
2. Katon WJ. Clinical and health services 
relationships between major depression, 
depressive symptoms, and general medical 
illness. Biol Psychiatry 2003;54:216-26.
3. Campbell LC, Clauw DJ, Keefe FJ. Persistent pain 
and depression: a biopsychosocial perspective. 
Biol Psychiatry 2003;54:399–409.
4. King M, Nazareth I, Levy G, Walker C, Morris R, 
Weich S, et al. Prevalence of common mental 
disorders in general practice attendees across 
Europe. Br J Psychiatry 2008;192:362-7.
5. Wells KB, Golding JM, Burnam MA. Psychiatric 
disorder in a sample of the general population 
with and without chronic medical conditions. 
Am J Psychiatry 1988;145:976-81.
6. Katon W, Ciechanowski P. Impact of major 
depression on chronic medical illness. J 
Psychosom Res 2002;53:859-63.
7. Muskin PR. Major depressive disorder and other 
medical illness: a two-way street. Ann Clin 
Psychiatry 2010;22:S15-20.
8. Kiecolt-Glaser JK, McGuire L, Robles TF, Glaser 
R. Emotions, morbidity, and mortality: new 
perspectives from psychoneuroimmunology. 
Annu Rev Psychol 2002;53:83–107.
9. Musselman DL, Evans DL, Nemeroff CB. The 
relationship of depression to cardiovascular 
disease: epidemiology, biology, and treatment. 
Arch Gen Psychiatry 1998;55:580-92.
10. Gold PW, Charney DS. Diseases of the mind and 
brain: depression: a disease of the mind, brain, 
and body. Am J Psychiatry 2002;159:1826.
11. Kop WJ, Gottdiener JS, Tangen CM, Fried LP, 
McBurnie MA, Walston J, et al. Inflammation 
and coagulation factors in persons >65 years of 
age with symptoms of depression but without 
evidence of myocardial ischemia. Am J Cardiol 
2002;89:419–24.
12. DiMatteo MR, Lepper HS, Croghan TW. 
Depression is a risk factor for noncompliance 
with medical treatment: meta-analysis of the 
GENERAL INTRODuCTION
1
17
effects of anxiety and depression on patient 
adherence. Arch Intern Med 2000;160:2101–7.
13. Glassman AH, Helzer JE, Covey LS, Cottler LB, 
Stetner F, Tipp JE, et al. Smoking, smoking cessation, 
and major depression. JAMA 1990;264:1546–9.
14. Ziegelstein RC, Fauerbach JA, Stevens SS, 
Romanelli J, Richter DP, Bush DE. Patients 
with depression are less likely to follow 
recommendations to reduce cardiac risk during 
recovery from a myocardial infarction. Arch 
Intern Med 2000;160:1818–23.
15. Dickens C, McGowan L, Clark-Carter D, Creed F. 
Depression in rheumatoid arthritis: a systematic 
review of the literature with meta-analysis. 
Psychosom Med 2002;64:52-60.
16. Pincus T, Griffith J, Pearce S, Isenberg D. 
Prevalence of self-reported depression 
in patients with rheumatoid arthritis. Br J 
Rheumatol 1996;35:879-83.
17. Morris A, Yelin EH, Panopalis P, Julian L, Katz 
PP. Long-term patterns of depression and 
associations with health and function in a panel 
study of rheumatoid arthritis. J Health Psychol 
2011;16:667–77.
18. Thombs BD, van Lankveld W, Bassel M, Baron M, 
Buzza R, Haslam S, et al. Psychological health 
and well-being in systemic sclerosis: state of 
the science and consensus research agenda. 
Arthritis Care Res 2010;62:1181–9.
19. Croyle RT. Appraisal of health threats: Cognition, 
motivation, and social comparison. Cog Ther 
Res 1992;16:165-82. 
20. Lazarus, RS, Folkman S. Stress, Appraisal, and 
Coping. New York: Springer; 1984.
21. Katsumoto TR, Whitfield ML, Connolly MK. The 
pathogenesis of systemic sclerosis. Annu Rev 
Pathol 2011;28:509–37.
22. Gabrielli A, Avvedimento EV, Krieg T. 
Scleroderma: mechanisms of the disease. N 
Engl J Med 2009;360:1989–2003.
23. Vonk MC, Broers B, Heijdra YF, Ton E, Snijder 
R, van Dijk AP, et al. Systemic sclerosis and its 
pulmonary complications in The Netherlands: 
an epidemiological study. Ann Rheum Dis 
2009;68:961–5.
24. Mayes MD, Lacey JV Jr, Beebe-Dimmer 
J, Gillespie BW, Cooper B, Laing TJ, et al. 
Prevalence, incidence, survival, and disease 
characteristics of systemic sclerosis in a large US 
population. Arthritis Rheum 2003;48:2246-55.
25. Ioannidis JP, Vlachoyiannopoulos PG, Haidich 
AB, Medsger Jr TA, Lucas M, Michet CJ, et al. 
Mortality in systemic sclerosis: an international 
meta-analysis of individual patient data. Am J 
Med 2005;118:2–10.
26. Tyndall AJ, Bannert B, Vonk M, Airò P, Cozzi F, 
Carreira PE, et al. Causes and risk factors for death 
in systemic sclerosis: a study from the EULAR 
Scleroderma Trials and Research (EUSTAR) 
database. Ann Rheum Dis 2010;69:1809-15.
27. LeRoy EC, Black C, Fleischmajer R, Jablonska 
S, Krieg T, Medsger TA Jr, et al. Scleroderma 
(systemic sclerosis): classification, subsets and 
pathogenesis. J Rheumatol 1988;15:202-5.
28. Schnitzer M, Hudson M, Baron M, Steele 
R, Canadian Scleroderma Research Group. 
Disability in systemic sclerosis — a longitudinal 
observational study. J Rheumatol 2011;38:685–92.
29. Poole JL, Watzlaf VJ, D’Amico F. A five-year 
follow up of hand function and activities of daily 
living in systemic sclerosis (scleroderma). J 
Hand Ther 2004;17:407–11.
30. Poole JL, Brandenstein J. Lower extremity 
impairment and activity limitations in 
persons with scleroderma. Arthritis Rheum 
2008;58:S599.
31. Sandqvist G, Eklund M, Akesson A, Nordenskiöld 
Ul. Daily activities and hand function in 
women with scleroderma. Scand J Rheumatol 
2004;33:102–7.
32. Sandqvist G, Hesslestrand R, Eberhardt K. A 
longitudinal follow-up of hand involvement 
and activities of daily living in early systemic 
sclerosis. Scand J Rheumatol 2009;38:304–10.
33. Bassel M, Hudson M, Taillefer SS, Schieir O, 
Baron M, Thombs BD. Frequency and impact 
of symptoms experienced by patients with 
systemic sclerosis: results from a Canadian 
National Survey. Rheumatology 2011;50:762-7
34. Hudson M, Thombs BD, Steele R, Panopalis P, 
Newton E, Baron M. Health-related quality of 
life in systemic sclerosis: a systematic review. 
Arthritis Rheum 2009;61:1112–20.
35. Thombs BD, Taillefer SS, Hudson M, Baron M. 
Depression in patients with systemic sclerosis: 
a systematic review of the evidence. Arthritis 
Rheum 2007;57:1089–97.
36. Roca RP, Wigley FM, White B. Depressive 
symptoms associated with scleroderma. 
Arthritis Rheum 1996;39:1035–40. 
37. Nietert PJ, Mitchell HC, Bolster MB, Curran MY, 
Tilley BC, Silver RM. Correlates of depression, 
including overall and gastrointestinal functional 
status, among patients with systemic sclerosis. J 
Rheumatol 2005;32:51–7.
GENERAL INTRODUCTION
1
18
38. Thombs BD, Hudson M, Taillefer SS, Baron 
M, Canadian Scleroderma Research Group. 
Prevalence and clinical correlates of symptoms 
of depression in patients with systemic sclerosis. 
Arthritis Rheum 2008;59:504–9.
39. Van Lankveld WGJM, Teunissen HA, Näring G, 
Vonk MC, van den Hoogen FHJ. Social support, 
disease-related cognitions and coping as 
predictors of depressed mood in systemic 
sclerosis. Cogn Ther Res 2008;32:434–47.
40. Hyphantis TN, Tsifetaki N, Pappa C, Voulgari 
RV. Clinical features and personality traits 
associated with psychological distress in 
systemic sclerosis patients. J Psychosom Res 
2007;62:47–56.
41. Canadian Scleroderma Research Group; http://
csrg-grcs.ca/, accessed May 30, 2012.
42. http://www.maartenskliniek.nl/kenniscentrum-
rde/afdelingverslag/4430733/, accessed May 30, 
2012.
43. Paguette DL, Falanga V. Cutaneous concerns of 
scleroderma patients. J Dermatol 2003;30:438–43.
44. Benrud-Larson LM, Heinberg LJ, Boling C, 
Reed J, White B, Wigley FM, et al. Body image 
dissatisfaction among women with scleroderma: 
extend and relationship to psychosocial 
function. Health Psychol 2003;22:130–9.
45. Malcarne VL, Hansdottir I, Greenbergs HL, 
Clements PJ, Weisman MH. Appearance self-
esteem in systemic sclerosis. Cogn Ther Res 
1999;23:197–208.
46. Van Lankveld WGJM, Vonk MC, Teunissen HA, 
van den Hoogen FHJ. Appearance self-esteem in 
systemic sclerosis- subjective experience of skin 
deformity and its relationship with physician-
assessed skin involvement, disease status 
and psychological variables. Rheumatology 
2007;46:972–6.
47. Amin K, Clarke A, Sivakumar B, Puri A, Fox Z, 
Brough V, et al. The psychological impact of 
facial changes in scleroderma. Psychol Health 
Med 2011;16:304–12.
48. Jewett LR, Hudson M, Malcarne VL, Baron M, 
Thombs BD; Canadian Scleroderma Research 
Group. Sociodemographic and disease 
correlates of body image distress among 
patients with systemic sclerosis. PLoS One 
2012;7:e33281. 
49. Schouffoer AA, Zirkzee EJ, Henquet SM, Caljouw 
MA, Steup-Beekman GM, van Laar JM, et al. 
Needs and preferences regarding health care 
delivery as perceived by patients with systemic 
sclerosis Clin Rheumatol 2011;30:815-24.
50. Rubenzik TT, Derk CT. Unmet patient needs 
in systemic sclerosis. J Clin Rheumatol 
2009;15:106-10.
51. Suarez-Almazor ME, Kallen MA, Roundtree 
AK, Mayes M. Disease and Symptom Burden in 
Systemic Sclerosis. J Rheumatol 2007;34:1718-26.
52. Joachim G, Acorn S. Life with a rare chronic 
disease: the scleroderma experience. J Adv 
Nurs 2003;42:598-606.
53. Dankert A, Duran G, Engst-Hastreiter U, Keller 
M, Waadt S, Henrich G, et al. Fear of progression 
in patients with cancer, diabetes mellitus 
and chronic arthritis. Rehabilitation (Stuttg) 
2003;42:155–63. In German.
54. Katon W, Sullivan M, Walker E. Medical 
symptoms without identified pathology: 
relationship to psychiatric disorders, childhood 
and adult trauma, and personality traits. Ann 
Intern Med 2001;134:917-25.
55. Astin JA, Beckner W, Soeken K, Hochberg 
MC, Berman B. Psychological interventions 
for rheumatoid arthritis: a meta-analysis of 
randomized controlled trials. Arthritis Rheum 
2002;47:291-302.
56. Bradley LA, Alberts KR. Psychological and 
behavioral approaches to pain management for 
patients with rheumatic disease. Rheum Dis Clin 
North Am 1999;25:215-32. 
57. Hewlett S, Ambler N, Almeida C, Cliss A, 
Hammond A, Kitchen K, et al. Self-management 
of fatigue in rheumatoid arthritis: a randomised 
controlled trial of group cognitive-behavioural 
therapy. Ann Rheum Dis 2011;70:1060-7.
58. Richards HL, Herrick AL, Griffin K, Gwilliam 
PD, Loukes J, Fortune DG. Systemic sclerosis: 
patients’ perceptions of their condition. 
Arthritis Rheum 2003;49:689–96. 
59. Thombs BD, Bassel M, McGuire L, Smith MT, 
Hudson M, Haythornthwaite JA. A systematic 
comparison of fatigue levels in systemic 
sclerosis with general population, cancer and 
rheumatic disease samples. Rheumatology 
2008;47:1559–63.
60. Swain MG. Fatigue in chronic disease. Clin Sci 
2000;99:1–8.
61. Sandusky SB, McGuire L, Smith MT, Wigley 
FM, Haythornthwaite JA. Fatigue: an 
overlooked determinant of physical function in 
scleroderma. Rheumatology 2009;48:165–9.
62. Thombs BD, Hudson M, Bassel M, Taillefer 
SS, Baron M, and the Canadian Scleroderma 
Research Group. Sociodemographic, disease, 
and symptom correlates of fatigue in systemic 
GENERAL INTRODUCTION
1
19
sclerosis: evidence from a sample of 659 
Canadian Scleroderma Research Group Registry 
patients. Arthritis Rheum 2009;61:966–73.
63. Benrud-Larson LM, Haythornthwaite JA, 
Heinberg LJ, Boling C, Reed J, White B, et al. The 
impact of pain and symptoms of depression in 
scleroderma. Pain 2002;95:267–75.
64. Schieir O, Thombs BD, Hudson M, Boivin JF, 
Steele R, Bernatsky S, et al. Prevalence, severity, 
and clinical correlates of pain in patients 
with systemic sclerosis. Arthritis Care Res 
2010;62:409–17.
65. Danieli E, Airo P, Bettoni L, Cinquini M, Antonioli 
CM, Cavazzana I, et al. Health-related quality 
of life measured by the Short Form 36 (SF-36) 
in systemic sclerosis: correlations with indexes 
of disease activity and severity, disability, 
and depressive symptoms. Clin Rheumatol 
2005;24:48–54.
66. Johnson SR, Glaman DD, Schentag CT, Lee P. 
Quality of life and functional status in systemic 
sclerosis compared to other rheumatic diseases. 
J Rheumatol 2006;33:1117–22.
67. Sokka T. Assessment of pain in patients 
with rheumatic diseases. Best Pract Res Clin 
Rheumatol 2003;17:427–49.
68. Katz WA, Rothenberg R. Section 2: the 
importance of improving function in patients 
with pain. J Clin Rheumatol 2005;11:S6–9.
69. Heiberg T, Kvien TK. Preferences for improved 
health examined in 1,024 patients with 
rheumatoid arthritis: pain has highest priority. 
Arthritis Rheum 2002;47:391–7. 
70. Malcarne VL, Hansdottir I, McKinney A, 
Upchurch R, Greenbergs HL, Henstorf GH, et 
al. Medical signs and symptoms associated with 
disability, pain, and psychosocial adjustment in 
systemic sclerosis. J Rheumatol 2007;34:359–67.
71. Fairclough DL. Patient reported outcomes as 
endpoints in medical research. Stat Methods 
Med Res 2004;13:115-38. 
72. Bren L. The importance of patient-reported 
outcomes...it’s all about the patients. FDA 
Consum 2006;40:26-32. 
73. Wells G, Li T, Maxwell L, Maclean R, Tugwell P. 
Responsiveness of patient reported outcomes 
including fatigue, sleep quality, activity 
limitation, and quality of life following treatment 
with abatacept for rheumatoid arthritis. Ann 
Rheum Dis 2008;67:260-5.
74. Her M, Kavanaugh A. Patient-reported 
outcomes in rheumatoid arthritis. Curr Opin 
Rheumatol 2012;24:327-34. 
75. Strand V, Cohen S, Crawford B, Smolen JS, 
Scott DL. Patient‐reported outcomes better 
discriminate active treatment from placebo 
in randomized controlled trials in rheumatoid 
arthritis. Rheumatology 2004;43:640–7.
76. Cohen SB, Strand V, Aguilar D, Ofman JJ. 
Patient‐ versus physician‐reported outcomes 
in rheumatoid arthritis patients treated 
with recombinant interleukin‐1 receptor 
antagonist (anakinra) therapy. Rheumatology 
2004;43:704–11.
77. Gotzsche PC. Sensitivity of effect variables in 
rheumatoid arthritis: a meta‐analysis of 130 
placebo controlled NSAID trials. J Clin Epidemiol 
1990;43:1313–8.
78. Kalyoncu U, Dougados M, Daurès JP, Gossec 
L. Reporting of patient-reported outcomes in 
recent trials in rheumatoid arthritis: a systematic 
literature review. Ann Rheum Dis 2009;68:183-90.
79. Tugwell P, Boers M. Developing consensus 
on preliminary core efficacy endpoints for 
rheumatoid arthritis clinical trials. OMERACT 
Committee. J Rheumatol 1993;20:555–6.
80. Felson DT, Anderson JJ, Boers M, Bombardier C, 
Chernoff M, Fried B, et al. The American College 
of Rheumatology preliminary core set of disease 
activity measures for rheumatoid arthritis 
clinical trials. The Committee on Outcome 
Measures in Rheumatoid Arthritis Clinical Trials. 
Arthritis Rheum 1993;36:729–40.
81. Boers M, Tugwell P, Felson DT, van Riel PL, 
Kirwan JR, Edmonds JP, et al. World Health 
Organization and International League of 
Associations for Rheumatology core endpoints 
for symptom modifying antirheumatic drugs in 
rheumatoid arthritis clinical trials. J Rheumatol 
1994;41:86–9. 
82. Boers M, Brooks P, Strand CV, Tugwell P. The 
OMERACT filter for Outcome Measures in 
Rheumatology. J Rheumatol 1998;25:198-9.
83. Jaeschke R, Singer J, Guyatt GH. Measurement 
of health status: ascertaining the minimal 
clinically important difference. Control Clin 
Trials 1989;10:407-15.
84. Revicki DA, Cella D, Hays RD, Sloan JA, 
Lenderking WR, Aaronson NK. Responsiveness 
and minimal important differences for patient 
reported outcomes. Health Qual Life Outcomes 
2006;4:70.
85. King MT. A point of minimal important 
difference (MID): a critique of terminology and 
methods. Expert Rev Pharmacoecon Outcomes 
Res 2011;11:171-84.
GENERAL INTRODUCTION
1
20
86. Zumbo BD. A handbook on the theory and 
methods of differential item functioning (DIF): 
Logistic regression modeling as a unitary 
framework for binary and likert-type (ordinal) 
item scores. Ottawa ON: Directorate of 
Human Resources Research and Evaluation, 
Department of National Defense; 1999.
87. Teresi JA. Different approaches to differential 
item functioning in health applications. 
Advantages, disadvantages and some neglected 
topics. Med Care 2006;44:S152-70.
88. Scleroderma Clinical Trials Consortium. http://
www.sctc-online.org/. Accessed April 12, 2012.
89. Tyndall A, Mueller-Ladner U, Matucci-Cerinic 
M. Systemic sclerosis in Europe: first report 
from the EULAR Scleroderma Trials and 
Research (EUSTAR) group database. Ann Rheum 
Dis 2005;64:1107.
90. Thombs BD, Jewett LR, Assassi S, Baron M, Bartlett 
SJ, Costa Maia A, et al. New directions for patient-
centred care in scleroderma: the Scleroderma 
Patient-centred Intervention Network (SPIN). 
Clin Exp Rheumatol 2012;30:S23-9.
91. Kowal-Bielecka O, Landewé R, Avouac J, 
Chwiesko S, Miniati I, Czirjak L, et al. EULAR 
recommendations for the treatment of systemic 
sclerosis: a report from the EULAR Scleroderma 
Trials and Research group (EUSTAR). Ann Rheum 
Dis 2009;68:620-8.
92. Bernatsky S, Panopolis P, Hudson M, Pope J, 
LeClercq S, Robinson D, et al. Demographic 
and clinical factors associated with physician 
service use in systemic sclerosis. J Rheumatol 
2009;36:96-8.
93. Johnson SR, Carette S, Dunne JV. Scleroderma: 
health services utilization from patients’ 
perspective. J Rheumatol 2006;33:1123-7.
94. Minier T, Péntek M, Brodszky V, Ecseki A, Kárpáti 
K, Polgár A, et al. Cost-of-illness of patients 
with systemic sclerosis in a tertiary care centre. 
Rheumatology 2010;49:1920-8.
95. Hassett AL, Williams DA. Non-pharmacological 
treatment of chronic widespread musculoskeletal 
pain. Best Pract Res Clin Rheumatol 2011;25:299-
309.
96. Vliet Vlieland TP, van den Ende CH. 
Nonpharmacological treatment of rheumatoid 
arthritis. Curr Opin Rheumatol 2011;23:259-64. 
97. Riemsma RP, Taal E, Kirwan JR, Rasker JJ. 
Systematic review of rheumatoid arthritis patient 
education. Arthritis Rheum 2004;51:1045-59.
98. Hazes JM, Taylor P, Strand V, Purcaru O, Coteur G, 
Mease P. Physical function improvements and relief 
from fatigue and pain are associated with increased 
productivity at work and at home in rheumatoid 
arthritis patients treated with certolizumab pegol. 
Rheumatology 2010;49:1900-10.
99. Evers AW, Kraaimaat FW, van Riel PL, de Jong 
AJ. Tailored cognitive-behavioral therapy in 
early rheumatoid arthritis for patients at risk: a 
randomized controlled trial. Pain 2002;100:141-53.
100. Dissanayake RK, Bertouch JV. Psychosocial 
interventions as adjunct therapy for patients 
with rheumatoid arthritis: a systematic review. 
Int J Rheum Dis 2010;13:324-34. 
101. Turk DC. The potential of treatment matching for 
subgroups of patients with chronic pain: lumping 
versus splitting. Clin J Pain 2005;21:44-55. 
102. Samuelson UK, Ahlmén EM. Development and 
evaluation of a patient education program for 
persons with systemic sclerosis (scleroderma). 
Arthritis Care Res 2000;13:141-7. 
103. Genth E, Baltscheit C. Patientenschulung 
“Systemische Sklerose”. Z Rheumatol 2003;62:25-
6. In German. 
104. Buenaver L, Mcguire L, Haythornthwaite JA. 
Cognitive-behavioral self-help for chronic pain. 
J Clin Psychol 2006;62:1389-96. 
GENERAL INTRODUCTION
1
21

ASSESSMENT
Part I

DIsease-ReLaTeD anD PsyChosoCIaL faCToRs 
assoCIaTeD wITh DePRessIve syMPToMs  
In PaTIenTs wITh sysTeMIC sCLeRosIs, 
InCLUDInG feaR of PRoGRessIon  
anD aPPeaRanCe seLf-esTeeM
Kwakkenbos L, van Lankveld WGJM, Vonk MC, Becker ES,  
van den Hoogen FHJ, van den Ende CHM. 
J Psychosom Res 2012;72:199-204.
2
absTRaCT
objective
The prevalence of depressive symptoms is high in patients with systemic sclerosis (SSc, 
scleroderma). This study was conducted to determine which disease-related and psychosocial 
factors are associated with depressive symptoms, independent of sociodemographic factors.
Methods
In total, 215 patients with SSc completed questionnaires on sociodemographics, physical 
functioning (HAQ-DI), pain (VAS), fatigue (CIS), psychosocial characteristics (CISS, ICQ, PRQ, 
ASE, FoP-Q-SF) and depressive symptoms (CES-D). Disease characteristics (disease duration, 
disease subtype, modified Rodnan Skin Score) were collected. Hierarchical linear regression 
analyses were conducted to assess associations with depressive symptoms.
Results
The mean CES-D score was 12.9 (SD = 9.7) and the prevalence of patients scoring ≥ 16 and 
≥ 19 were 32.1% and 25.1%, respectively. The variance explained by sociodemographics and 
disease characteristics was negligible (R2 ≤ 0.09). Fatigue and pain were independently 
associated with depressive symptoms (R2 change = 0.35). After adding psychological factors 
(R2 change = 0.21), satisfaction with social support, emotion-focused coping and helplessness 
were also significantly associated with depressive symptoms. Higher fear of progression was 
associated with more depressive symptoms (P ≤ 0.01), and appearance self-esteem showed a 
marginally significant association (P = 0.08).
Conclusion 
Depressive symptoms were common in the present sample of patients with SSc and were 
independently associated with pain, fatigue, social support, emotion-focused coping, 
helplessness and fear of progression. Results suggest that, in addition to assessment of disease 
characteristics, attention should be given also to psychosocial factors found to be associated 
with depressive symptoms. For the development and testing of psychological interventions, 
fear of progression could be an important target.
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InTRoDUCTIon
Psychological consequences in patients with rheumatic diseases are increasingly recognized. 
Many studies focus on patients with rheumatoid arthritis and other inflammatory rheumatic 
diseases. Recently, the literature on psychological problems in patients with systemic sclerosis 
(scleroderma, SSc) is growing [1]. However, much is still unknown about the psychological 
problems of patients with SSc and their relationship with the disease. 
Systemic sclerosis is a rare connective-tissue disease, with an estimated prevalence of 8.9 
per 100,000 adults in the Netherlands and an estimated incidence of 0.77 per 100,000 [2]. 
The disease is characterized by thickening of the skin as a result of fibrosis. Furthermore, 
SSc can lead to severe dysfunction and failure of almost any internal organ [3] and Raynaud’s 
phenomenon is common. Although there is considerable heterogeneity in SSc manifestation, it 
has serious consequences in many patients. SSc confers a high mortality risk, with standardized 
mortality ratios of 1.5 to 7.2 [4]. The presence of anti–topoisomerase I antibodies and internal 
organ involvement are important determinants of mortality [4]. No effective treatments are 
available yet, and existing treatments mainly focus on symptom reduction. 
As a consequence of the disease, patients with SSc report impairments in their physical as 
well as mental health-related quality of life [5]. Fatigue and pain are often reported by patients 
with SSc [6,7] and SSc causes increased disability over time [8]. Elevated levels of depressive 
symptoms were observed in 35 - 65% of the patients with SSc [9].
Unlike most other rheumatic diseases, SSc is a potential life-threatening disease. Fear of 
progression of the disease (FoP) is often reported as a major concern for patients with SSc 
and is related to mental health in diverse medical conditions [6,7,10–13]. However, there are no 
studies examining the relationship of FoP and psychological distress in SSc. 
SSc also differs from other rheumatic diseases in terms of the changes in appearance it 
may cause. Most affected parts are the face and hands [14]. Previous studies of body image 
satisfaction and appearance self-esteem (ASE) in patients with SSc suggest that changes in the 
hands, fingers and face are most relevant in predicting overall ASE [15,16]. Low appearance self-
esteem is related to psychological variables [15–17], and it is suggested that ASE is a mediator of 
the relationship between skin thickening and psychological distress [16]. 
As of now, it is hard to come to a conclusion as to which factors are of importance and 
could be targeted in treating depressive symptoms in SSc patients. Previous studies examining 
variables related to depressive symptoms revealed varying results [18–22]. This is to some extent 
due to the fact that different concepts were included. Some studies report that SSc severity or 
physical functioning are associates of depressive symptoms [19,20], but this finding was not 
always replicated in other studies [18,21]. Some studies [18,21,22] included physical as well as 
psychological measures e.g., aspects of personality [18, 22], adequacy of emotional or social 
support [18,21], and acceptance, and found these [21] to be independently associated with 
depressive symptoms. None of the previous studies included fear of progression and appearance 
self-esteem, which are both often found as highly distressing to patients with SSc [6,7,11,17]. 
For a more systematic approach, this study was conducted to determine the independent 
association of sociodemographic variables, health status and psychological variables with 
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depressive symptoms, as was recommended in the review of depression in SSc by Thombs 
et al. [9]. Factors included were derived from literature on associates of depression as well as 
factors patients reported as distressing in previous studies (appearance self-esteem, fear of 
progression). Examining all these variables in one model might provide us with starting points for 
developing (interdisciplinary) interventions for patients with SSc and symptoms of depression. 
MeThoDs 
Patients and procedure
Data were collected in the baseline assessment of the cohort study “Psychological factors in 
scleroderma,” including patients with a definitive diagnosis of SSc according to the preliminary 
ACR classification criteria [23] under treatment in the Sint Maartenskliniek or Radboud 
University Medical Center Nijmegen, The Netherlands. The main objective of the cohort study 
is to determine which psychological variables (e.g., coping, cognitions, social support) predict 
psychological distress. Patients in the cohort study complete sets of physical and psychological 
questionnaires every 6 months over 3 years. Furthermore, a number of disease characteristics 
were assessed by a rheumatologist (e.g., modified Rodnan Skin Score (mRSS)). 
Exclusion criteria for participation in the cohort were a life expectancy of less than a year 
(because of the burden of the study), acute serious complications (e.g., acute renal crisis), 
severe psychiatric comorbidity (e.g., severe substance abuse, psychosis or dementia), other 
serious comorbidities (e.g., cancer) and insufficient knowledge of the Dutch language. The 
attending rheumatologist assessed whether a patient met one or more of the exclusion criteria 
based on clinical experience, using a checklist stating the exclusion criteria. Data on the reasons 
for exclusion for individual patients are not available. 
All eligible patients in both clinics were invited to participate in the study by their attending 
rheumatologist. After they read the written patient information, they had the opportunity to 
ask questions to their rheumatologist or the researcher. Informed consent was obtained before 
the patients completed their first questionnaire at home. The study was approved by the local 
medical ethics board (CMO 2008/109). In total, 279 patients were invited to participate, of 
whom 215 completed the baseline questionnaire (response rate 77.1%). Non-responders did 
not differ from responders regarding age and gender. Data were collected between June 2008 
and February 2010.
Measures
Sociodemographics
The sociodemographic variables assessed were: age, sex, marital status, education and current 
employment status. 
Disease characteristics
The attending rheumatologist assessed disease duration (time since onset of first non-
Raynaud’s symptoms), SSc disease subtype (limited or diffuse), and mRSS. Furthermore, auto-
antibodies (ANA, ACA, Anti-TOPO, Anti-RNP) were assessed to describe our sample.
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Physical functioning 
Patients completed the Dutch version of the Scleroderma Health Assessment Questionnaire 
(SHAQ). The SHAQ consists of the Health Assessment Questionnaire (HAQ) and Visual Analogue 
Scales measuring perceived severity of six disease symptoms. The Disability Index score consists 
of 20 items, measuring 8 dimensions of functioning (dressing and grooming, ability to get 
up, eating, walking, personal hygiene, reach, grip strength and activities). The score of each 
dimension ranges from 0 (best function) to 3 (worst function), and the mean of these scores 
can be calculated as an indicator of overall physical functioning (HAQ-DI) with higher scores 
depicting worse functioning. The HAQ was originally developed for use in rheumatoid arthritis 
[24] but has demonstrated good reliability and validity in patients with SSc [25].
Pain was assessed using a Visual Analogue Scale (VAS) of 10 cm, ranging from 0 (no pain) to 
100 (severe pain).
Fatigue was assessed with the “subjective experience of fatigue” subscale of the Checklist 
Individual Strength [26]. This subscale consists of 8 items, scored on a 7-point Likert scale. 
Higher scores depict higher levels of fatigue. The CIS has shown to be valid and reliable across 
different settings [26].
Depressive mood
The Center for Epidemiologic Studies- Depression Scale (CES-D) was used to assess depressive 
mood. The CES-D was originally developed to measure depressive symptomatology in the 
general population [27]. Recently, the scale has shown to be a reliable and valid measure 
of depressive symptoms in patients with SSc [28]. The CES-D is a 20-item measure, with 
the frequency of each depressive symptom rated on a 4-point Likert scale ranging from 
0 to 3 (“rarely or none of the time” to “most or all of the time”). A score of ≥ 16 on the CES-D is 
considered as the cut-off for possible depression [27], while the cut-off ≥ 19 is identified as the 
most accurate cut-off for identifying major depression in arthritis [29].
Social support was measured using the Personal Resources Questionnaire 85 - Part2 
(PRQ85) [30]. Part 2 of the PRQ85 consists of 25 items measuring the patient’s perceived 
level of social support. Items are scored on a 7-point Likert scale, ranging from 1 (strongly 
disagree) to 7 (strongly agree). Higher scores on the PRQ85 depict greater availability of 
and satisfaction with social support. The questionnaire has shown to be reliable and valid in 
healthy adults [31]. Furthermore, some support for the validity of the PRQ85 in patients with 
SSc was provided by Moser et al. [32].
Coping strategies were assessed using the Coping Inventory Stressful Situations (CISS) 
[33]. The CISS consists of 48 items, measuring three coping strategies: problem-focused 
coping, emotion-focused coping, and avoidance. Items are scored on a 5-point Likert scale, 
ranging from 1 (not at all) to 5 (very much). The CISS showed good psychometric properties 
in diverse samples [33,34]. Disease cognitions were measured using the Illness Cognition 
Questionnaire (ICQ) [34]. The ICQ consist of 18 items, measuring helplessness, acceptance, 
and disease benefits. Participants rate their agreement with the statements on a 4-point 
Likert scale, ranging from 1 (not at all) to 4 (completely). Higher scores on subscales reflect 
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higher levels of agreement with that particular illness cognition. The scale has excellent 
construct and internal validity in chronic diseases [35]. In this study we only used the subscales 
acceptance and helplessness. 
Satisfaction with appearance was measured using the 6-item subscale ‘Appearance self-
esteem’ of the State Self Esteem Scale [36]. The items are scored from 1 (not at all) to 5 (extremely). 
Higher scores depict more satisfaction with appearance. A previous study in patients with SSc 
using this questionnaire demonstrated good internal consistency reliability [16].
Fear of progression was measured using the Short Form of the Fear of Progression 
Questionnaire (FoP-Q) [12]. The FoP-Q was developed to measure the fear of disease 
progression in patients with chronic illnesses. The original questionnaire comprises 43 items. 
The Short Form is a 12-item measure based on the FoP-Q. Each item is scored from 1 (never) to 
5 (very often). The reliability and validity of the FoP-Q-SF in patients with breast cancer appears 
to be good [13]. As far as we know, this questionnaire was not previously used in patients with 
SSc. Higher scores depict more fear of progression. All questionnaires showed good internal 
consistency in our sample, Cronbach’s α ranging from 0.77 – 0.92.
sTaTIsTICaL anaLysIs
Descriptive statistics are provided as means and standard deviations (SD) for continuous variables 
and percentages for categorical variables. Univariate associations of all sociodemographic and 
study variables with depressive symptoms were calculated. Hierarchical multiple regression 
analyses were conducted to determine the associations of the disease-related stressors 
with depressive mood. CES-D scores were used as the dependent variable. The independent 
variables were entered in the regression equation in five steps. Following the model of Thombs 
et al. [20], step 1 contained demographics (age, sex) and step 2 contained socioeconomic 
status (education, married/cohabiting). In step 3, disease characteristics were added (limited/
diffuse disease, disease duration, mRSS). Step 4 consisted of physical functioning variables 
(HAQ, pain, fatigue). In the fifth step, psychological variables were added (disease cognitions, 
social support, coping, appearance self-esteem, fear of progression). We chose to include all 
psychological variables together in one step, as there is no consensus on the order of coping 
and cognitions [37, 38]. Given the fact that fatigue is an important characteristic of depression, 
and the relatively high correlation of fatigue with depressive symptoms, as a sensitivity analysis 
(to examine the robustness of our findings), step 4 and 5 were repeated omitting fatigue. 
The assumption for the regression analysis (normal distribution of residuals) was tested 
using a normal probability plot. There were no indications of violation of this assumption. 
Furthermore, correlations between independent variables and tolerances were calculated to 
check for multicollinearity. All tolerance values were between 0.36 and 0.92, and all correlations 
were ≤ 0.58, indicating multicollinearity was not an issue [39]. All statistical analyses were 
conducted using Stata/IC 10.1 software (StataCorp LP, College Station, TX).
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Table 1: Sociodemographic variables (N = 215), disease variables, study variables, and univariate 
associations with depressive symptoms (CES-D, range 0 - 60)
variables value Correlationa P
Demographic
     Gender (% female) 146 (67.9%) -0.17 0.01
     Mean age in years 56.4 (SD = 12.0, range 17.9 - 86.7) -0.08 0.23
Socioeconomic status
     Higher education (> 12 yrs) 87 (41.2%) -0.05 0.51
     Currently employed 70 (32.6%) -0.10 0.13
     Married/ cohabitating 162 (75.4%) -0.16 0.02
Disease characteristics
      Time since onset first Non-Raynaud 
symptom, yrs
9.2 (SD = 7.9, range 0.2 - 51.8 ) 0.07 0.34
     Patients with limited SSc 158 (74.9%) 0.02 0.74
     Mean mRSS 6.4 (SD = 5.9, range 0 - 37) 0.06 0.36
     ANA positive 196 (91.2%)
     ACA positive 54 (25.1%)
     Anti-TOPO positive 57 (26.6%)
     Anti-RNP positive 14 (6.5%)
Physical functioning
    HAQ-DI (0 - 3) 1.04 (SD = 0.74) 0.35 < 0.01
    Pain visual analogue scale (0 - 100) 28.6 (SD = 24.5) 0.37 < 0.01
    Fatigue (CIS) (7 - 56) 36.2 (SD = 12.6) 0.62 < 0.01
Psychosocial factors
     Social support (PRQ)(25 - 175) 131.5 (SD = 20.2) -0.36 < 0.01
     Helplessness (ICQ)(6 - 24) 12.7 (SD = 4.3) 0.59 < 0.01
     Acceptance (ICQ)(6 - 24) 16.4 (SD = 4.1) -0.43 < 0.01
     Problem-focused coping (CISS)(16 - 80) 50.6 (SD = 11.0) 0.02 0.81
     Emotion-focused coping (CISS)(16 - 80) 34.0 (SD = 11.7) 0.49 < 0.01
     Avoidance coping (CISS)(16 - 80) 40.4 (SD = 9.9) 0.10 0.13
     Appearance self esteem (ASE)(6 - 30) 19.6 (SD = 4.1) -0.43 < 0.01
     Fear of progression (FoP-Q-SF)(1 - 60) 30.0 (SD = 9.0) 0.58 < 0.01
mRSS, modified Rodnan Skin Score; ANA, antinuclear antibody; ACA, anticentromere antibody; anti-TOPO, 
antitopomerase antibody; anti-RNP, antiribonuclear protein antibody
aPearson correlations for continuous variables, point-biserial correlations for dichotomous variables
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ResULTs
Participants
In total, 69 men and 146 women completed the baseline questionnaires. Most patients (75.4%) 
were married or cohabitating. Sociodemographic and disease characteristics are displayed in 
Table 1. The mean depression score was 12.9 (SD = 9.7) and the prevalence of patients scoring ≥ 16 in 
our sample was 32.1%. The prevalence of probable depression (CES-D ≥ 19) was 25.1%.
hierarchical regression analysis
Table 2 shows the results from the hierarchical multiple regression analysis. In step 1 to 3, the 
variance explained was negligible (R2 ≤ 0.09). Sex and marital status were significantly associated with 
depressive symptoms. Of the disease characteristics (disease type, disease duration, mRSS) added in 
step 3, only mRSS showed a borderline significant association with depressive symptoms (P = 0.09). 
Of the physical function measures added in step 4, fatigue and pain were significant correlates while 
HAQ-DI score was not. Patients who experienced more fatigue or pain, reported more depressive 
symptoms (P < 0.01 and P = 0.03, respectively). After adding these physical functioning measures, sex 
was no longer significantly associated with depressive symptoms. The amount of variance explained 
increased remarkably (+35%) in step 4. Psychological factors were added in step 5. In this final model, 
significant correlates were pain (P = 0.05), fatigue (P < 0.01), social support (P = 0.01), emotion-focused 
coping (P < 0.01), helplessness (P = 0.03), and fear of progression (P < 0.01). The total explained amount 
of variance in depressive symptoms was 64.7%. Patients who were more satisfied with their social 
network reported less depressive symptoms, while patients using emotion-focused coping as an 
important strategy, had higher depression scores. Feelings of helplessness were associated with more 
depressive symptoms. Higher fear of progression was associated with more depressive symptoms. 
The p-value of appearance self-esteem indicated a trend (P = 0.08), suggesting that patients with 
higher appearance self-esteem reported less depressive symptoms. 
The sensitivity analysis omitting fatigue revealed highly similar results (not shown). 
Differences with the original model were, that in step 4 (adding HAQ-DI and pain), the HAQ-DI 
was now significantly associated with depressive symptoms (B = 2.38, P = 0.03), and R2 was 
substantially lower (R2 = 0.21). In the final model, the only difference was the significance level 
of appearance self-esteem (B = −0.37, P < 0.01). The amount of variance explained was only 
slightly lower than in the original model (R2 = 0.60). 
DIsCUssIon
This study assessed the independent association of sociodemographic, disease, and 
psychosocial variables, including appearance self-esteem and fear of progression, with 
depressive symptoms. Depressive symptoms were prevalent in our sample, comparable to 
those in previous studies [21,28], as was the percentage of patients scoring above the cut-offs 
for possible and probable depression (32.1% and 25.1%, respectively) [9]. 
Significant correlates of depressive symptoms were found, in addition to pain and fatigue, 
mostly in the psychological domain. Depressive symptoms were associated with lower satisfaction 
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Table 2: Hierarchical regression analysis of demographics, disease status and psychological variables 
associated with depressive symptoms (CES-D, range 0 - 60).
variable b [95% CI] P beta Total R2
Step 1) Demographics Age -0.05 [-0.16, 0.05] 0.33 -0.07
Sex -3.35 [-3.00, 1.28] 0.02 -0.16 0.03*
Step 2) Socioeconomic status Age -0.07 [-0.19, 0.04] 0.21 -0.09
Male sex -3.06 [-5.84, -0.27] 0.03 -0.15
Higher education -1.42 [-4.18, 1.35] 0.31 -0.07
Married/Cohabitating -3.92 [-6.97, -0.88] 0.01 -0.17 0.07
Step 3) Disease characteristics Age -0.08 [-0.21, 0.04] 0.20 -0.10
Male sex -3.95 [-6.93, -0.97] 0.01 -0.19
Higher education -1.41 [-4.32, 1.50] 0.34 -0.07
Married/Cohabitating -3.76 [-7.00, -0.52] 0.02 -0.16
Limited disease -0.95 [-4.40, 2.50] 0.59 -0.04
Disease duration 0.04 [-0.13, 0.21] 0.64 0.03
mRSS 0.22 [-0.03, 0.47] 0.09 0.13 0.09
Step 4) Physical functioning Age -0.08 [0.18, 0.02] 0.13 -0.09
Male sex -1.42 [-3.89, 1.06] 0.26 -0.07
Higher education -0.92 [-3.30, 1.45] 0.44 -0.04
Married/Cohabitating -2.48 [-5.08, 0.12] 0.06 -0.11
Limited disease 0.87 [-1.93, 3.67] 0.54 0.04
Disease duration 0.03 [-0.11, 0.17] 0.71 0.02
mRSS 0.11 [-0.10, 0.32] 0.32 0.07
HAQ score -0.52 [-2.45, 1.41] 0.60 -0.04
Pain 0.06 [0.01, 0.12] 0.03 0.15
Fatigue 0.44 [0.34, 0.54] < 0.01 0.56 0.44**
Step 5) Psychosocial factorsa Age -0.04 [-0.12, 0.05] 0.37 -0.05
Male sex -0.86 [-3.00, 1.28] 0.43 -0.04
Higher education -0.37 [-2.42, 1.69] 0.73 -0.02
Married/Cohabitating -2.00 [-4.41, 0.43] 0.11 -0.09
Limited disease -0.04 [-2.38, 2.31] 0.98 0.00
Disease duration 0.02 [-0.10, 0.14] 0.74 0.02
mRSS 0.08 [-0.10, 0.26] 0.41 0.05
HAQ score -1.16 [-2.95, 0.62] 0.20 -0.09
Pain 0.05 [0.00, 0.09] 0.05 0.11
Fatigue 0.23 [0.13, 0.33] < 0.01 0.31
Social support -0.03 [-0.12, -0.01] 0.01 -0.14
Helplessness 0.39 [0.04, 0.75] 0.03 0.17
Acceptance 0.06 [-0.26, 0.37] 0.69 0.03
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with social support, emotion-focused coping, helplessness, and higher fear of progression. The 
variance explained by the sociodemographic measures and disease characteristics assessed in 
the present study was negligible. Therefore, it is recommended that, in addition to assessment 
of physical functioning, attention should be paid to pain, fatigue, and psychological factors 
found to be associated with depressive symptoms. A recent study of patients with rheumatoid 
arthritis showed that long-term patterns of depression are associated with worse function and 
perceptions of poor health [40]. Appropriate and timely treatment of depressive symptoms 
might therefore contribute to an improvement in health outcomes, also for patients with SSc. 
To our knowledge, this is the first study that included appearance self-esteem and 
fear of progression as correlates of depression, in addition to sociodemographics, disease 
characteristics and physical functioning. Body image concerns as well as fear of the future were 
identified as important psychological stressors in patients with SSc in many existing studies 
[6,7,10,11]. Moreover, the present study suggests that they both are independently associated 
with depressive symptoms, although the association of appearance self-esteem with depressive 
symptoms should be interpreted with caution since it was only marginally significant. More 
research is needed to confirm our findings on appearance self-esteem. 
An important finding from this study was that fear of progression is associated with 
depression. Because SSc is a serious and potentially life-threatening disease, disease progression 
is a real concern for most patients. However, although fear of progression may have some basis 
in reality, patients could overestimate their fear of progression in comparison to the likelihood 
of actual progression. Decreasing this dysfunctional fear to a more functional level might lead 
to fewer depressive symptoms and an increased quality of life. A recent study showed that two 
short psychotherapeutic group interventions in cancer patients were effective in reducing 
fear of progression in the long term [41]. The authors also found significant improvements 
in depression, anxiety and health-related quality of life. Since, in the present study, fear of 
progression showed a higher association with depressive symptoms than actual indicators of 
the likelihood of progression (disease type, disease duration, mRSS), this could be an important 
Table 2: Continued
variable b [95% CI] P beta Total R2
Problem-focused 
coping
-0.03 [-0.12, 0.07] 0.62 -0.03
Emotion-focused 
coping
0.18 [0.08, 0.28] < 0.01 0.23
Avoidance coping 0.06 [-0.05, 0.16] 0.30 0.06
Appearance self-
esteem
-0.23 [-0.49, 0.03] 0.08 -0.10
Fear of progression 0.20 [0.05, 0.34] < 0.01 0.18 0.65**
a Final model
* P-value for the change in variance accounted for (∆R2 ) ≤ 0.05
** P-value for the change in variance accounted for (∆R2 ) ≤ 0.001
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target of intervention in patients with SSc as well. As of now, it is not clear whether this finding 
is unique for patients with SSc, or if it is also true for patients with other chronic diseases (like 
rheumatoid arthritis), for which fear of progression might play an important role as well. 
Ideally, psychological interventions for depressive symptoms in SSc should be integrated 
into interdisciplinary care, taking levels of fatigue and pain into account. Solving sleep problems 
or changing unhelpful coping behaviour could help patients decrease fatigue levels. In addition, 
exercises matched to patients’ physical abilities could help increase physical condition and 
reduce fatigue. 
Since this study was cross-sectional, no causal relationships could be established. 
Longitudinal research is needed to identify which factors predict the development of 
depressive symptoms over time. This study could however be a starting point in determining 
which variables to include in longitudinal studies. Another limitation is that not all possible 
physical consequences of SSc were included in the present study. For example, the involvement 
of specific organs was not taken into account. Furthermore, the use of self-report measures is 
a limitation of this study. Beyond the lack of validation studies concerning Dutch versions of 
the instruments used (including the CES-D), in SSc, method overlap can inflate associations 
between depression scores and other self-report measures. Patients with depressive symptoms 
might respond to the other self-report measures in a more negative manner as well. Another 
limitation of the use of self-report measurements in this study is that the association of 
helplessness and fatigue with depressive symptoms could partly be explained by the fact 
that both are an important characteristic of depression. Helplessness as used in this study is 
a cognitive concept, and therefore might have overlapped with the learned helplessness in 
depression. A recent study by Thombs et al. [42] showed that, although patients with SSc had 
inflated scores on the somatic items of the CES-D compared to matched controls, this had no 
substantial impact on the overall score of the measure. Also, the sensitivity analysis omitting 
fatigue revealed only a minor difference in the variance explained in the final model. 
Strengths of the present study were that data were collected in a relatively large and well-
defined sample of patients and that a number of physical and psychological variables were 
examined in a standardized way. All variables were included in the model without preselection, 
providing us with a precise and valid insight into variables that are independently associated with 
depressive symptoms. The patients included in the study are comparable with the large Dutch 
sample in a recent study by Vonk et al. [2] with regard to disease characteristics and demographics, 
except that our sample included slightly more men, indicating that results are generalizable. 
In conclusion, depressive symptoms were common in the present study of patients with SSc 
and were independently associated with pain, fatigue, social support, emotion-focused coping, 
helplessness and fear of progression. Results suggest that, in addition to assessment of disease 
characteristics, attention should be given also to psychosocial factors found to be associated 
with depressive symptoms. For the development and testing of psychological interventions, 
fear of progression could be an important target.
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absTRaCT
objective 
To validate the Dutch translation of the Fear of Progression Questionnaire-Short Form 
(FoP-Q-SF) for patients with systemic sclerosis (SSc). Although concerns about the future are 
often expressed by patients with SSc, there is no valid quantitative measure available to assess 
the extent to which patients with SSc are troubled by those concerns. 
Methods
Measurement properties of the FoP-Q-SF were assessed using a cross-sectional design that 
included 215 patients with SSc. Patients completed the FoP-Q-SF as well as questionnaires 
on physical and psychological functioning. Psychometric properties of the FoP-Q-SF were 
assessed using the Consensus-Based Standards for the Selection of Health Status Measurement 
Instruments checklist. 
Results 
The mean ± SD FoP-Q-SF score in patients with SSc was 30.05 ± 8.97. There were no indications 
of floor or ceiling effects. Confirmatory factor analysis supported the single-factor structure of 
the questionnaire (Χ2 (52) = 96.84, P < 0.001, root mean square error of approximation = 0.064, 
CMIN/DF = 1.86). Cronbach’s alpha was 0.86 for the questionnaire. Most of our a priori 
hypotheses (11 of 12) were confirmed, supporting the construct validity of the questionnaire. 
Conclusion 
A valid measure is now available to assess fear of disease progression in patients with SSc, which 
is significant since fear of progression is one of the most important stressors in this patient 
population. 
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InTRoDUCTIon
Living with life-threatening or recurrent diseases like cancer or rheumatic diseases causes 
uncertainty about and possible fear of the future for many patients. Patients have to deal 
with complications and relapses of the disease, increasing restrictions in daily functioning, 
progression of the disease, and reduced life expectancy; therefore, fear of disease progression 
is among the most important stressors for patients with these diseases [1]. 
Systemic sclerosis (SSc, scleroderma) is a rare connective tissue disease. The disease is 
characterized by abnormalities of the vascular and immune systems, which lead to fibrosis [2]. In 
addition to thickening of the skin, widespread fibrosis can lead to significant organ dysfunction in 
the gastrointestinal tract, kidneys, heart, and lungs [2], resulting in a reduction in life expectancy. 
Physical functioning is impaired in most patients and disability increases over time [3]. 
Patients with SSc have reported uncertainty about the future, fear of disease progression, 
dependency on others, and fear of becoming physically disabled in previous studies assessing 
patients’ perspectives on the disease [4]. Fear of disease progression has been defined as a 
reactive, consciously perceived fear that develops from a serious, potential life-threatening or 
disabling disease or its treatment [1]. Since SSc has serious consequences in most patients, they 
perceive disease progression as a realistic threat. In this respect, fear of disease progression 
does not belong in the group of anxiety disorders for which an irrational fear is usually one of 
the key characteristics.
Although concerns about the future are often expressed by patients with SSc, the 
psychometric characteristics of fear of progression measures in patients with SSc have not 
been assessed. For the assessment of fear of disease progression in breast cancer, diabetes 
mellitus, and rheumatic diseases, Herschbach et al. [5] recently developed the Fear of 
Progression Questionnaire (FoP-Q). The questionnaire was developed and tested in Germany, 
with the final version consisting of 43 items. Five subscales were designated (affective 
reactions, partnership/family, occupation, loss of autonomy, and coping with anxiety) with 
a total score that could be calculated across all of the anxiety scales and a single total score 
for the coping scale. The questionnaire showed good psychometric properties in a sample 
of breast cancer, diabetes mellitus, rheumatoid arthritis, and ankylosing spondylitis patients 
[5]. The short form (FoP-Q-SF) consists of 12 items, derived from all of the subscales except 
coping. The FoP-Q-SF has been demonstrated to be reliable and valid in a sample of German 
breast cancer patients [6]. 
The purpose of the present study was to validate the Dutch translation of the FoP-Q-SF 
questionnaire for patients with SSc. 
MeThoDs 
The measurement properties of the FoP-Q-SF were assessed using the baseline data of 
215 patients with SSc participating in a cohort study. Patients completed the FoP-Q-SF and 
questionnaires on physical and psychological functioning. 
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Patients 
Data were collected during the baseline assessment of a longitudinal cohort study of patients with 
a diagnosis of SSc according to the preliminary American College of Rheumatology classification 
criteria [7] undergoing treatment at Sint Maartenskliniek or Radboud University Medical Center 
Nijmegen, The Netherlands. The patients completed sets of questionnaires every 6 months for 3 years. 
Furthermore, disease characteristics were assessed by the attending rheumatologist at baseline. 
Exclusion criteria for participation in the cohort were a life expectancy < 1 year, acute complications 
(e.g., acute renal crisis), severe psychiatric comorbidity, other serious comorbidities (e.g., cancer), 
and insufficient knowledge of the Dutch language. The attending rheumatologist assessed whether 
a patient met ≥ 1 of the exclusion criteria based on their clinical experience. All eligible patients were 
invited to participate in the study by their attending rheumatologist. The study was approved by the 
local medical ethics board (CMO 2008/109). Of the 279 invited patients, 215 completed the baseline 
questionnaire (response rate 77.1%) between June 2008 and February 2010. 
Procedure 
Psychometric properties of the FoP-Q-SF were assessed using the Consensus-Based Standards 
for the Selection of Health Status Measurement Instruments checklist [8] and quality criteria 
for measurement properties as proposed by Terwee et al [9]. With permission from the initial 
developer of the FoP-Q, the questionnaire was translated from German to Dutch using the 
forward–backward translation method. 
The criterion for having a floor or ceiling effect was > 15% of the participants had to have 
scored the lowest or highest possible score of 12 or 60, respectively [9]. Furthermore, missing 
values were counted for each item to assess interpretability of the items. The criteria for 
internal consistency and structural validity were a Cronbach’s alpha between 0.70 and 0.95 and 
replication of the 1-factor structure, respectively [9]. 
To examine the construct validity of the questionnaire, hypotheses were formulated 
about the associations between the FoP-Q-SF and measures of psychological and physical 
functioning outcomes. The FoP-Q-SF was considered valid if ≥ 75% of our a priori hypotheses 
were confirmed [9]. Hypotheses on the direction and magnitude of correlations with other 
variables were based on the existing studies in the literature examining the FoP-Q [5,6,10] and 
the constructs measured with the distinct variables. The magnitude of the correlations was 
interpreted as small (|r| ≤ 0.3), moderate (0.3 < |r| < 0.5), or large (|r| ≥ 0.5) [11]. We expected 
moderate to large correlations of the FoP-Q-SF with anxiety and other psychological variables 
because an association between the constructs can be expected, but no complete overlap. 
Small to moderate correlations were expected for the FoP-Q-SF with physical variables, since it 
was expected that fear of disease progression might be associated with actual disease status to 
some degree. Specific hypotheses are shown in Table 3. 
Measures 
Age, sex, marital status, and current employment status were assessed to describe our sample. 
The attending rheumatologist assessed disease duration (time since the onset of the first non-
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Raynaud’s phenomenon symptom), SSc subtype (limited or diffuse), modified Rodnan Skin 
Score, and the presence of autoantibodies (antinuclear antibody, anticentromere antibody, 
antitopoisomerase antibody, and anti-RNP). 
Fear of progression was measured using the Dutch translation of the FoP-Q-SF [5,6]. The 
FoP-Q-SF consists of 12 items that are scored from 1 (never) to 5 (very often), where higher 
scores indicate more fear of progression. 
Anxiety was measured using the shortened version of the Dutch Spielberger State-Trait 
Anxiety Inventory (STAI), which is included in the Impact of Rheumatic Diseases on General 
Health and Lifestyle [12]. The anxiety subscale (trait anxiety) consists of 10 items that are rated 
on a 4-point Likert scale. The correlation with the original Dutch version of the STAI was high 
in a sample of rheumatoid arthritis patients (r = 0.96) [13]. Higher scores indicate more anxiety. 
Depressive mood was measured using the Center for Epidemiologic Studies Depression Scale 
(CES-D) [14]. The CES-D is a 20-item measure with the frequency of each depressive symptom rated 
on a 4-point Likert scale ranging from 0 (rarely or none of the time) to 3 (most or all of the time).
Problem-focused coping was assessed using the problem-focused subscale of the Coping 
Inventory for Stressful Situations (CISS) [15]. The problem-focused subscale consists of 16 items 
scored on a 5-point Likert scale, ranging from 1 (not at all) to 5 (very much). 
Quality of life was measured using the Medical Outcomes Study Short Form 36 (SF-36) 
[16]. The SF-36 measures 8 domains of health status (physical functioning [10 items], physical 
health-related role limitations [e.g., difficulty performing work; 4 items], bodily pain [2 items], 
general health [5 items], vitality [4 items], social functioning [2 items], role limitations related 
to mental health [e.g., amount of work accomplished; 3 items], and mental health [5 items]). 
In all subscales, lower scores indicate more problems or impact with respect to that domain. 
statistical analysis 
Descriptive statistics are provided as the mean ± SD for continuous variables and the percentages for 
categorical variables. The means, SDs, and item intercorrelations were calculated for each item of 
the FoP-Q-SF as well as the questionnaire’s total score, for illustrative purposes. Confirmatory factor 
analysis (CFA) was conducted to confirm the single-factor structure of the questionnaire. Cronbach’s 
alpha was calculated to assess internal consistency. Pearson’s correlations were calculated to assess 
whether our a priori hypotheses were confirmed (Table 3). To detect a correlation (1-tailed) of 0.30 
with α = 0.05 and power = 0.80, ≥ 68 participants are required [11]. CFA was conducted using LISREL 
software (SSI). All other statistical analyses were conducted using Stata/IC 10.1 software.
ResULTs
sample characteristics 
In total, 69 men and 146 women with SSc completed the baseline questionnaires. Demographics 
and disease characteristics are shown in Table 1. Most patients (75.4%) were married or 
cohabitating. One-third of the patients were employed at the time of the study. The mean ± SD 
time since the onset of non-Raynaud’s phenomenon symptoms was 9.2 ± 7.9 years. 
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Questionnaire characteristics 
The mean ± SD FoP-Q- SF score in our sample of SSc patients was 30.1 ± 9.0 (range 14 – 54). The 
distribution of the FoP-Q-SF total scores was symmetrical (skewness = 0.37, kurtosis = 2.48). The 
mean ± SD for each item is shown in Table 2. The highest and second-highest scores were for 
item 11 (family) and item 8 (hobbies), respectively. The lowest and second-lowest scores were 
for item 2 (appointments) and item 6 (children), respectively. 
Interpretability 
Item 6 (children) had the most missing values (n = 11, 5.1%), followed by item 12 (work) with 9 
missing values (4.2%). For 4 patients (1.9%), the overall score could not be calculated because 
there were ≥ 4 missing values (30%) on the questionnaire. None of the patients had the lowest 
possible score and none had the maximum score on the questionnaire, indicating there was no 
floor or ceiling effect. 
Internal consistency and structural validity
Results of the CFA (standardized solution) are shown in Table 3. The initial CFA, in 
which measurement errors between all items were specified as uncorrelated, did not 
fit the data well (Χ2 (54) = 226.01, P > 0.001, root mean square error of approximation 
[RMSEA] = 0.122, CMIN/DF = 4.18). Inspection of the modification indices indicated a correlated 
error term of item 4 with item 12 and item 9 with item 10, which was probably due to an overlap 
in the items’ content. This was also reflected in the high intercorrelations between the items 
(r = 0.75, P < 0.001 and r = 0.65, P < 0.001, respectively); therefore, the model was refitted to the 
data, allowing the error terms of these items to be correlated. These changes resulted in a model 
with a reasonable fit to the data (Χ2 (52) = 96.84, P < 0.001, RMSEA = 0.064, CMIN/DF = 1.86). 
Inspection of the modification indices indicated that further improvement was possible, but it 
Table 1: Patient demographic and disease characteristics 
variables values*
Women 146 (67.9)
Age, mean ±SD (range), years 56.4 ± 12.0 (17.9 - 86.7)
Higher education (> 12 yrs) 87 (41.2)
Currently employed 70 (32.6)
Married/ cohabitating 162 (75.4)
Time since onset of nonRaynaud’s phenomenon symptoms,  
mean ±SD (range), years
9.2 ± 7.9 (0.2 - 51.8 )
Patients with limited SSc † 158 (74.9)
mRSS, mean ± SD (range) 6.4 ± 5.9 (0 - 37)
FoP-Q-SF score, mean ± SD (range) 30.1 ± 9.0 (14 - 54)
* Values are the number (percentage). SSc= systemic sclerosis; mRSS = modified Rodnan Skin Score; FoP-Q-SF = 
Fear of Progression Questionnaire-Short Form 
† Limited SSc defined as skin involvement distal to the elbows and knees only, with or without face involvement
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Table 2. Characteristics of the Fear of Progression Questionnaire- Short Form
Item
Mean  
± sD score*
Missing  
no. (%)
factor  
loading†
1. Being afraid of disease progression 2.87 ± 0.98 1 (0.5) 0.72
2. Being nervous prior to doctor’s appointments or periodic 
examinations
2.05 ± 1.02 2 (0.9) 0.56
3. Being afraid of pain 2.47 ± 1.06 4 (1.9) 0.51
4. Being afraid of becoming less productive at work 2.20 ± 1.20 4 (1.9) 0.52
5. Having physical symptoms, e.g. rapid heartbeat, stomach ache 2.51 ± 1.05 2 (0.9) 0.63
6. Being afraid by the possibility that the children could contract 
the disease
2.19 ± 1.30 11 (5.1) 0.50
7. Being afraid of relying on strangers for activities of daily living 2.28 ± 1.16 3 (1.4) 0.57
8. Being afraid of no longer being able to pursue hobbies 2.94 ± 1.21 3 (1.4) 0.58
9. Being afraid of severe medical treatments in course of illness 2.30 ± 1.19 5 (2.3) 0.61
10. Worrying that medications could damage the body 2.59 ± 1.21 4 (1.9) 0.66
11. Worrying what will become of family if something happens to me 3.00 ± 1.20 1 (0.5) 0.67
12. Being afraid of not being able to work anymore 2.57 ± 1.42 9 (4.2) 0.56
Total score 30.05 ± 8.97 4(1.9)‡
* On a 1-5 Likert scale, where 1= ‘never’ and 5=’very often’. 
† Standardized solution
‡Total score was considered missing if patient had ≥4 missing items scores
was decided not to include these changes because of model parsimony. Cronbach’s alpha was 
0.86 for the questionnaire, confirming the internal consistency of the FoP-Q-SF in our sample. 
Intercorrelations among the items of the questionnaire ranged from r = 0.16, P < 0.001 (items 3 
and 12) to r = 0.75, P < 0.001 (items 4 and 12). 
Construct validity 
In total, 12 hypotheses were determined (Table 3). Results revealed high correlations of the 
FoP-Q-SF with anxiety, depressive symptoms, and mental health. Moderate correlations of the 
FoP-Q-SF were found with social functioning, role limitations related to mental health and physical 
health, bodily pain, general health, and vitality. A small but significant correlation of the FoP-Q-SF 
was established with age. In contrast with our hypothesis, no significant correlation was found 
with active problem-oriented coping. All other hypotheses (11 of 12, 91.7%) were confirmed. 
DIsCUssIon
In this study, internal consistency and construct validity of the Dutch translation of the FoP-Q-SF 
were established in a large and well-defined sample of scleroderma patients. Since fear of 
progression is one of the most important stressors for patients with SSc, it is significant that a 
quantitative measure is now available to assess fear of disease progression in these patients. 
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Since most of our a priori hypotheses (> 75%) were confirmed, the FoP-Q-SF could be 
considered a valid measure of the construct in SSc [9]. As hypothesized, high correlations 
were found between FoP-Q-SF scores and general measures of anxiety, depressive symptoms, 
and mental health and small to moderate correlations with physical functioning and pain. This 
indicates that the FoP-Q-SF is a measure of mental well-being rather than physical well-being. 
Our hypothesis of a moderate to high correlation of fear of disease progression with active, 
problem-oriented coping (CISS) was not confirmed, in contrast with the correlation reported 
in a previous study [10]. This might be due to the use of different questionnaires to measure 
active coping. Mehnert et al. [10] used the Dealing with Illness Inventory-German Revised, 
while the CISS was used in the present study. 
Although the present study assessed some important measurement properties of the 
FoP-Q-SF in SSc, other properties like reliability, responsiveness, and possible cut-offs for 
high fear of progression must be assessed in future studies. Comparing FoP-Q-SF scores 
with, for example, the results of the judgment of a clinical psychologist on the levels of fear of 
progression a patient experiences might help us to gain more insight into the criterion validity 
and the sensitivity and specificity of possible cut- offs for the questionnaire. Establishing a cutoff 
score for the FoP-Q-SF would help to identify for which patients an intervention to reduce 
dysfunctional fear of progression might be indicated. Although progression of SSc is a realistic 
threat to most patients, fear of progression might become dysfunctional at a certain point. A 
Table 3. Hypotheses and correlations of variables with Fear of Progression Questionnaire- Short Form
hypothesis Correlation P Confirmed
Moderate to large positive correlation with:
Anxiety (IRGLa) .59 <.001 Yes
Depressive symptoms (CES-Db) .58 <.001 Yes
Active problem-oriented coping (CISSc) -.01 .862 No
Moderate to large negative correlation with:
Social functioning (subscale SF-36d) -.39 <.001 Yes
Role-emotional (subscale SF-36) -.47 <.001 Yes
Mental health (subscale SF-36) -.58 <.001 Yes
small to moderate negative correlation with:
Physical functioning (subscale SF-36) -.25 <.001 Yes
Role-physical (subscale SF-36) -.37 <.001 Yes
Bodily pain (subscale SF-36) -.34 <.001 Yes
General health (subscale SF-36) -.42 <.001 Yes
Vitality (subscale SF-36) -.45 <.001 Yes
Age (years) -.15 .031 Yes
a Impact of Rheumatic Diseases on General Health and Lifestyle
b Center for Epidemiologic Studies- Depression
c Coping Inventory Stressful Situations
d Medical Outcomes Trust Short Form-36
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recent study [17] showed that 2 short psychotherapeutic group interventions were effective in 
reducing fear of progression in cancer patients. Also, improvements in depression, anxiety, and 
health-related quality of life were found. The FoP-Q-SF might be a useful questionnaire in the 
development and testing of such interventions for patients with SSc. 
In conclusion, results of the present study demonstrate that the FoP-Q-SF is a useful and valid 
instrument for the measurement of fear of disease progression in patients with SSc, which is significant 
since fear of progression is one of the most important stressors in this patient population. 
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absTRaCT 
objective
In rare diseases, such as systemic sclerosis (SSc), effective research often requires international 
collaboration, including pooling of results across patients who have completed outcome 
measures in different languages. In order to pool or compare these outcomes, instruments 
should be measurement equivalent (invariant) across cultural or linguistic groups. The objective 
of this study was to examine the cross-language measurement equivalence of the Center for 
Epidemiologic Studies Depression (CES-D) scale between English-speaking Canadian and 
Dutch SSc patients.
Methods
The CES-D was completed by 922 English-speaking Canadian and 213 Dutch SSc patients. A 
confirmatory factor analysis (CFA) was applied to assess the factor structure in both samples. 
The Multiple-Indicator Multiple-Cause (MIMIC) model was utilized to assess the amount of 
differential item functioning (DIF).
Results 
A two-factor model (positive and negative affect) showed excellent fit in both samples. 
Statistically significant DIF was found for 4 of 20 items on the CES-D. The English-speaking 
Canadian sample endorsed more feeling-related symptoms (item 3, “blues” and item 4, “good”), 
whereas the Dutch sample endorsed more somatic/retarded activity symptoms (item 7, “effort” 
and item 20, “get going”). However, the overall estimate in depression latent scores between 
English and Dutch was not influenced substantively by DIF.
Conclusions
Although there were several CES-D items with evidence of minor DIF between the English and 
Dutch sample, there was no evidence that these differences influenced overall scores. Therefore, 
CES-D scores from English-speaking Canadian and Dutch SSc patients can be compared and 
pooled without concern that measurement differences may substantively influence results. 
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InTRoDUCTIon 
Health-related patient-reported outcome (HR-PRO) measures assess patient health, well-being, 
and response to treatment based on patient perspectives. They may reflect complex constructs, 
such as health-related quality of life, or narrower constructs, such as individual symptoms (e.g., 
pain or fatigue) that are used to assess health status in patients with rheumatic diseases [1-4]. 
Growing recognition of the importance of HR-PROs and their increasing integration into both 
research and clinical practice has led to initiatives to improve their operationalization.
In the rheumatic diseases, OMERACT (Outcome Measures in Rheumatology) [5] has 
delineated a set of standards by which measures can be evaluated, including the truth or validity, 
discrimination, and feasibility of measures. Recently, the COSMIN checklist (Consensus-based 
Standards for the selection of health status Measurement Instruments) [6] was developed to 
establish criteria for evaluating the methodological quality of studies on HR-PROs. In addition 
to the standards described by OMERACT, the COSMIN checklist emphasizes the importance of 
establishing the cross-cultural validity of HR-PRO measures. The cross-cultural validity of HR-PRO 
measures is increasingly important, particularly in rare diseases, such as systemic sclerosis 
(SSc), where effective research often requires international collaboration. The Scleroderma 
Clinical Trials Consortium [7] and the EULAR Scleroderma Trials and Research group [8], for 
instance, routinely conduct multicentre drug trials involving patients from multiple countries 
and measures translated into multiple languages. Recently, the Scleroderma Patient-centered 
Intervention Network was organized and will test psychosocial and rehabilitation interventions 
in patients from across Europe and North America [9].
As described in the COSMIN checklist [6], it is important to assess the degree to which 
outcome measures generate scores that are equivalent or invariant across linguistic or cultural 
groups, meaning that individuals from different groups with similar levels of an outcome of 
interest (e.g., fatigue), should obtain equal scores on the measure and respond similarly to 
individual items of the measure. This is because differences in the meaning of items due to 
translation or cultural differences in item interpretation can lead to responses that differ 
across groups even when levels of the outcome being measured are similar. Measurement 
differences between translated questionnaires can be a serious threat to the validity of 
cross-cultural comparisons, because when measures are not equivalent metrically, it is not 
possible to determine if any observed differences between groups reflect real differences 
or are a consequence of measurement artifacts due to linguistic or cultural differences [10]. 
Therefore, cross-cultural validity should be established if HR-PROs are to be pooled among 
study participants from different countries or used to compare results between patients from 
different cultural or linguistic groups [11].
Differential item functioning (DIF) is said to occur when an item of a HR-PRO has different 
measurement properties for one group compared to another, irrespective of true differences 
of the construct measured. Diverse statistical methods for assessing the presence of DIF are 
available, based on non-parametric, parametric or latent variable models, each with its own 
advantages and disadvantages [12]. Generally, however, the presence of DIF is assessed by 
identifying differences in individual item scores across groups that are present even after 
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controlling for levels of the overall construct being measured. When DIF is identified, it is 
assumed that scores on the item are influenced by group characteristics that are not directly 
related to the construct being measured. When translated versions of HR-PROs are administered 
in different cultural settings, DIF may occur because of alterations in item meaning due to 
translation or because of cultural factors that influence interpretation of item meaning.
Depression is increasingly an outcome of interest among patients with chronic medical 
illness [13,14], including systemic sclerosis (SSc), which is an autoimmune disease characterized 
by thickening of the skin as a result of fibrosis, as well as involvement of multiple internal 
organs, most commonly the lungs, gastrointestinal tract, and heart [15]. In SSc, the Center 
for Epidemiologic Studies Depression Scale (CES-D) [16] has been used to assess depressive 
symptoms in English [17-20], French [19,20], Dutch [21], and German [22]. The CES-D was originally 
developed in the USA to measure depressive symptomatology in the general population [16]. 
The scale has also shown to be a reliable and valid measure of depressive symptoms across 
various patient samples, including SSc [23]. No studies, however, in any patient group have 
assessed the degree to which translated versions of the CES-D are measurement equivalent or, 
on the other hand, may exhibit substantive DIF, possibly due to the unfamiliarity of researchers 
and clinicians with the need for assessment of cross-language measurement properties or the 
methods by which this can be done. The objective of the present study was to conduct the first 
such study by assessing the measurement equivalence of the CES-D between English-speaking 
Canadian and Dutch SSc patients.
MeThoDs 
Patients and Procedures
English-speaking sample. The English-speaking study sample consisted of patients enrolled 
in the Canadian Scleroderma Research Group Registry who completed the CES-D in English 
from September 2004 through April 2011. Patients in the Registry are recruited from 15 centers 
across Canada. To be eligible for the Registry, patients must have a diagnosis of SSc confirmed 
by a Registry rheumatologist, be 18 years of age, and be fluent in English or French. Registry 
patients undergo extensive clinical history, physical evaluation, and laboratory investigations at 
annual visits. They also complete a series of self-report questionnaires on physical and mental 
health, lifestyle, and disease symptoms. Patients complete the measures in their preferred 
language (English or French). Patients from all centers provided informed consent, and the 
data collection protocol was approved by the research ethics board of each study site. For 
patients who completed the CES-D at multiple annual visits, only data from the most recent 
visit was included in analyses in the present study.
Dutch sample. The Dutch study sample consisted of SSc patients treated at the Sint 
Maartenskliniek or Radboud University Medical Center Nijmegen, The Netherlands who 
completed the baseline assessment of a 3-year cohort study, including the CES-D in Dutch, 
between June 2008 and February 2010. To be eligible, patients had to have a diagnosis of SSc 
according to the preliminary American College of Rheumatology classification criteria [24]. 
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Exclusion criteria for participation in the cohort were a life expectancy of less than a year, 
acute serious complications (e.g. acute renal crisis), severe psychiatric comorbidity that 
would prevent completion of questionnaires, other serious comorbidities (e.g. cancer) and 
insufficient knowledge of the Dutch language. All patients provided informed consent, and the 
study was approved by the local medical ethical board (CMO 2008/109). 
Measures
Demographics and disease characteristics. Demographic variables for both samples included 
age, sex, marital status, education and current employment status. Disease characteristics were 
assessed by study rheumatologists in both samples, including disease duration, SSc subtype, and 
the modified Rodnan Skin Score (mRSS). Disease duration was defined as time since onset from 
first non-Raynaud’s symptom. Patients were classified as having limited or diffuse SSc. Limited 
SSc was defined as skin involvement distal to the elbows and knees only, with or without face 
involvement, whereas diffuse SSc was defined as skin involvement proximal to the elbows and 
knees, and the trunk also [25]. The mRSS is a standardized rating of skin involvement ranging 
from 0 (no involvement) to 3 (severe thickening) in 17 body areas (total score range 0 – 51) [26]. 
Symptoms of depression. The CES-D [16] is a 20-item measure that assesses the frequency 
of symptoms during the past week on a 0 - 3 Likert scale (“rarely or none of the time” to “most 
or all of the time”). Standard cut-offs are ≥ 16 for “possible depression” and ≥ 23 for “probable 
depression” [16]. A cutoff of ≥ 19 has been suggested in arthritis [27]. The CES-D used in the 
English-speaking sample was the original version [16], which has shown to be a reliable and valid 
measure of depressive symptoms in patients with SSc [23]. In the Dutch sample, the original 
translation [28], which has been shown to be reliable and valid across diverse settings was used. 
statistical analysis
Demographics and disease characteristics were compared between the English-speaking and Dutch 
samples using the chi-square statistic for categorical variables and t-tests for continuous variables.
A flowchart of steps undertaken in the DIF analysis is depicted in Figure 1. First, the factor 
structure of the CES-D was assessed for each sample separately using confirmatory factor 
analysis (CFA). Ideally for DIF assessment, the simplest structure with reasonable fit will be used. 
Thus, an initial CFA model was constructed with Mplus [29] to determine if a single-dimensional 
structure of the CES-D in SSc could be reasonably used in the DIF analysis versus an alternative 
structure. Selection of an alternative structure was based on a previous validation study of 
the CES-D in SSc [27]. Item responses for the CES-D were ordinal Likert data, so the weighted 
least squares estimator with a diagonal weight matrix, robust standard errors, and a mean- and 
variance-adjusted chi-square statistic was used with delta parameterization [29]. Modification 
indices were used to identify pairs of items within scales for which model fit would improve if 
error estimates were freed to covary and for which there appeared to be theoretically justifiable 
shared method effects (e.g., similar wording) [30]. To assess model fit, the chi-square test, the 
Tucker-Lewis Index (TLI) [31], the Comparative Fit Index (CFI) [32], and the Root Mean Square 
Error of Approximation (RMSEA) [33] were used. Since the chi-square test is highly sensitive to 
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sample size, it can lead to the rejection of well-fitting models [34]. Therefore, the TLI, CFI and 
RMSEA fit indices were emphasized. Good fitting models are indicated by a TLI and CFI ≥ 0.95 
and RMSEA ≤ 0.06 [35]. Once the factor structure was established for each sample separately, a 
CFA model was fit that included patients from both samples combined. 
 The Multiple-Indicator Multiple-Cause (MIMIC) model was utilized to determine if items 
of the CES-D exhibited DIF for English-speaking versus Dutch patients. MIMIC models for DIF 
assessment are based on structural equation models, in which the group variable (English versus 
Dutch) is added to the basic CFA model as an observed variable. Thus, the base MIMIC model 
consists of the CFA factor model with the additional direct effect of group on the latent factors, 
which serves to control for group differences on the level of the latent factors. Then, to assess 
potential DIF, in addition to regressing the latent factor on linguistic group, the direct effect 
of group on CES-D items is assessed for each item separately, by regressing the items, one at a 
time, on group (see Figure 2). Each item is tested separately to determine if there is statistically 
significant DIF, represented by a statistically significant link in the model from group to the item, 
Compare base model and corected model
(diference on latent factors between groups) 
Base model: fit factor model 
for both samples combined
MIMIC Model: determine DIF items 
(include direct efect of group on each item separately) 
MIMIC Model: corect for DIF
(include direct efect of group on item with highest DIF) 
MIMIC Model: corect for DIF on al items
(include direct efect of group on al items with DIF) 
Repeat until corected for 
al DIF items
Determine factor structure 
for each sample separately 
Figure 1: Flowchart of steps to be undertaken in DIF analysis
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after controlling for any differences in the overall level of the latent factor between groups. If there 
is DIF for one or more items, the item with the largest magnitude of DIF is considered to have DIF, 
and the link between the linguistic group variable and that item is included in the model. Then, 
this procedure is repeated until none of the remaining items show significant DIF. Once all items 
with significant DIF are identified, the potential magnitude of DIF items collectively, identified 
via assessment of statistical significance, can be evaluated by comparing the difference on the 
latent factor between groups in the baseline CFA model and after controlling for DIF. Since the 
CES-D consists of a large number of items, Hommels’ [36] correction for multiple testing was 
applied. CFA and DIF analyses were conducted using Mplus [29], and all other analyses were 
conducted using Stata/IC 10.1 software (StataCorp LP, College Station, TX). 
Item 8
Item 4
Item 16
Item 12
Item 2
Item 1
Item 5
Item 3
Item 7
Item 6
Item 10
Item 9
Item 13
Item 11
Item 15
Item 14
Item 18
Item 17
Item 20
Item 19
POSITIVE
NEGATIVE
Language
CES-D items Latent Factors Grouping variable
Possible DIF effect
Figure 2: the MIMIC Model for the Centre for Epidemiologic Studies Depression Scale (CES-D)
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ResULTs
sample characteristics
Demographics and disease characteristics for both samples are displayed in Table 1. 
English-speaking sample. In total, 976 patients completed the CES-D in English. Six patients 
were excluded from analysis, because they had > 2 missing values on the CES-D. Furthermore, 
48 patients were excluded because they were diagnosed with sine SSc, but not diffuse or limited 
SSc. Of the remaining 922 patients, 84.8% were female. Most patients (82.9%) were married 
or cohabitating. The mean CES-D score was 14.3 (SD = 10.3) and the percentage of patients 
scoring ≥ 16 was 37.7%. The percentage of patients with CES-D ≥ 19 was 28.7%.
Dutch sample. In total, 215 patients completed the baseline questionnaires. Two patients 
were excluded from analysis because they had > 2 missing values on the CES-D. Of the 213 
patients in the sample, 67.6% were female. Most patients (75.6%) were married or cohabitating. 
The mean CES-D score was 12.8 (SD = 9.6) and the percentage of patients scoring ≥ 16 was 31.9%. 
The percentage of patients with CES-D ≥ 19 was 24.9%. 
Compared with the English-speaking sample, patients in the Dutch sample were significantly 
more likely to be male and to have limited disease. They were less likely to have completed more 
than 12 years of education, or to be currently working. Furthermore, patients in the Dutch sample 
had significantly shorter disease duration and lower mean mRSS scores. Mean CES-D scores in 
the Dutch sample were somewhat lower than in the English-speaking sample (P = 0.05). The 
proportion of patients with CES-D ≥ 16 (P = 0.11) and CES-D ≥ 19 (P = 0.27) did not differ significantly.
Confirmatory factor analysis
For both samples, a single-factor structure was assessed initially. In both the English-speaking 
sample and the Dutch sample, the fit was poor (English-speaking: χ2 (76) = 2218.8, P < 0.001, 
CFI =0.71, TLI = 0.88, RMSEA = 0.18; Dutch: χ2 (50) = 259.0, P < 0.001, CFI = 0.87, TLI = 0.94, RMSEA = 0.14). 
Inspection of the modification indices for both samples indicated correlated error terms of all 
Table 1: Demographic and disease characteristics for both SSc samples
variable english-speaking (n = 922) Dutch (n = 213) P value
Female (%) 782 (84.8) 144 (67.6) < 0.001
Mean age, years (SD) 55.2 (12.3)a 56.4 (12.0) 0.17
Higher education (% > 12 years) 451 (49.2)b 86 (41.1)c 0.04
Currently working (%) 383 (41.7)d 70 (32.9) 0.02
Married or living as married (%) 764 (82.9) 161 (75.6) 0.01
Limited disease (%) 556 (60.3) 157 (75.1)c < 0.001
Mean disease duration (SD) 11.1 (9.3)e 9.2 (8.0)f 0.01
Mean modified Rodnan Skin Score (SD) 10.5 (9.6)g 6.4 (6.0)h < 0.001
CES-D score, mean (SD) 14.3 (10.3) 12.8 (9.6)  0.05
Due to missing values: aN=920, bN=918, cN=209, dN=919, eN=879, fN=206, gN=905, hN=207 
MEASUREMENT EQUIVALENCE OF THE CES-D
4
56
positively worded items (items 4, 8, 12 and 16). Since allowing the error terms of these items to be 
correlated with each other would essentially result in specifying a second factor, a two-factor model 
was refitted, with two correlated factors: positive (items 4, 8, 12 and 16) and negative (other items) [27]. 
The two-factor model showed good fit to the data in both the English-speaking and Dutch samples 
(English-speaking: χ2 (81) = 572.6, P < 0.001, CFI = 0.93, TLI = 0.98, RMSEA = 0.08; Dutch: χ2 (51) = 128.3, 
P < 0.001, CFI = 0.95, TLI = 0.98, RMSEA = 0.08). In both samples, inspection of modification indices 
indicated that freeing error terms to covary for items 15 and 19, items 17 and 18, and items 7 and 
20, would improve model fit, and in each case there was clearly recognizable overlap in the items’ 
content. Therefore, the model was refitted to the data, allowing the error terms for those items to 
be correlated. This change resulted in a model with excellent fit to the data in both samples (English-
speaking: χ2 (81) = 345.1, P < 0.0001, CFI = 0.96, TLI = 0.99, RMSEA = 0.06; Dutch: χ2 (51) = 94.6, P < 0.0001, 
CFI = 0.97, TLI = 0.99, RMSEA = 0.06). 
Differential Item functioning
The two-factor model that was fit for each sample individually was fit with all patients in the 
same model, along with a direct effect of group (English-speaking versus Dutch) on both factors 
(“positive” and “negative”). As shown in Table 2, model fit for the combined sample for this base 
model was excellent. Prior to accounting for DIF, English-speaking patients had higher latent 
factor scores than Dutch-speaking patients: 0.15 standard deviations for “positive” factor scores, 
and 0.10 standard deviations for “negative” factor scores, although neither difference was 
statistically significant. Initially, four items showed significant DIF: items 3, 4, 7 and 20. Item 3 (“ 
I felt that I could not shake of the blues even with help from my family and friends,” z = 4.7, 
P < 0.001) and item 4 (“ I felt that I was just as good as other people,” z = 4.1, P < 0.001) had higher 
scores in the English-speaking sample, controlling for differences on the latent factors. On the 
other hand, item 7 (“I felt that everything I did was an effort,” z = -4.1, P < 0.001) and item 20 (“I 
could not get ‘going’, ” z = -3.7, P < 0.001) had higher scores in the Dutch sample. All four items 
continued showing DIF, throughout the sequence of correcting for DIF on the other items. 
After correcting for DIF, compared to the base model, there was a decrease of 0.08 
standard deviations on the “positive” latent factor and an increase of 0.03 standard deviations 
on the “negative” latent factor in the difference between English-speaking and Dutch patients, 
and confidence intervals were overlapping, as shown in Table 2. Thus, although there was 
statistically significant DIF on four CES-D items, this did not influence the overall estimates of 
depression latent factor scores between English-speaking and Dutch patients substantively.
As a sensitivity analysis, the MIMIC model was refit, controlling for demographic and 
disease variables (age, sex, marital status, education, current employment status, SSc subtype, 
mRSS, and disease duration), with similar results. Since the sensitivity analysis yielded virtually 
the same results, these results are not presented.
DIsCUssIon 
In order to compare or pool data obtained with HR-PRO measures that are administered 
in different languages, cross-cultural or cross-linguistic equivalence of scores should be 
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Table 2. Factor loadings on the “positive” and “negative” factors of the CES-D
base modela DIf corrected modelb
factor  
loading
95% Confidence 
Interval
factor  
loading
95% Confidence 
Interval
Positive factor items:
    4. Good 0.57 [0.51, 0.63] 0.56 [0.50, 0.62]
    8. Hopeful 0.74 [0.70, 0.78] 0.74 [0.70, 0.78]
    12. Happy 0.91 [0.87, 0.95] 0.91 [0.87, 0.95]
    16. Enjoy 0.83 [0.79, 0.87] 0.83 [0.79, 0.87]
negative factor items:
    1. Bothered 0.74 [0.71, 0.78] 0.74 [0.71, 0.78]
    2. Appetite 0.54 [0.49, 0.60] 0.54 [0.49, 0.60]
    3. Blues 0.86 [0.83, 0.89] 0.86 [0.83, 0.89]
    5. Mind 0.72 [0.68, 0.76] 0.72 [0.68, 0.76]
    6. Depressed 0.91 [0.89, 0.93] 0.91 [0.89, 0.93]
    7. Effort 0.68 [0.64, 0.72] 0.68 [0.64, 0.72]
    9. Failure 0.77 [0.73, 0.82] 0.77 [0.73, 0.82]
    10. Fearful 0.69 [0.65, 0.74] 0.69 [0.65, 0.74]
    11. Sleep 0.50 [0.44, 0.55] 0.50 [0.45, 0.55]
    13. Talk 0.69 [0.65, 0.74] 0.69 [0.65, 0.74]
    14. Lonely 0.78 [0.75, 0.82] 0.78 [0.75, 0.82]
    15. Unfriendly 0.52 [0.44, 0.59] 0.52 [0.44, 0.59]
    17. Cry 0.74 [0.69, 0.78] 0.74 [0.69, 0.78]
    18. Sad 0.85 [0.83, 0.88] 0.85 [0.83, 0.88]
    19. Dislike 0.68 [0.62, 0.75] 0.68 [0.62, 0.75]
    20. Get going 0.71 [0.67, 0.74] 0.71 [0.67, 0.74]
Direct effects on items attributable to english language:
    Item 3. Blues 0.31 [0.16, 0.46]
    Item 4. Good 0.34 [0.18, 0.50]
    Item 7. Effort -0.27 [-0.40, -0.13]
    Item 20. Get going -0.28 [-0.43, -0.13]
structural effect of english language on latent factors:
    Group on positive 0.15 [-0.04, 0.34] 0.07 [-0.13, 0.26]
    Group on negative 0.10 [-0.07, 0.27] 0.13 [-0.05, 0.30]
Correlation of positive  
and negative latent factors: 
0.46 [0.41, 0.51] 0.46 [0.41, 0.51]
Model fit summary:
    Model chi-square (df), P-value
457.30 (96),  
P < 0.001
422.20 (94), 
 P < 0.001
    CFI 0.96 0.96
    TLI 0.98 0.99
    RMSEA 0.06 0.06
a Not corrected for DIF, b Corrected for DIF for item 3, 4, 7 and 20
CFI= Comparative Fit Index; TLI= Tucker-Lewis Index; RMSEA= Root Mean Square Error of Approximation
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established. In the present study, cross-linguistic measurement equivalence was assessed for 
the CES-D in English-speaking Canadian and Dutch SSc patients. Significant DIF was found for 
4 of 20 items on the CES-D. However, the magnitude of DIF for each of these items was very 
small, and the effect on overall CES-D scores was negligible. This means that if there is DIF, it is 
so small that CES-D scores would not be influenced meaningfully by it.
Small-magnitude DIF was found for some items in our study. DIF in cross-linguistic 
comparisons may be caused by a lack of conceptual equivalence due to differences in content, 
format, difficulty or cultural relevance for the English-speaking compared to the Dutch sample 
[10]. The Dutch sample scored higher, even after controlling for latent depression symptom 
levels, on 2 items that were similar in meaning and related to energy levels and effort. Canadian 
English-speaking patients, on the other hand, appeared to endorse more ‘feeling’ symptoms. 
It is possible that this is related to cultural differences in how symptoms are experienced or 
expressed. It is also possible, however, that these differences may be related to translation. 
For items 7 (“Effort”) and 20 (“Get going”), no remarkable differences were found in the 
translations. This was not the case, however, for items 3 (“Blues”) and 4 (“Good”). In fact, 
there are many examples of discussions in the published literature related to the difficulty 
of translating from English “feeling blue” and related expressions such as “having the blues” 
[39-41]. In many languages, including Dutch, a strictly lexical translation for these terms is 
meaningless. Therefore, in translated versions, words need to be found with sufficient similarity 
to convey the concept, which might lead to slight differences between translated versions. For 
item 4 (“I felt that I was just as good as other people”), in the Dutch version of the CES-D, the 
translation of “good” is interpreted as “worth,” which has a slightly different connotation, and 
therefore might have influenced responses differently across groups. 
Despite the identification of minor DIF for several items, this study found that CES-D scores 
for English and Dutch SSc patients with equal levels of depressive symptoms would be expected 
to be highly similar. In other words, possible DIF on single items was of very small magnitude 
and had negligible influence on the overall score. Therefore, scores generated with the English 
and Dutch versions of the CES-D are comparable and do not require adjustment for linguistic 
differences. This is an important result given the increasingly common use of multinational 
collaborations to conduct research in rare diseases, such as SSc [7-9]. Future studies should 
extend the current assessment of the CES-D into other languages. In addition, measurement 
equivalence should also be assessed for other frequently used HR-PRO measures central to 
research in SSc and other rheumatic diseases, including, for instance, the Health Assessment 
Questionnaire [42], the Medical Outcomes Study Short Form-36 [43], and commonly-used 
measures of pain and fatigue.
There are limitations that should be considered in interpreting the results of this study. 
Because of the difference in sample size between the English-speaking and Dutch samples, the 
core model used to assess DIF relied more on data from English-speaking patients than Dutch 
patients. However, since the initial factor analysis yielded the same results in both samples, 
it does not seem likely that this would have influenced the results substantially. A second 
limitation relates to differences in sample recruitment. Dutch patients were recruited from 
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two hospitals, between 2008 and 2010, whereas the English-speaking Canadian patients were 
recruited from 15 centers from across Canada between 2004 and 2011. Furthermore, there were 
some differences in inclusion criteria for the two samples and in the demographic (in particular, 
sex) and disease characteristics (in particular, disease subtype and duration) of the samples. 
However, the sensitivity analysis correcting for differences in demographics and disease 
characteristics between samples yielded virtually the same results as the non-corrected model, 
which suggests that differences in sample characteristics did not likely influenced the results. 
In conclusion, there were several CES-D items with evidence of minor DIF between the 
English and Dutch samples. Overall, however, there was no evidence that these minor differences 
influenced overall scores. Therefore, CES-D scores from English-speaking Canadian and Dutch 
SSc patients can be compared and pooled without concern that measurement differences may 
substantively influence results. Given the importance of international collaborations and multi-
center trials in research on rare diseases, such as SSc, additional studies are needed that assess 
the measurement of other key HR-PROs across languages.
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absTRaCT
objective 
To compare psychometric properties of the EQ-5D and SF-6D utility measures, to assess 
agreement between these measures and to estimate minimal important differences (MID) in 
patients with systemic sclerosis (SSc).
Methods 
Both measures were assessed twice in an observational prospective design over a 12-month 
period (Baseline N = 211; Follow-up N = 154). Agreement was assessed using Lin’s concordance 
coefficient (LCC) and a Bland-Altman plot. MIDs were estimated using three different anchors, 
including the global rating of change item (SF-36) and changes on the Health Assessment 
Questionnaire- Disability Index (HAQ-DI) of ≥ 0.14 and ≥ 0.22.
Results 
At baseline, the mean EQ-5D and SF-6D scores were 0.64 (SD = 0.25) and 0.65 (SD = 0.11), 
respectively. Moderate agreement was found (LCC = 0.49 [95% CI: 0.42-0.56]). The Bland-
Altman plot showed a mean difference of 0.003 [95% CI: -0.024 to 0.030] but wide limits of 
agreement (-0.38 to 0.39) and a structural bias for lower scores. The mean MID estimate for the 
EQ-5D was 0.07 for the improved subgroups, and -0.11 for the deteriorated subgroups. For the 
SF-6D, mean MID estimate was 0.05 for the improved and -0.04 for the deteriorated subgroups. 
Conclusion 
The moderate agreement between the EQ-5D and SF-6D, implies that caution is needed when 
interpreting and comparing results that are obtained with the two distinct utility measures 
especially for lower scores. The larger sensitivity and responsiveness of the SF-6D compared 
with the EQ-5D, indicates that the SF-6D should be preferred over the EQ-5D to assess 
treatment outcomes in SSc. 
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InTRoDUCTIon
Self-administered preference-based or utility measures are increasingly used in economic 
evaluations of treatments and policy-making [e.g.,1,2]. Preference-based measures like the 
EQ-5D (EuroQol 5D) [3,4] and SF-6D [5] (derived from the Medical Outcomes Trust Short 
Form-36; SF-36) (6) are designed to assess value of health in a single summary measure, with a 
value of 0 for death and 1 for perfect health. Utility measures cover different domains of health 
related quality of life that might be influenced by (chronic) diseases, for instance pain, physical 
limitations, and mental health. 
The EQ-5D and SF-6D are frequently used and considered as well-established measures of 
utility across a diversity of chronic diseases, including rheumatic diseases [7,8]. Although both 
utility measures seem promising, the interchangeability of the two measures generally is low, 
especially for the lower and higher ranges of utility scores [9-11]. Because of the low agreement 
between measures, also differences in calculations of cost-effectiveness outcomes were found, 
decreasing the comparability of (cost-) effectiveness studies tremendously and leading to 
different resource allocation decisions [12]. In previous studies, levels of agreement differed 
wildly across diseases and patient samples [11]. Thus, the level of agreement should preferably be 
examined in a patient sample in which the instruments will be applied as an outcome measure.
Improvement of health related quality of life is one of the most important goals of 
pharmacological as well as non-pharmacological interventions in many chronic diseases, 
especially in the absence of cure, like in systemic sclerosis (SSc, scleroderma). SSc is a rare 
disease of connective tissue, characterized by abnormalities of the vascular and immune system 
[13]. Fibrosis leads to thickening of the skin and might lead to significant organ dysfunction in 
the internal organs as well. Usually, two clinical subtypes are recognized based on the extent 
of skin involvement; limited SSc, with skin involvement distal to the elbows and knees, with or 
without face involvement and diffuse SSc, with skin involvement proximal to the elbows and 
knees and the trunk also [14].
SSc was found to have an impact on physical as well as mental health related quality of 
life [15]. Currently there is no treatment available to cure SSc, but an increasing number of 
interventions are being developed and tested [e.g., 16-18]. To improve health care, accurate 
measurement of outcomes is crucial. Studies assessing the psychometric properties of 
patient-reported outcome measures usually include properties such as construct validity, 
discriminative ability and responsiveness. In addition, in the evaluation and interpretation of 
the effectiveness of treatments, it is important to determine the clinical significance of change 
scores, and which changes in outcomes could be interpreted as meaningful improvements 
to patients and clinicians. The minimal important difference (MID) could be defined as “the 
smallest difference in score in the domain of interest which patients perceive as beneficial and 
which would mandate, in the absence of troublesome side effects and excessive cost, a change 
in the patient’s (health care) management” [19]. For a particular instrument, MIDs may vary by 
population and context, for instance the baseline from which the patient starts, and whether 
they are improving or deteriorating [20]. Therefore, MIDs for utility measures, notably the 
EQ-5D and SF-6D, should be estimated also in patients with SSc. 
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According to the current evidence [21], the SF-6D showed to be a valid measure of utility in 
a sample of patients with diffuse SSc, while the EQ-5D has not yet been tested in SSc. Therefore, 
the purpose of the present study was to assess agreement, compare the validity and estimate 
minimal important differences (MID), effect sizes (ES), and standardized response means (SRM) 
of the EQ-5D and SF-6D utility measures in SSc patients. Patients with limited as well as diffuse 
disease were included in our sample.
MeThoDs
Design
Measurement properties of the EQ-5D and SF-6D were assessed using prospective data 
collection in the cohort study “Psychological factors in scleroderma” in patients with SSc. 
Patients completed both questionnaires, in addition to others, at inclusion (baseline) and after 
12 months follow-up. Details of this study are described elsewhere [22]. The study was approved 
by the local medical ethics board (CMO 2008/109).
Patients and Procedures
Patients with SSc of the Sint Maartenskliniek or Radboud University Nijmegen Medical Center, both 
in Nijmegen, the Netherlands, were included between June 2008 and August 2009. All patients 
had a diagnosis of SSc according to the preliminary ACR classification criteria [23]. Exclusion 
criteria for participation in the cohort were a life expectancy of less than a year, acute serious 
complications, severe psychiatric comorbidity, other serious comorbidities, and insufficient 
competence in the Dutch language. For the current analyses, patients were included if they 
completed either the EQ-5D or SF-6D at baseline. For 4 out of the 215 patients who completed 
the baseline measures, both the EQ-5D and SF-6D could not be calculated due to missing values. 
In addition, 4 patients had missing values for the EQ-5D (N = 207) and 12 patients for the SF-6D 
(N = 199). Of the 211 patients who were included at baseline, 163 (77.3%) also completed the 
follow-up measure. Drop-out reasons were: death (N = 8), illness (N = 3), organisational reasons 
(N = 11), unknown (N = 26). Additionally, 9 patients had missing values preventing the calculation 
of both the EQ-5D and SF-6D scores at follow-up (N = 154). Of the patients included at follow-up, 
6 patients had no EQ-5D score (N = 148) and 7 patients had no SF-6D score (N = 147). 
 assessments
Demographics and disease characteristics. Age, sex, marital status and current employment status 
were assessed by questionnaire. In addition, at baseline the attending rheumatologist assessed 
disease duration (time since onset of first non-Raynaud’s symptom), SSc limited or diffuse subtype 
[15], and the modified Rodnan Skin Score (mRSS), which is a rating of skin involvement ranging 
from 0 (no involvement) to 3 (severe thickening) in 17 body areas (total score range 0–51) [24]. 
The SF-36, EQ-5D, and Scleroderma modified disability index of the Health Assessment 
Questionnaire (SHAQ) were self-assessed by the patient at home using paper versions.
EQ-5D (EuroQol 5D) [3,4]. The EQ-5D is a 5-item standardized health-related quality of life 
questionnaire, measuring 5 dimensions (mobility, self-care, usual activities, pain/discomfort, 
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and anxiety/depression). The items are rated from 1 (no problems) to 3 (extreme problems). 
The EQ-5D ranges from -.59 to 1.00, with 1.00 indicating full health and 0 representing death. 
Since negative EQ-5D scores are possible, these indicate health status valued worse than death. 
Medical Outcomes Trust Short Form-36 (SF-36) [6]. The SF-36 measures eight domains of 
health status using 36 items; physical functioning (10 items), role-physical (4 items), bodily pain 
(2 items), general health (5 items), vitality (4 items), social functioning (2 items), role-emotional 
(3 items), and mental health (5 items). In addition, one item assesses global rating of change 
(GRoC) on a 5-point scale from “Much better now than one year ago” [1] to “Much worse now 
than one year ago” [5]. For the calculation of the SF-6D, 11 items are used covering six domains 
[5]; social functioning, bodily pain, mental health, physical functioning, role-limitation, and 
vitality. The SF-6D ranges from 0.29 to 1.00, with 1.00 indicating full health. 
Scleroderma Health Assessment Questionnaire (SHAQ) [25]. The SHAQ consists of the 
disability index of the Health Assessment Questionnaire (HAQ) [26] and six Visual Analogue 
Scales (VAS) measuring perceived severity of pain, digital ulcers, Raynaud’s phenomenon, lung 
involvement, gastrointestinal problems, and patient global assessment (PGA). A VAS was added to 
measure fatigue, since this is perceived as an important symptom of SSc [27]. The HAQ- Disability 
Index score consists of 20 items, measuring 8 dimensions of functioning (dressing and grooming, 
ability to get up, eating, walking, personal hygiene, reach, grip strength, and activities). The score 
of each dimension ranges from 0 (best function) to 3 (worst function), and the mean of these 
scores can be calculated as an indicator of overall physical functioning (HAQ-DI) with higher 
scores pointing to worse functioning. The HAQ was originally developed for use in Rheumatoid 
Arthritis [26] but has also demonstrated to be reliable and valid in patients with SSc [25].
statistical analysis
Descriptive statistics were provided as mean and standard deviation (SD) or median (P25 - P75) 
for continuous variables and percentages for categorical variables. For the EQ-5D and SF-6D, 
descriptive statistics (mean, median, SD, minimum, maximum, and frequencies) were calculated 
at baseline and follow-up. 
The COSMIN recommendations [28] were followed in the assessment of measurement 
properties if applicable, except for the recommendation on responsiveness. The COSMIN 
recommendation includes hypothesis testing and considers traditionally accepted methods 
such as standardized response mean (SRM) and effect sizes (ES) inappropriate. However, the 
SRM and ES are particularly used to compare which outcome measure detects changes over 
time more accurately, and could be considered appropriate for this purpose, especially also in 
the absence of a gold standard or external criterion available [29]. 
Floor- and ceiling effects were assessed by calculating the percentage of patients scoring 
the lowest and highest possible score, respectively. Agreement between the EQ-5D and SF-6D 
at baseline was assessed using Lin’s concordance coefficient [30] and a Bland-Altman plot [31]. 
The construct validity of the EQ-5D and SF-6D was assessed by calculating the correlation 
of both measures with HAQ-DI scores, VAS scores and Skin Score (mRSS). A-priori, it was 
hypothesized that both measures would have 1) at least a moderate correlation (r > 0.40) 
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with HAQ-DI scores and with PGA; 2) low correlations (r ≤ 0.40) with the 6 VAS scores, and 3) 
no correlation (0.00 ≤ r ≤ 0.20) with Skin Score [21]. Correlations were interpreted following 
Franzblau [32]; 0.00 - 0.20 indicating no correlation, 0.21 - 0.40 indicating a low correlation, 
0.41 - 0.60 indicating a moderate correlation, 0.61 - 0.80 indicating a marked correlation, and 
0.81 - 1.00 indicating a high correlation. The utility measures were considered valid if ≥ 75% of 
our a priori hypotheses were confirmed [33].
The discriminative ability among baseline HAQ-DI and PGA categories was assessed for 
both measures. HAQ-DI scores were classified by convenience in three categories: no-to-mild 
disability (0.00 - 1.00), moderate disability (1.01 - 2.00), and severe disability (2.01 - 3.00). For 
PGA, a score of 0.00 - 33.00 was conveniently categorised as mild disease activity, 33.10 - 66.00 
as moderate disease activity and 66.10 - 1.00 as severe disease activity. Differences between the 
HAQ-DI and PGA categories were assessed for the EQ-5D and SF-6D using MANOVA.
The Minimal Important Difference (MID) was defined as “the smallest difference in score in 
the domain of interest which patients perceive as beneficial and which would mandate, in the 
absence of troublesome side effects and excessive cost, a change in the patient’s (health care) 
management” [19]. To calculate MIDs for the EQ-5D and SF-6D, three different anchors were 
used: 1) the global rating of change item (GRoC) of the SF-36, 2) the HAQ-DI minimal important 
difference (0.22 points) for patients with rheumatoid arthritis [35], and 3) the upper bound of a 
published MID of the HAQ-DI for patients with diffuse SSc (0.14 points) [36]. For the GRoC, patients 
who score 2 (somewhat better) or 4 (somewhat worse) on the item “Compared to a year ago, 
how would you rate your health now?” of the SF-36 were considered the minimally improved and 
deteriorated subgroups, respectively. Patients with a score of 3 (about the same) were considered 
the unchanged group. For the HAQ-DI groups, minimally improved and deteriorated subgroups 
were categorized as patients with a decrease or increase of at least 0.22 (or 0.14 points for the 
third anchor) on the HAQ-DI, respectively. Patients with a change score < |0.22| (or < | 0.14| for the 
third anchor) were considered the unchanged group. MIDs were compared between the SF-6D 
and EQ-5D using paired sample t-tests to assess whether they differed significantly.
To assess responsiveness, a distribution-based approach was used. For the abovementioned 
anchors, responsiveness was calculated by using Effect Size (ES= D/SD
baseline
) [36] and 
Standardized Response Mean (SRM=D/SD
difference
) [37], in which D is the difference between 
baseline and follow-up measures, and SD
baseline
 and SD
difference
 are the standard deviations of the 
baseline measures and difference scores, respectively. Effect sizes were interpreted following 
Cohen’s criteria [36]; small (0.2), moderate (0.5) or large (0.8). ES and SRMs of the improved 
and deteriorated groups were compared with those of the unchanged groups. All statistical 
analyses were conducted using Stata/IC 10.1 software (StataCorp LP, College Station, TX).
ResULTs
sample characteristics
Demographics and disease characteristics were displayed in Table 1. The majority of patients 
were female and middle-aged. Most patients were living together or married. One-third of the 
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patients were employed at time of the study, and a large minority received higher education. 
Time since the onset of the first non-Raynaud’s symptom ranged from 0.2 to 51.8 years. 
Distribution and agreement
At baseline, the mean EQ-5D score was 0.64 (SD = 0.25, range = -0.18 - 1.00). The mean SF-6D score 
was 0.65 (SD = 0.11, range = 0.38 - 1.00). Mean follow-up scores for the EQ-5D and SF-6D were 0.63 
(SD = 0.27, range = -0.26 - 1.00) and 0.65 (SD = 0.12, range = 0.36 - 1.00), respectively. Neither 
the EQ-5D nor the SF-6D showed a floor effect (both 0.0%) or a ceiling effect (7.7% and 0.5%, 
respectively) at baseline. Lin’s concordance coefficient for baseline was 0.49 (95% CI = 0.42 - 0.56), 
indicating moderate concordance between the EQ-5D and SF-6D. The Bland-Altman plot 
(Figure 1) showed a mean difference of 0.003 (CI = -0.024 to 0.030) but wide limits of agreement 
(-0.38 to 0.39). A structural bias was found for the lower scores on the utility measures. In an 
additional analysis, only EQ-5D scores < 0.45 were taken into account. In this group (N = 24), the 
mean difference between the EQ-5D and SF-6D measures was -0.44 (SD = 0.14).
Validity: Construct
Correlations of the EQ-5D and SF-6D with physical functioning measures are displayed in Table 2. 
Conform our hypotheses, a marked correlation was found for both utility measures and HAQ-DI 
and PGA scores, and a small (< 0.20) correlation was found with Skin Score. Our hypotheses 
regarding a low correlation with the six VAS scores were confirmed for ulcers, Raynaud’s 
phenomenon and gastrointestinal tract. For lung symptoms, a low correlation was found for the 
EQ-5D, but a moderate correlation with the SF-6D. Furthermore, pain and fatigue both showed a 
moderate to marked correlation with the EQ-5D and SF-6D. There were no significant differences 
between the EQ-5D and SF-6D in correlations with HAQ-DI, PGA, the 6 VAS scores and Skin Score. 
For the EQ-5D, 77.8% of the a-priori hypotheses were confirmed, and 66.7% for the SF-6D.
Table 1: Baseline patient demographic and disease characteristics 
Variables Values (N = 211)
Female (%) 143 (67.8)
Mean age, years (SD) 56.4 (12.0)
Median time since onset first Non-Raynaud’s symptom (P25 - P75) 7.4 (3.5 - 12.3)a
Higher education (% > 12 years) 86 (41.6)b
Currently working (%) 69 (32.7)
Married or living as married (%) 159 (75.4)
Limited disease (%) 154 (74.4)
Mean modified Rodnan Skin Score (SD; range) 6.3 (6.0; 0 - 37)
Mean HAQ-DI score (SD; range) 1.04 (0.73; 0.0 - 3.0)c
Mean EQ-5D score (SD; range) 0.64 (0.25; -0.18 - 1.00)d
Mean SF-6D score (SD; range) 0.65 (0.11; 0.38 - 1.00)e
Due to missing values: aN=204, bN=207, cN=210, dN=207, eN=199 
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validity: Discrimination
Discrimination between the HAQ-DI and PGA categories for both utility measures at baseline 
are displayed in Figure 2. According to the MANOVA, both the EQ-5D and SF-6D were able to 
discriminate between HAQ-DI categories (F(2,203) = 41.2, P < 0.001 and F(2,195) = 35.9, P < 0.001, 
respectively), and between PGA levels (F(2,200) = 53.3, P < 0.001 and F(2,192) = 32.9, P < 0.001, 
respectively). Post-hoc analyses revealed that both measures were able to discriminate 
between all HAQ-DI and PGA categories.
Figure 1: Bland and Altman plot of differences between EQ-5D and SF-6D for patients with systemic sclerosis. 
Lower line: Mean difference +1.96 SD (Value = -0.38); Upper line: Mean difference -1.96 SD (Value = 0.39)
Table 2: Correlations [95% CI] of SF-6D an EQ-5D with physical functioning measures and disease-related 
visual analogue scales at baseline
sf-6D
hypothesis 
confirmed eQ-5D
hypothesis 
confirmed
HAQ-DI -0.63 [-0.71, -0.54] Yes -0.63 [-0.71, -0.54] Yes
PGA -0.58 [-0.66, -0.48] Yes -0.62 [-0.70, -0.53] Yes
Pain VAS -0.57 [-0.65, -0.46] No -0.55 [-0.64, -0.45] No
Ulcer VAS -0.36 [-0.48, -0.23] Yes -0.30 [-0.42, -0.17] Yes
Raynaud’s VAS -0.32 [-0.44, -0.19] Yes -0.28 [-0.40, -0.15] Yes
Lung VAS -0.45 [-0.56, -0.33] No -0.38 [-0.49, -0.26] Yes
GI VAS -0.31 [-0.43, -0.18] Yes -0.32 [-0.44, -0.19] Yes
Fatigue VAS -0.63 [-0.71, -0.54] Yes -0.55 [-0.64, -0.44] Yes
Skin Score -0.15 [-0.29, -0.01]* Yes - 0.13 [-0.27, 0.01]** Yes
HAQ-DI, Health Assessment Questionnaire- Disability Index; PGA, Patient Global Assessment; VAS, Visual 
Analogue Scale; GI, Gastrointestinal. 
All P < 0.001; *P < 0.05; **P > 0.06
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Figure 2: Discriminative ability of the EQ-5D and SF-6D between mild, moderate and severe HAQ-DI and 
PGA levels at baseline. The box-plots present the median, quartiles and extreme values for the EQ-5D and 
SF-6D utility scores for each HAQ-DI and PGA category.
Minimally important differences and responsiveness
MIDs, SRMs and effect sizes for the three utilized anchors are displayed in Table 3. The HAQ-DI based 
MID estimated were equal for both cut-offs (0.14 and 0.22 points), for the unchanged, improved 
and the deteriorated subgroups. For the minimally improved categories, MIDs range from 0.04 
to 0.08 for the SF-6D and EQ-5D, are equal for both questionnaires and of larger magnitude than 
the unchanged groups. For the minimally deteriorated categories, MIDs are structurally larger for 
the EQ-5D compared to the SF-6D (all differences between EQ-5D and SF-6D; P < 0.05), and larger 
than the unchanged groups for both measures. The mean MID estimate for the EQ-5D was 0.07 
for the improved subgroups, and -0.11 for the deteriorated subgroups. For the SF-6D, the mean 
MID estimate was 0.05 for the improved and -0.04 for the deteriorated subgroups. The SRMs and 
ES for the SF-6D ranged from -0.37 to -0.51 for the deteriorated categories and from 0.36 to 0.87 
for the improved categories and were mainly small to moderate [36]. The SRMs and ES for the 
EQ-5D ranged from -0.41 to -0.50 for the deteriorated categories and from 0.30 to 0.45 for the 
improved categories and were all small to moderate [36]. 
DIsCUssIon
This was the first study to compare measurement properties of the EQ-5D and SF-6D utility 
measures, assess agreement between these measures and estimate MIDs in a sample of patients 
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with SSc. Agreement between the EQ-5D and SF-6D in the present study was moderate. 
Especially for lower scores (including about 10% of the sample), results revealed a systematic 
bias between the EQ-5D and SF-6D scores, implying that, in particular for patients with worse 
health status, both measures are not interchangeable. Neither of the measures showed floor- 
and ceiling effects, the mean scores were comparable for both measures, and the EQ-5D and 
SF-6D were both able to discriminate between levels of disability and PGA of health. For the 
EQ-5D, 77.8% of our a-priori hypotheses were confirmed, whereas for the SF-6D this percentage 
was 66.7%. Based on our a-priori cut-off (≥75% confirmed), our results support the construct 
validity of the EQ-5D but not for the SF-6D. However, the difference between the correlations 
of the EQ-5D and SF-6D with lung involvement is only 0.07, and confidence intervals are highly 
overlapping. Therefore, we would argue that both measures should be considered equally valid. 
In contrast to our a-priori hypotheses, a moderate to marked correlation was found with 
pain and fatigue for both measures. However, both symptoms are experienced frequently by 
patients with SSc [27], and were found to have at least moderate impact on daily activities in the 
majority of patients, indicating that pain and fatigue might significantly reduce health related 
quality of life in patients with SSc. Therefore, it might not be surprising that these symptoms 
are associated with lower utility scores in SSc, and our hypotheses regarding pain and fatigue 
might have been suboptimal.
The MIDs obtained in this study for the deteriorated subgroups were all of a larger magnitude 
for the EQ-5D compared to the SF-6D, supporting the larger sensitivity of the SF-6D to detect 
deterioration as was found in previous studies in rheumatoid arthritis [7]. For the improved 
subgroups, the differences in MIDs between the EQ-5D and SF-6D were less profound, but 
MIDs were also slightly smaller for the SF-6D. The MIDs were comparable to those obtained in 
previous studies of the EQ-5D and SF-6D in rheumatic diseases [7]. Although the MIDs for the 
changed groups were relatively small, these MIDs were at least twice as large as the estimates 
in the unchanged groups. The MIDs found in the present study could therefore be used to 
calculate sample sizes for clinical trials involving patients with SSc, and in interpreting the 
relevance and importance of treatment effects.
Table 3: Minimal important differences and responsiveness (SRM and ES) of the EQ-5D and SF-6D measures
anchor
sf-6D eQ-5D
n MID [95%CI] sRM es n MID [95%CI] sRM es
GRoC (unchanged) 67 -0.02 [-0.04, 0.00] -0.28 -0.22 67 0.00 [-0.04, 0.04] -0.01 -0.01
GRoC (somewhat worse) 36 -0.04 [-0.07, -0.01] -0.51 -0.47 38 -0.10 [-0.17, -0.02] -0.44 -0.49
GRoC (somewhat better) 19  0.04 [-0.01, 0.09]  0.39  0.36 21 0.05 [-0.02, 0.11]  0.32  0.18
HAQ-DI (unchanged) 68 -0.02 [-0.04, 0.00] -0.31 -0.19 74 -0.03 [-0.07, 0.01] -0.16 -0.13
HAQ-DI (≥ .14/.22 worse) 48 -0.04 [-0.07, -0.02] -0.48 -0.37 46 -0.11 [-0.18, -0.04] -0.49 -0.41
HAQ-DI (≥ .14/.22 better) 24 0.06 [0.01, 0.11] 0.52  0.90 25 0.07 [0.00, 0.15]  0.44  0.30
GRoC, Global Rating or Change; HAQ-DI, Health Assessment Questionnaire- Disability Index; MID = Minimal 
important difference; ES = D/SD
baseline
; SRM = D/SD
difference
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Furthermore, in the present study the responsiveness (SRM and ES) of the SF-6D was 
structurally larger than for the EQ-5D, especially for the improved subgroups. This might 
indicate that, since the treatment induced health gains in SSc are usually small, the SF-6D 
should be preferred over the EQ-5D to assess treatment outcomes in SSc. Further investigation 
is warranted to assess whether and to what extent the choice for the EQ-5D versus SF-6D to 
measure utility might have an influence on cost-utility evaluations and treatment decisions. To 
facilitate comparison, both EQ-5D and SF-6D may be assessed, but SF-6D may be preferred as 
the primary outcome measure in cost-utility studies.
Compared with the study of Khanna et al [21], the MIDs and ES for the SF-6D found in our 
sample were larger for all three anchors (differences ranging from 0.028 to 0.09). This could 
possibly be due to differences between samples; the study by Khanna et al. included only 
patients with the diffuse SSc subtype, who generally have a less favourable outcome compared 
to patients with limited SSc [38], while our sample consisted mainly (approximately 75%) of 
patients with limited SSc. Furthermore, mean disease duration of the sample by Khanna et al. 
was shorter than that of the sample in the present study. Since the mean SF-6D score in both 
samples was similar (0.64 versus 0.65), this indicates that the sample of Khanna et al. included 
patients with a worse disease progression, which might be reflected in smaller improvements 
that are perceived as important by patients.
There are some limitations of the present study that should be taken into account when 
interpreting our results. First, comparisons between the measures were relative; there was no 
external standard to compare with, like physician-rated disease severity. Furthermore, we did 
not differentiate between baseline levels of health status while assessing MIDs, assuming that 
minimally important change values are equal for patients with relatively mild and worse disease 
status. The small numbers of patients per subgroup did not allow us to differentiate among levels 
of health status. Also, no imputation was applied for missing values, so in particular the estimates 
using the follow-up data reported in the study might be biased due to the assumption that the 
missingness of data was completely at random. However, since the purpose of the study was to 
compare psychometric properties of the EQ-5D and SF-6D measures, it does not seem likely that 
this would have influenced our results substantially. Finally, test-retest reliability for the EQ-5D 
and SF-6D was not assessed in the present study. In the study of Khanna et al. [21], the test-retest 
reliability of the SF-6D was found to be excellent. In future studies, assessing both utility measures 
twice in a narrower timeframe contributes to the comparability of the stability over time. 
In conclusion, the present study is the first to compare measurement properties and MIDs 
of two widely used utility measures, notably the EQ-5D and SF-6D, in patients with SSc. The 
moderate agreement between the measures, especially for lower scores, implies that caution is 
needed when interpreting and comparing results that are obtained with the two distinct utility 
measures as were used in the present study, especially for patients with low utility scores. The 
larger sensitivity and responsiveness of the SF-6D compared with the EQ-5D, indicates that the 
SF-6D should be preferred over the EQ-5D to assess treatment outcomes in SSc.
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absTRaCT
objectives 
To assess health care utilization in systemic sclerosis (SSc) and its associated factors. To evaluate 
patients’ perspectives on quality of care and its association with health care use.
Methods
In a cross-sectional design, 198 Dutch patients with SSc (recruited by the Dutch patient 
organization) completed an anonymous survey concerning health care utilization, quality of 
care (CQ Index) and quality of life (SF-36).
Results 
In the last 12 months, 95% of the patients had contact with at least one medical specialist and 
two-thirds contacted at least one health professional (HP). The median numbers of visits to 
medical specialists and health professionals were 7 and 7.5, respectively. Having a partner and 
reduced physical health status (SF-36 Role-Physical) were significantly associated with more 
visits to medical specialists and HPs. The median numbers of disciplines contacted since the 
onset of SSc and in the last 12 months were 8 and 4, respectively. Patients with less fatigue 
(SF-36 Vitality) and more pain (SF-36 Bodily Pain) contacted more disciplines. A higher number 
of disciplines involved in the care was significantly associated with less satisfaction with 
cooperation and alignment of care (r = -0.14, P = 0.03).
Conclusion
Health care utilization in SSc is substantial, as is reflected in the high number of visits and the 
number of disciplines. Patients’ rating of alignment of care was lower if more disciplines were 
involved in their care. To further improve patient satisfaction with care, it might be useful to 
appoint a case manager in the management of SSc.
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InTRoDUCTIon
Systemic sclerosis (SSc, scleroderma) is a rare, multisystem, autoimmune disease characterized 
mainly by fibrosis of the skin. Symptoms include thickening and tightening of the skin, Raynaud’s 
phenomenon and digital ulcers, joint pain and difficulty breathing. SSc often also affects internal 
organs such as the kidneys, lungs, heart and gastro-intestinal tract [1,2]. Physical functioning 
in patients with SSc is often impaired, and disability increases over time [3]. As a consequence 
of this complex disease, patients have indicated physical as well as mental impairments in their 
quality of life [4] and often require treatment from a variety of health care providers [5,6].
As yet little is known about the extent to which SSc patients use health care services and how 
they evaluate the quality of care. Moreover, insight into health care utilization and associated 
factors in Western European countries is lacking. Research so far has been restricted to three 
studies (two in Canada and one in Hungary) with a suboptimal approach [5,6,7]. These studies 
concluded that the rheumatologist and general practitioner were the most frequently visited 
physicians [6,7]; however, they assessed only a limited range of health care providers. They 
also reported that factors associated with more frequent visits to physicians included a higher 
income, more skin involvement, more comorbidities, and lower physical health status [5]. 
Finally, divergent results were found in Canada and Hungary concerning the number of contacts 
per year with medical specialists (3.8 and 7.1, respectively) and GPs (3.5 and 10.3, respectively) 
[5,7]. Generalizability of these findings to Western European countries is restricted due to 
differences in health care system and differences in accessibility of health care services (e.g. 
because of travel distances). In addition, there might be differences in disease presentation, 
since more severe SSc cases have been reported in Eastern European countries than in Western 
European countries [8]. Therefore, it is important to assess health care utilization by patients 
with SSc in Western European countries, such as the Netherlands, to identify possible areas for 
improvement of the care provided to patients with SSc. 
Inconsistent treatment plans due to a lack of information and communication result in 
inadequate disease management [9,10]. Therefore, strong integration and good communication 
between health care providers are regarded as imperative in chronic disease management 
[11,12]. Since multiple health care providers are involved in the treatment of SSc, it might be a 
challenge to coordinate and integrate patient care into a coherent treatment plan. Therefore, 
to identify those domains in which improvements are warranted, it is important to gain 
insight into how patients with SSc evaluate the health care received, especially with regard to 
communication between health care providers and the alignment of care. 
The aims of this study were 1) to assess health care use in a Dutch sample of patients with 
SSc and the association with demographic characteristics and health-related quality of life, and 
2) to evaluate patients’ perspectives on quality of care and to examine the association between 
quality of care and health care use.
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MeThoDs
Patients and procedure
Between June and August 2011, the Dutch patient organization for patients with systemic 
autoimmune diseases (NVLE) asked 501 patients with SSc and 198 patients with mixed connective 
tissue disease (MCTD) to complete an anonymous survey, based on the diagnosis at registration 
with the patient organization. Patients with a diagnosis of SSc or MCTD by a physician (patient-
reported), age 18 years or older, and sufficient knowledge of the Dutch language, were invited 
to complete the survey online or received a paper version on request. The response rate was 
69% (N = 481), of which 82% (N = 396) answered the survey online and 18% (N = 85) used the 
paper version (see flowchart in Figure 1). Based on a comparison of demographic variables, 
28 questionnaires were classified as duplicates. Furthermore, 25 patients were excluded from 
the analyses because they failed to complete more than the demographic questions of the 
survey and 33 patients were excluded because they did not report a diagnosis. Only patients 
with limited and diffuse systemic sclerosis were included in this study; patients with MCTD and 
other diseases were excluded. Of the 240 potentially eligible patients, 42 patients answered 
inconsistently that they had never visited a medical specialist while also reporting that a 
medical specialist had confirmed the diagnosis. Therefore, these patients were excluded from 
this study. Thus, a total of 198 SSc patients were included in the analyses. Ethical approval was 
obtained from the local medical ethics board (CMO 2011/203). 
The Dutch survey was partly based on a Canadian survey [1], which was translated and 
adjusted for the Dutch health care system. Questions about health care utilization relating to 
SSc, quality of care and quality of life were added to the original Canadian survey. Furthermore, 
but beyond the scope of the present study, questionnaires on fatigue, medication use, and the 
frequency and impact of 40 SSc symptoms were included. Draft versions of the questionnaire 
were commented on by two patient representatives and adjusted accordingly.
MeasURes
Demographic variables assessed were: sex, age, education, marital status, current employment 
status, self-reported disease subtype (limited SSc/CREST, diffuse SSc, unknown), and the time 
since diagnosis. 
Health care use related to SSc was assessed using a list of 26 health care providers, with the 
possibility for the patient to indicate other health care providers. Patients were asked whether 
they had had contact with a health care provider because of their SSc since the onset of the 
disease (yes/no) and during the last 12 months (yes/no). Health care use was classified according 
to four categories (see Table 2): medical specialists, health professionals, complementary 
therapists (manual therapist, touch therapist, acupuncturist, homeopathist, anthroposophist, 
hypnotherapist), and home care (home help, domestic help, community nurse). If patients 
indicated that they had contacted a health care provider during the last year, they were asked 
how often they had visited this health care provider during the past year.
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699 (100%) SSc and 
MCTD patients
481 (69%)
 respondents
240 (34%)
 SSc respondents
198 (28%)
 SSc respondents
218 (31%) 
non-responders
241 (35%) 
excluded
42 (6%) 
excluded
4 deceased
3 other reason
21 unknown reason
16 blank surveys
28 possible duplicates
33 unknown diagnosis
155 other diagnosis
9 uncompleted surveys
42 no visit to medical specialist
Perceived quality of care was assessed with questions based on the Consumer Quality Index 
(CQ Index), which has been found to be a reliable measure of patients’ experiences with the quality 
of rheumatic health care [13]. The subscale “cooperation and alignment” (6 items) measures 
how patients rate the cooperation and alignment between different health care providers (e.g., 
“Were parallel treatments aligned with one another?”). The subscale “visit to most important 
health care provider” (5 items) measures how patients evaluate the interaction with their most 
important health care provider during appointments (e.g., “Did the health care provider explain 
things clearly?”). The subscales were assessed on a four-point Likert scale (1 = never to 4 = always) 
and were presented as both continous and dichotomous variables. For dichotomous analyses, 
responses were coded “never or sometimes” versus “most of the time or always”. Higher scores 
on the CQ Index indicate higher satisfaction with the received health care. In addition, patients 
were asked to rate the quality of care by their most important health care provider on an 11-point 
Figure 1: Study flow chart
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scale (0 = very poor to 10 = excellent). The CQ Index showed good internal consistency in our 
sample, with a Cronbach’s α of 0.87, and the subscales Cronbach’s α was 0.80 for “cooperation and 
alignment” and 0.89 for “visit to most important health care provider”.
The Medical Outcomes Study 36-item Short-Form Health Survey (SF-36) is a generic 
questionnaire measuring health-related quality of life [14]. The questionnaire consists of 36 
items that measure 8 domains of health status: physical functioning, role-physical, bodily pain, 
general health, vitality, social functioning, role-emotional, and mental health. The subscales 
can be divided into two summary scales: the physical and the mental component summary 
scales. Lower scores indicate lower quality of life. The SF-36 has shown to be a valid measure of 
quality of life across diverse samples, including SSc [15-17]. The SF-36 showed excellent internal 
consistency in our sample, with a Cronbach’s α of 0.94.
statistical analysis
Descriptive statistics were used to describe demographic characteristics and health care use. 
Univariate linear regression analyses were performed to examine the association of sociodemographic 
and disease characteristics with health care use (number of different disciplines and number of visits). 
The variables that showed a univariate association (P < 0.20) with health care use were entered into 
multiple regression analyses, adjusted for sex, age, and time since diagnosis. Tolerance values were 
calculated to check for multicollinearity. In the final analyses, all tolerance values were between 0.39 
and 0.97, indicating multicollinearity was not an issue. 
Associations between perceived quality of care (including the mean scores of the CQIndex 
subscales and the rating of the most important health care provider), the number of different 
disciplines and the number of visits in the last 12 months were investigated using partial Kendall’s 
tau, corrected for sex, age, educational level, employment status, marital status, disease 
subtype, and time since diagnosis. All statistical analyses were conducted using Stata/IC 10.1 
software (StataCorp LP, College Station, TX).
ResULTs
Demographics and disease characteristics 
Demographics and disease characteristics are displayed in Table 1. In total, 27 men and 
171 women were included, with a mean age of 58.1 years (SD = 11.3) and a mean time since 
diagnosis of 11.1 years (SD = 9.5). About half of the respondents had received higher education 
and most respondents were married or cohabiting. The majority of the patients (65%) had 
limited SSc/CREST, and 31% had diffuse SSc.
health care use
Medical specialists: Health care use is displayed in Table 2. Since the onset of the disease, the 
majority of the patients had contacted a rheumatologist (93%), general practitioner (89%), 
cardiologist (72%), lung specialist (70%), dermatologist (58%) or an internist (52%). Most 
patients  (95%) had contact with at least one medical specialist in the last 12 months. Patients 
HEALTH CARE UTILIZATION
6
86
reported a median of 7 visits to medical specialists in the last year. In terms of medical specialists, 
patients who had at least one contact most frequently visited nephrologists and rheumatologists.
Health professionals: Most patients (88%) had contact with at least one health professional 
since the onset of the disease, and 67% of the patients visited a health professional in the last 
12 months, with the physical therapist being mentioned most frequently. About half of the 
patients (45%) had contacted a nurse specialist at some point. In total, patients reported a median 
of 7.5 visits to health professionals. In terms of health professionals, patients who had at least one 
contact most frequently visited physical therapists and exercise therapists. Besides contacts with 
health professionals, one-third of the patients had contact with at least one complementary 
therapist and home care had been used by 75 patients (38%) since the onset of the disease. 
In total, patients visited a median of 8 different disciplines (range 0-14) since the onset of 
their disease, including 5 medical specialists and 2 health professionals. In the last 12 months, 
involvement of a median of 4 different disciplines was reported, comprising 3 medical specialists 
and 1 health professional.
associated factors of health care use
Univariate and multiple regression analyses are shown in Table 3, both for the number of 
visits and the number of different disciplines in the last 12 months. The multivariate analyses 
show that a higher SF-36 vitality score (Beta = 0.26, P < 0.05) and lower SF-36 bodily pain score 
(Beta = -0.21, P < 0.05) were significantly associated with a higher number of disciplines. Thus, 
patients with less fatigue or more pain visited more different disciplines. Having a partner 
(Beta = 0.16, P < 0.05) and lower SF-36 role physical score (Beta = -0.31, P < 0.01), meaning 
Table 1. Demographic and disease characteristics of 198 patients with SSc
Characteristics
Female, N (%) 171 (86.4)
Age, years; mean (SD), range 58.1 (11.3), 29-85
education level, n (%)
   0-12 years 101 (51.5)
   > 12 years 95 (48.5)
Living with partner, N (%) 139 (70.9)
Paid employment, N (%) 37 (18.9)
Disease subtype, n (%)
   Limited/CREST 129 (65.2)
   Diffuse 61 (30.8)
   Subtype unknown 8 (4.0)
Time since diagnosis, years; mean (SD), range 11.1 (9.5), 0-64
SF-36 Physical component summary; mean (SD) 33.5 (9.4)
SF-36 Mental component summary; mean (SD) 45.7 (10.7)
SF-36: The Medical Outcomes Study 36-item Short-Form Survey 
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more problems with daily activities due to physical functioning, were found to be significantly 
associated with a higher number of visits.
Perceived quality of care
Table 4 shows the perceived quality of care and its correlations with health care use. The mean 
scores for the subscales “cooperation and alignment” and “visit to most important health care 
provider” were 2.9 (SD = 0.8) and 3.6 (SD = 0.5), respectively. On average, patients gave their 
most important health care provider an 8.4 (SD = 1.4) on a scale of 0 to 10. 
More than 90% of the patients reported that the most important health care provider took him/
her seriously, listened carefully, explained things clearly, and spent enough time during appointments, 
and that they were satisfied about the opportunity to ask questions (Figure 2). Approximately 70% of 
the patients reported that treatments and advices were aligned with one another, and 63% felt that 
health care providers communicated well with each other. Scores on alignment of care correlated 
Table 2. Health care utilization of 198 patients with SSc 
health care service
Contacted  
since onset ssc  
n (%)
Contacted  
in last 12 monthsa 
n (%) 
number of visits, 
if at least one  
Median (p25-p75)
Medical specialists 198 (100) 187 (95) 7 (4-11)b
   Rheumatologist 184 (93) 164 (83) 4 (2-4)
   General practitioner 177 (89) 99 (50) 3 (2-5)
   Cardiologist 143 (72) 92 (47) 1 (1-2)
   Lung specialist 139 (70) 90 (46) 1 (1-2)
   Dermatologist 115 (58) 50 (25) 2 (1-3.5)
   Internist 102 (52) 42 (21) 2 (2-4)
   Gastroenterologist 81 (41) 37 (19) 2 (1-3)
   Nephrologist 11 (6) 4 (2) 4 (1-4)
   Other medical specialists 22 (11) 26 (12) 3 (2-5)
Health professionals 175 (88) 132 (67) 7.5 (0-52)b
   Physical therapist 149 (75) 106 (53) 52 (22-55)
   Nurse specialist 89 (45) 30 (15) 1 (1-3)
   Occupational therapist 72 (36) 26 (13) 3 (1-6)
   Dietician 45 (23) 17 (9) 3 (1-4)
   Psychologist 38 (19) 14 (7) 3 (2-4)
   Social worker 35 (18) 8 (4) 4 (3-6)
   Exercise therapist 12 (6)  3 (2) 52 (5-52)
   Other health professionals 4 (2) 9 (5) 5 (3-17.5)
Complementary therapists 60 (30) 30 (15) 0 (0-0)b
Home care 75 (38) 59 (30) 0 (0-0)b
a1 missing value; b number of visits including patients with no visits 
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Table 3. Results of univariate and multiple regression analysis of the association of sociodemographic and 
disease variables with the number of disciplines and the number of visits to health care providers in the 
last 12 months
Characteristic
number of disciplinesa number of visitsa
Univariate 
regression 
beta (95% CI)
Multiple 
regression 
beta (95% CI)
Univariate 
regression 
beta (95% CI)
Multiple 
regression 
beta (95% CI)
Age -0.06 (-0.04, 0.02) -0.07 (-0.05, 0.02) -0.09 (-1.08, 0.28) -0.06 (-1.02, 0.51)
Gender, female -0.03 (-1.20, 0.77) -0.00 (-0.99, 0.96) -0.00 (-21.58, 21.77) 0.01 (-20.07, 23.31)
> 12 years education 0.11 (-0.17, 1.19)γ 0.14 (-0.06, 1.36) -0.03 (-18.10, 12.97)
Paid employment -0.07 (-1.28, 0.44) -0.00 (-20.60, 19.46)
Living with partner -0.02 (-0.83, 0.66) 0.11 (-4.53, 28.98)γ 0.16 (0.67, 35.27)*
Disease subtype 0.02 (-0.62, 0.83) 0.02 (-14.62, 19.18)
Time since diagnosis -0.13 (-0.07, 0.00)γ -0.11 (-0.07, 0.01) -0.14 (-1.58, 0.07)γ -0.15 (-1.66, 0.05)
sf-36 scales 
Physical functioning -0.25 (-0.09, -0.02)∞ -0.16 (-0.08, 0.01) -0.23 (-1.83, -0.40)∞ -0.18 (-1.92, 0.13)
Role-physical -0.28 (-0.11, -0.03)∞ -0.22 (-0.11, 0.00) -0.31 (-2.66, -0.94)∞ -0.31 (-3.15, -0.46)∞
Bodily pain -0.28 (-0.10, -0.03)∞ -0.21 (-0.10, -0.00)* -0.20 (-1.88, -0.25)* -0.04 (-1.30, 0.90)
General health -0.15 (-0.08, -0.00)* -0.08 (-0.07, 0.03) -0.12 (-1.64, 0.21)γ -0.01 (-1.21, 1.10)
Vitality -0.11 (-0.07, 0.01)γ 0.26 (0.01, 0.12)* -0.15 (1.74, 0.03)γ 0.12 (-0.53, 1.97)
Social functioning -0.17 (-0.07, -0.01)* 0.06 (-0.03, 0.06) -0.13 (-1.37, 0.11)γ 0.07 (-0.64, 1.38)
Role-emotional 0.01 (-0.02, 0.03) 0.04 (-0.45, 0.73)
Mental health 0.04 (-0.03, 0.05) -0.07 (-1.23, 0.44)
∞ p < 0.01, * p < 0.05, γ p < 0.20; aMedical specialists and health professionals
significantly with the number of different health care providers (r = -0.14, P = 0.03), but not with 
number of visits, reflecting that a greater use of different disciplines is associated with less satisfaction 
in terms of cooperation among health care providers and alignment of care.
DIsCUssIon
This study was conducted to assess health care use and perceived quality of care in patients 
with SSc. Our findings demonstrate that health care use in a Dutch sample of patients with SSc 
is substantial and involves multiple care providers. Physical health status and having a partner 
were found to be the most important factors associated with health care utilization. In addition, 
a greater number of different disciplines involved in the care of SSc was associated with less 
satisfaction in terms of the cooperation among health care providers and the alignment of care. 
To date, few studies have focussed in detail on the health care utilization in complex, chronic 
diseases such as SSc. In our study, patients with SSc reported many visits to health care providers. 
The reported number of visits to medical specialists was similar to that in a Canadian study of SSc 
patients [5] and a Dutch study of patients with systemic lupus erythematosus (SLE) [18], another 
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Figure 2: Satisfaction with quality of care (CQ-Index) 
Score 0-10 8.4 (1.4) -0.06 -0.03
* p < 0.05;  a Kendalls tau correlation corrected for: sex, age, educational level, employment status,  
marital status, disease subtype, time since diagnosis
More than 90% of the patients reported that the most important health care provider took 
him/her  seriously,  listened  carefully,  explained  things  clearly,  and  spent  enough  time  during 
appointments,  and  that  they  were  satisfied  about  the  opportunity  to  ask  questions  (Figure  2). 
Approximately  70%  of  the  patients  reported  that  treatments  and  advices  were  aligned  with  one 
another,  and  63% felt  that  health  care  providers  communicated  well  with  each  other.  Scores  on 
alignment of care correlated significantly with the number of different health care providers (r = -0.14, 
P  =  0.03),  but  not  with  number  of  visits,  reflecting  that  a  greater  use  of  different  disciplines  is 
associated with less satisfaction in terms of cooperation among health care providers and alignment of  
care.
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Discussion
This  study was conducted to  assess health  care  use 
and perceived quality of care in patients with SSc. Our findings 
demonstrate that health care use in a Dutch sample of patients 
with  SSc is  substantial  and involves multiple care providers.  Physical  health status and having a 
partner were found to be the most important factors associated with health care utilization. In addition, 
a  greater  number  of  different  disciplines  involved  in  the  care  of  SSc  was  associated  with  less 
satisfaction in terms of the cooperation among health care providers and the alignment of care. 
To date, few studies have focussed in detail on the health care utilization in complex, chronic 
diseases such as SSc. In our study, patients with SSc reported many visits to health care providers.  
The reported number of visits to medical specialists was similar to that in a Canadian study of SSc 
patients [5]  and a Dutch study of  patients with systemic lupus erythematosus (SLE) [18],  another 
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A3: Did caregivers make good appointments with each other?
A4: Were caregivers aware of other activities of caregivers?
A5: After leaving a message at the hospital, were you called 
within one workday?
A6: Did you make appointments with the caregivers about what 
to do when the disease worsens?
Section B “Visit to most important health care provider” 
B1: Did the caregiver took you seriously?
B2: Did the caregiver spend enough time?
B3: Did the caregiver listen carefully to you?
B4: Did the caregiver explain things clearly?
B5: Did you get the opportunity to ask questions?
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chronic systemic autoimmune disease. However, the number of visits to health professionals in 
our study was considerably higher than that reported in the study of SLE patients [18]. 
Less than half of the participants in our study reported ever having visited a nurse specialist 
and only one out of six patients had contact with a nurse specialist during the last year. These 
findings are not concordant with the EULAR recommendations on the role of the nurse in the 
management of rheumatic diseases, which states that all patients should have access to a nurse 
specialist throughout the course of the disease [19], and that specialist nurses should have a 
role in improving communication, continuity and satisfaction with care. This means that, in SSc, 
the health care might benefit from a more active role by nurse specialists. 
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Table 4. Perceived quality of health care rated by patients with SSc and correlation coefficients (r) between 
CQ-Index, number of different disciplines and number of visits (N = 197)
CQ-Index 
range
CQ-Index 
mean (sD)
number of different 
disciplinesa
r
number of 
visits a
r
Cooperation and alignment 1-4 2.9 (0.8) -0.14* -0.07
Care of your most important health 
care provider
1-4 3.6 (0.5) -0.01 0.01
Score 0-10 8.4 (1.4) -0.06 -0.03
* p < 0.05; a Kendalls tau correlation corrected for: sex, age, educational level, employment status, marital status, 
disease subtype, time since diagnosis
One of the findings of our study is that the greater the number of disciplines involved in the 
treatment of SSc, the lower the patient satisfaction with the cooperation among health care providers 
and with the alignment of care. This is in line with previous studies that found that the involvement of 
a large number of health care providers could result in overlap of treatment or contradictory advice 
leading to inadequate care [9] and a higher disease burden for the patient [10]. Therefore, to further 
improve patient satisfaction with communication among health care providers and the coordination 
of care, it might be useful to enhance the role of the nurse specialist in the management of SSc, for 
instance as a case manager to coordinate the care of patients. On the other hand, patients may wish 
to be their own advocate in the management of their disease [20]. Therefore, to find the best solution 
to improving communication and coordination of care, patients’ perspectives regarding this topic 
should be examined in future investigations. 
An interesting finding in our study was that having a partner correlated with more 
visits to health care providers, even after controlling for demographic and disease-related 
characteristics. A possible explanation for this finding is that married individuals are more 
likely to be subject to health-related social control than unmarried individuals [21] and receive 
more encouragement from their partners to visit a health care provider. Existing literature is, 
however, inconclusive regarding the association between marital status and health care use 
[22]. Although the majority of the published studies found that marital status had no impact on 
health care utilization [22], other studies found that being unmarried or living alone is associated 
with greater health care utilization. Possibly, in rare diseases like SSc, the encouragement and 
involvement of partners might have an influence on health care use, since information about 
the disease and its treatment is not readily available [23]. 
Another unexpected finding was that higher levels of fatigue were significantly associated 
with the involvement of fewer different disciplines in the patient’s care. This indicates that tired 
patients are less likely to seek treatment from various care providers less often, even though 
such treatment might be more necessary. This finding suggests that health care use might not 
yet be properly attuned to the patients’ needs in SSc. Possibly, fatigue may prevent certain 
patients from seeking the treatments they need for their SSc symptoms. In addition, fatigued 
patients might be frustrated or disappointed by the care offered to them and therefore abstain 
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from consulting additional health care disciplines for a solution to their fatigue. Since fatigue 
has been found to be one of the main symptoms of SSc [1], our findings warrant specific 
attention to the impact of fatigue on visits to health care providers. 
This study has certain limitations that should be taken into account when interpreting the 
results. First, the level of health care use was based on a patient-reported outcome, potentially 
leading to recall bias. According to the literature [24,25], self-reported physician visits in the last 
year are less precise than computerized provider records and are biased due to underreporting, 
which is likely to increase as the number of visits increases. Thus, health care use in SSc might 
be even higher than described in this study. Furthermore, due to the use of patient-reported 
outcomes and the anonymous nature of the survey, it was not possible to verify the patient-
reported diagnosis. However, previous data show that patients with rheumatic diseases rarely 
report a diagnosis that is incompatible with their clinical diagnosis [26]. Finally, the sample in this 
study might not be reflective of the whole patient population because only members of the patient 
organization were included. However, with regard to demographic and disease characteristics, 
the patients in our study were comparable to another large and well-described Dutch sample [27]. 
A strength of the present study was the inclusion of a relatively large number of patients 
from all regions of the Netherlands, thereby avoiding geographical differences such as access 
to care biasing our results. In addition, a broad range of health care providers was included, 
providing a detailed and comprehensive insight in health care utilization in SSc. 
In conclusion, health care use in SSc in the Netherlands is substantial and involves a range 
of care providers. The involvement of a greater number of different disciplines in the care of 
SSc was associated with less patient satisfaction in terms of communication among health care 
providers and alignment of care. This implies that, for patients with a complex disease who 
receive care from multiple providers, attention should be given to the coordination of care, 
including communication among health care providers and synchronization of treatments.
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absTRaCT
objective 
Patients diagnosed with systemic sclerosis (SSc) report a high need for education and support. 
To address these needs, a short, group-based psycho-educational programme for patients 
with SSc was developed and evaluated. 
Methods 
A pre-post test design was utilized. Participants completed questionnaires on physical and 
psychological functioning. Furthermore, patients were asked to evaluate the content of the 
programme by questionnaire. 
Results
Data from 41 patients were available for analysis. Patients reported less helplessness after the 
intervention, and higher acceptance of their limitations. However, no difference in depressed 
mood and physical functioning was observed. Patients reported high satisfaction with the 
content of the programme. 
Conclusion
Despite the limited changes in psychological and physical functioning, this psycho-educational 
programme addresses patients’ needs reported in previous studies and therefore contributes 
to the improvement of care for patients with SSc. 
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InTRoDUCTIon
Systemic sclerosis (SSc, scleroderma) is a rare multisystemic connective tissue disease of 
unknown etiology, characterized by vascular abnormalities and fibrosis. The disease affects 
many areas of life resulting in high levels of disease burden in the individual patient [1]. The 
hallmark feature of SSc is thickening of the skin [2] caused by the fibrosis of connective tissue. 
The fibrotic process can affect internal organs and leads to morbidity and decreased life 
expectancy in the majority of the patients [2]. Although advances in medical treatment have 
been made, medical interventions as yet have a limited effect on disease progression and 
symptom manifestation [3]. In most patients, physical functioning is impaired [4,5] and patients 
report high levels of pain, fatigue, and impaired health-related quality of life [6,7]. In addition 
to these physical impairments and symptoms, the disease often results in psychological 
problems as well [8], including low appearance self esteem [9-11], problems adjusting to the 
disease [12], and increased levels of anxiety [13]. Not surprisingly, the prevalence of depressive 
symptoms in SSc is high, with 36 to 65% of patients scoring above a cut-off threshold on self-
reported questionnaires [14,15]. 
Apart from a high need for information about the condition and its treatment, high 
unmet needs of education and support about anxiety and stress, fear of the future, coping 
with symptoms, fatigue, feeling down, and change in appearance have been reported [16,17]. 
Therefore, the urgency to develop educational and psycho-educational interventions in 
patients with SSc is increasingly recognized [10,18]. 
As yet, little is known about the effect of psycho-educational interventions in SSc. In 
other rheumatic conditions, in particular rheumatoid arthritis (RA), psycho-educational 
interventions have been shown to be successful on functional disability, patient global 
assessment, psychological status, and depression [19]. One could expect a psychoeducational 
intervention to have similar effects in SSc as well. 
Only three published studies addressed interventions targeting psycho-social needs 
[20-22]. In two studies an interdisciplinary group education programme was described, whereas 
the third study described a cognitive-behavioural self-help programme for scleroderma, 
consisting of 2 in-person sessions and 5 telephone sessions with a psychologist and home 
assignments. The efficacy of a psycho- educational intervention in SSc was reported in only 
one study, including six patients [20]. Therefore, the current study was conducted to determine 
changes between pre- and post treatment in a larger sample of patients participating in a 
psycho-educational intervention for SSc. 
The short intervention under study was developed with the aims to increase patients’ 
knowledge about the disease and its treatment, to familiarise patients with multidisciplinary 
treatment options, and to facilitate patient interaction. 
The aims of this pre-post test study were to study the effects of the intervention on disease 
related cognitions, depressed mood, and physical functioning and to evaluate the patients’ 
satisfaction with the programme. 
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MeThoDs 
Development of the programme 
The intervention was based on one of the previously developed programmes [21], but tailored 
to the setting and results of earlier research in our hospitals. In a previous study, patients’ 
needs for education and support were assessed in all patients with a definitive diagnosis 
of SSc according to the preliminary ACR-classification criteria [23] under treatment in the 
rheumatology wards of the Sint Maartenskliniek and Radboud University Medical Center in 
Nijmegen, the Netherlands [16]. Patients rated their need for education and training of 16 
potential relevant topics at a 4-point Likert scale ranging from 1 (not at all) to 4 (very much). 
Results of this study revealed that many patients reported a need for professional support; 
78.6% of the patients indicated that they ‘much’ or ‘very much’ needed education or support 
(score 3 or 4) on at least one of the topics. The most frequently reported topics were information 
about the disease, information on medication, coping with pain, perception of the future, 
changes in appearance, information on social services, coping with stress, ADL scheduling 
and planning, interpreting signals of pain and fatigue, and alternative medicine, respectively. 
The results of this questionnaire study and the organisation of the programme were discussed 
in 3 individual interviews and a focus group including 6 patients. These patients indicated 
that they preferred a group based intervention of short duration, accessible for all patients, 
regardless of disease duration or physical status. They also suggested that the partner should 
be present when information about the disease is provided and that the programme should 
involve active elements like physical exercises. Finally, patients suggested that the sessions 
of the programme should address broadly defined topics as determined in an earlier study 
[16] and that interactive discussions should be encouraged. On the basis of these results, a 
multidisciplinary, group based psycho-educational programme was developed. 
Content of the programme 
Groups consist of 6 to 10 patients. The programme consists of modules of 1.5 hours each, 
covering 13 different topics, scheduled over three weekends. Patients are invited to bring their 
partner or a significant other person at the first day (Table III).
For each topic, a short protocol was written to give structure to the intervention. At the 
start of each session, the participating patients’ questions and problems related to that topic 
are individually assessed to determine the exact content of the session. 
The programme consists of the following broad topics: goal setting and evaluation (social 
worker), education about disease characteristics, diagnosis and treatment (rheumatologist), 
education about joint protection and energy conservation (occupational therapist), discussing 
psychosocial aspects of the disease (psychologist), and education about the benefits of 
exercise (physical therapist). Furthermore, an introduction lesson of Tai Chi was provided to 
give patients the opportunity to practice and experience this form of low intensity exercise. 
The detailed programme is available on request by the first author. 
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Patients and procedure 
Patients were informed about the intervention through publications in the magazine of the 
patient organisation and leaflets distributed by their attending rheumatologists. Patients with 
a diagnosis of SSc for more than one year were able to subscribe for the programme, or could 
be referred by their rheumatologist of the Sint Maartenskliniek and the Radboud University 
Medical Centre. It was chosen to include patients with a diagnosis of at least one year, to give 
patients the opportunity to acclimate to their diagnosis before participation. After subscription, 
an intake assessment took place with a social worker, nurse and psychologist. Information was 
given about the programme and its evaluation. The psychologist examined whether there 
were dominating psychopathological problems or whether patients had serious concerns 
about meeting other patients that made participation in a group impossible. The intervention 
was scheduled over 3 weekends. The measurements took place before, 6 weeks after the 
intervention and 6 months post-intervention. Between the three consecutive intervention 
weekends, there were no measurement occasions. 
Patient gave their oral consent. In the Netherlands, no approval from the medical ethics 
review board is required for studies with a pre-post test design utilising questionnaires. 
Measures 
Demographics. The following demographics were assessed: age, sex, disease duration, marital 
status and employment. 
Physical functioning was assessed with the Dutch version of the Scleroderma Health 
Assessment Questionnaire (SHAQ) [24], consisting of the Health Assessment Questionnaire 
(HAQ) [25] and 6 Visual Analogue Scales measuring subjective severity of disease symptoms. A 
VAS was added for fatigue, because this was rated as an important problem in previous studies 
[7,9]. The Disability Index score consists of 20 items, measuring 8 dimensions of functioning 
ranging from 0 (best function) to 3 (worst function). The mean of these scores can be 
calculated as an indicator of overall physical functioning (HAQ-DI). The HAQ was originally 
developed for use in Rheumatoid Arthritis and demonstrated good reliability and validity in 
patients with SSc [24,27]. 
Psychological mood was measured with the Depressed Mood subscale of the Impact of 
Rheumatic Diseases on General Health and Lifestyle (IRGL) [28], a Dutch questionnaire that is 
frequently used in patients with rheumatic conditions. Participants rate the extent to which they 
experienced six mood states (depressed, gloomy, disheartened, low spirited, disconsolate, and 
sad) during the last week, using a 5-point Likert scale ranging from 0 (not at all) to 4 (a lot). The 
six items are summed to calculate the depressed mood scale. Higher scores at this scale depict 
higher levels of depressed mood. A score > 4 on the Depressed Mood subscale of the IRGL 
represent clinical or subclinical depression. 
Illness cognitions were measured using the Illness Cognitions Questionnaire (ICQ) [29] 
and Acceptance Limitations Scale (ALS) [30]. The ICQ is an 18-item questionnaire measuring 
three generic illness cognitions: helplessness, acceptance, and disease benefits. Participants 
rate the extent to which they agree with the statements on a 4-point Likert scale, ranging from 
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1 (not at all) to 4 (completely). Higher scores at subscales reflect higher levels of agreement 
with that generic illness cognition. The scale has excellent construct and internal validity [29]. 
In this study we used the subscales acceptance and helplessness. The Acceptance Limitations 
Scale (ALS) measures acceptance of limitations perceived by the patient. The ALS is a 10-item 
questionnaire. Patients rate their agreement with the statements (e.g. ‘The limitations of my 
disease are annoying’) on a 4-point Likert scale ranging from 1 (totally disagree) to 4 (totally 
agree). The questionnaire has shown good internal consistency [30]. 
Coping was assessed using the active coping (7 items) and avoidant coping (8 items) 
subscales of the Utrechtse Coping List (UCL) [31]. All items are rated at a 4-point Likert scale 
ranging from 1 (seldom or never) to 4 (very often). Higher scores depict more use of the 
particular coping style. The UCL has shown to be valid and reliable [31]. The IRGL, ICQ, ALS 
and UCL have not been validated in SSc, and no information is available about validity and 
sensitivity to change in SSc. 
Patient satisfaction. A self-constructed single-item question was used to measure the 
usefulness of each distinct module. Three answers were possible: very useful, rather useful, not 
useful. In addition, a single item was used to ask patients about their experience of meeting 
other patients with SSc (“What was your experience meeting other patients?”). Five answer 
categories were available: very pleasant, pleasant, neutral, unpleasant, very unpleasant. 
Furthermore, for each distinct profession, the question was asked how well their individual 
questions were answered (answer categories: good, reasonable, bad). 
statistical analysis 
Descriptive statistics are provided as mean and standard deviation (SD) for continuous variables 
and percentages for categorical variables. Missing data were imputed using the last observation 
carry forward (LOCF) method. 
To test whether cognitions changed between pre- and post-treatment assessment, a 
repeated measures MANOVA was conducted with acceptance, helplessness, and acceptance 
of limitations as dependent variables, and time (3) as within-subject factor. Furthermore, 
repeated measures ANOVAs and posthoc tests were conducted on each cognition separately. 
A repeated measures ANOVA was conducted with depressed mood (IRGL) as dependent 
variable and time (3) as within-subject factor to test the hypothesis that depressive mood 
changed between pre- and post-treatment assessment. Furthermore, repeated measures 
ANOVAs were conducted with physical functioning (HAQ-DI), pain (VAS) and fatigue (VAS) as 
dependent variables respectively, and time (3) as within-subject factor. Significance levels were 
set at P < 0.05. In line with our specified hypothesis, all P-values reported are onetailed. Effect 
size (Cohen’s d) [32] was calculated for each variable. Cohen’s d could be interpreted as small (d 
= 0.2), medium (d = 0.5) or large (d = 0.8). 
All analyses were repeated with data of completers only. Since both methods revealed the 
same results overall, only the analyses using the LOCF method are presented. The Statistical 
Package for the Social Sciences (SPSS), Windows version 15.0 was used. 
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ResULTs
Participants 
Data were gathered between June 2006 and May 2009. In total, 46 patients attended an intake. 
Of these patients, three were advised not to participate as they suffered from serious emotional 
and psychopathological problems that were unrelated to SSc. Furthermore, one participant 
dropped out because of hospitalization after completing the first questionnaire and was 
excluded from analysis. One participant was excluded from analysis as a result of structural 
outliers in data (deviation of ≥ 1.5 IQR at more than 40% of the relevant measures). This patient 
died as a result of progression of SSc shortly after completing the last questionnaire. So, data 
from 41 patients of 6 groups were available for analysis. Patient satisfaction questionnaires were 
available from 36 participants. 
Demographics 
The majority of the participants were married woman of middle age, and one-third of the patients 
was employed at baseline (34%) (Table 1). Thirteen patients had a diagnosis of dSSc (31.7%), 26 
(63.4%) patients had lSSc and of 2 patients, disease type was unknown at baseline (4.9%).
Comparison of pre-, post and follow-up measures 
Table 2 shows mean scores on disease cognitions and depressed mood for each assessment. 
A repeated measures MANOVA with time (3) as within-subject factor and acceptance, 
helplessness and acceptance of limitations as dependent variables revealed a trend in change 
of cognitions, F(6,33)=1.74, P = 0.07. 
Acceptance did not change significantly over time. Compared to baseline, average levels of 
helplessness were lower at post-treatment assessment, F(1,40)= 6.0, P = 0.01 and 6 months after the 
intervention, F(1,40) = 4.7, P = 0.02. Acceptance of limitations scores decreased significantly between 
pre- and post-treatment assessment, F(1,40) = 4.0, P = 0.03 and after 6 months, F(1,40) = 9.2, P < 0.01. 
Because scores at this questionnaire are reversed, this decrease in average scores depicts an increase 
Table 1: Patient characteristics at baseline (N=41)
Mean age in years 52.8 (SD = 12.2, range = 23 - 76)
Mean disease duration in years 9.5 (SD = 10.5, range = 1 - 62)
Female 83%
Patients with limited SSc 63%
Currently employed 34%
Marital status
           Married 73%
           Never married 17%
           Divorced 5%
           Widowed 5%
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in acceptance of limitations. Effect sizes show that the improvement post-intervention as well as 
follow-up was of small magnitude for both helplessness (d = -0.32 and d = -0.26, respectively) and 
acceptance of limitations (d = -0.28 and d = -0.44, respectively). 
Changes in depressive mood were assessed with a repeated measures ANOVA with time (3) 
as within-subject factor and depressive mood (IRGL) as dependent variable. Results revealed 
no change in depressive mood. Also, no changes in physical functioning (HAQ-DI, pain, and 
fatigue) were found. Furthermore, there were no changes in coping (results not shown). 
Patient satisfaction 
Percentages on the usefulness of the different modules are displayed in Table 3. Results reveal 
high patient satisfaction with the content of the programme (75 – 92%), except for the session 
on Tai Chi (49%). 
The majority (80%) of the patients evaluated meeting other patients as very pleasant. Only 
one patient judged meeting other patients as unpleasant. Satisfaction with the answers on 
questions put forward by the participants ranged from 79 – 100% for the different topics. 
DIsCUssIon
The results of our study revealed that a psycho-educational intervention results in small 
changes in two disease-related cognitions: patients reported more acceptance of disease-
related limitations and less helplessness after the intervention. No changes were found in 
depressive symptoms, physical functioning, and coping. 
Table 2: Results of the repeated measures ANOVAs for cognitions and depressed mood
Mean (sD) 
Pre
Mean
diff 
[95% CI]
Post-Pre es*
Mean
diff 
[95% CI]
fU – Pre es* P**
Acceptance (ICQa) 15.7 (3.8) 0.53 [-0.43, 1.49] 0.13 0.75 [-0.14, 1.65] 0.21 0.13
Helplessness (ICQa) 13.1 (4.2) -1.24 [-2.27, -0.22] -0.32 -1.05 [-2.03, -0.08] -0.26 0.02
Acceptance of limitations (ALSb) 29.0 (4.9) -1.60 [-3.22, 0.02] -0.28 -2.24 [-3.73, -0.75] -0.44 0.01
Depressive mood (IRGLc) 4.2 (4.6) 0.13 [-1.07, 1.32] 0.02 -0.05 [-1.47, 1.37] -0.02 0.48
Physical functioning (HAQ-DId) 0.89 (0.6) 0.03 [- 0.07, 0.14] -0.06 -0.05 [-0.06, 0.17] -0.09 0.52
Pain (VASe) 30.2 (25.0) 2.41 [-4.5, 9.3] 0.10 2.97 [-3.2, 9.14] 0.13 0.58
Fatigue (VASe) 44.3 (23.1) -0.40 [-7.3, 6.5] 0.02 1.28 [-3.9, 6.4] 0.05 0.85
The intervention was scheduled over 3 weekends. The measurements took place before, 6 weeks after the 
intervention and 6 months post-intervention. Between the three consecutive intervention weekends, there 
were no measurement occasions.
ICQ, Illness Cognitions Questionnaire
ALS, Acceptance Limitations Scale
IRGL, Impact of Rheumatic Diseases on General Health and Lifestyle
HAQ-DI, Health Assessment Questionnaire-Disability Index
VAS, Visual Analogue Scale
*ES = M
post
-M
pre
 / SD
pooled 
(Negative sign denotes improvement)
**P-values reported: repeated measures ANOVA with time (3) as within-subject factor
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Table 3: Usefulness (% of patients rating ‘very useful’ and ‘rather useful’) of the different topics. 
% very useful % Rather useful
General
   Goal setting 83% 17%
Rheumatologist
   Characteristics of the disease 89% 11%
   Diagnosis 89% 11%
   Medical treatment 86% 14%
Physical therapist
   Theoretical background 83% 17%
   Exercises 89% 11%
   Relaxation training 75% 25%
   Tai Chi 49% 36%
occupational therapist
   Practical aids 89% 11%
   Individual questions 92% 8%
Psychologist
   Psychosocial aspects of disease 83% 17%
   Stress 75% 25%
   Social aspects 89% 11%
Remarkably, a discrepancy was found between change in acceptance of the disease and 
acceptance of limitations. Acceptance of the disease did not change between assessments, 
whereas acceptance of limitations improved. One possible explanation is that acceptance of the 
disease SSc is particularly hard to achieve because of the serious and possible life-threatening 
character of the disease. The disease might evoke abstract cognitions including worst case 
scenarios (e.g. early death), that are not easy to get to terms with. This suggestion is supported 
by an earlier study showing that acceptance of the disease in patients with SSc is lower than 
acceptance in patients with RA [15]. It could be argued that acceptance of consequences of the 
SSc in everyday life may be easier to achieve. 
In contrast to the effects of psycho-education in RA [19], no effect of the intervention on 
depressed mood was observed. One explanation is that psycho-education in general, and the 
intervention we developed in particular, does not target depressed mood using psychological 
intervention techniques such as used in cognitive-behavioural therapy. As a result, the 
intervention may be insufficient for patients with elevated levels of depressed mood in SSc. 
Our results can be generalised to other populations of SSc patients. Characteristics of 
participants concerning physical or psychological functioning, including coping in our study 
did not differ from a cohort of SSc patients in a previous study [9]. Therefore, it seems that the 
programme did not include patients with a specific physical or psychological profile. 
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To our knowledge, our study is the first evaluating the effects of a psycho-educational 
programme in a relatively large group of patients with SSc. However, the study is not without 
its limitations. Not having a comparison group limits the conclusions that can be made. As a 
result, the observed changes cannot be attributed to the intervention with absolute certainty. 
The lack of a control group in the present study makes it difficult to interpret and understand 
the observed changes. As yet, there are no data available on the stability of cognitions in usual 
care. Future intervention studies in patients with SSc should include a control group. 
Another limitation of the study is that we did not assess all variables that might be positively 
effected by the intervention, like fear for the future [16,17], use of non-pharmaceutical treatment 
options, and knowledge about SSc. 
Since this study reveals no changes in depressive mood, we suggest an alternative, 
more intensive intervention for patients with SSc suffering from depressed mood. As 
depressive mood is a common problem in SSc [14,15], development of such an intervention is 
recommended. Due to the heterogeneity of the disease, an intervention targeting depression 
should preferably be individual. Cognitive-behavioural interventions have shown to be 
effective in other rheumatic conditions, like RA [33]. Therefore, one would expect a cognitive-
behavioural intervention to be effective in decreasing depressed mood in patients with 
SSc as well. Also, the present intervention could be adapted to improve outcome. Possibly, 
increasing the period between the weekends or including a booster weekend could help 
patients to incorporate the information in daily life. 
In conclusion, although changes in psychological functioning were limited, this psycho-
educational programme addresses patients’ needs reported in previous studies [16,17] and 
therefore contributes to improvement of care for patients with SSc.
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TaILoReD CoGnITIve-behavIoURaL  
TheRaPy TaRGeTInG DePRessIon anD feaR  
of PRoGRessIon In sysTeMIC sCLeRosIs:  
a Case sTUDy
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absTRaCT 
objective
To illustrate an individually, tailored cognitive-behavioural protocol for the treatment of 
depressive symptoms and fear of progression in a patient with systemic sclerosis, and to 
preliminary study its effectiveness.
Methods
An intervention protocol consisting of an intake and 10 face-to-face sessions with a psychologist 
was developed based on cognitive-behavioural principles. Because of the complexity of 
symptoms and complaints due to systemic sclerosis, the psychological intervention was 
embedded in an interdisciplinary care program also consisting of physical therapy, occupational 
therapy, and specialized nurse care. A case study was conducted including a 53 years old female 
with a diagnosis of systemic sclerosis for 9 years. Diary measures utilizing visual analogue 
scales for depression, fear of progression, fatigue and pain were completed twice a week 
and validated questionnaires were completed pre- post and at follow-up. Primary outcome 
measures were depressive symptoms (Center for Epidemiologic Studies- Depression; CES-D) 
and fear of disease progression (Fear of Progression-Questionnaire Short Form; FoP-Q-SF).
Results
The diary measures showed no clear effect of the intervention. The post- and follow-up 
measures showed substantial changes decreases in depression and fear of progression. The 
secondary outcomes fatigue (Checklist Individual Strength; CIS) and helplessness (Illness 
Cognitions Questionnaire; ICQ) showed the most remarkable changes.
Conclusion
The presented intervention is an example and starting point for the treatment of depressive 
symptoms and fear of disease progression in systemic sclerosis and other progressive chronic 
somatic diseases. Elements of the presented intervention can be integrated in psychological 
care in medical health settings. The effectiveness of the intervention should be established in 
future studies.
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InTRoDUCTIon
Systemic sclerosis (SSc), or scleroderma, is a rare autoimmune disease, causing fibrosis of 
the skin and internal organs [1,2]. Patients experience, in addition to tightening of the skin 
and internal organ dysfunction, symptoms of Raynaud’s phenomenon, joint pain, digital 
ulcers and fatigue. Usually, two clinical subtypes are recognized based on the extent of skin 
involvement; limited SSc, with skin involvement distal to the elbows and knees, with or without 
face involvement and diffuse SSc, with skin involvement proximal to the elbows and knees, 
and the trunk also [3]. The rate of onset of SSc is the highest between the ages of 30 - 50 years, 
and women contract the disease 4 - 5 times more often than men [4]. Although the clinical 
manifestations of SSc vary widely across individuals, the disease is associated with a significant 
reduction in life expectancy, in particular for patients with internal organ involvement [5,6], 
with a median survival time from diagnosis of approximately 11 years [4]. 
Despite the recent progress in the medical treatment for patients with SSc, no cure 
is available yet. Therefore, non-pharmacological treatment by for instance physical and 
occupational therapists, and specialized nurses is often provided as an adjunct to medical 
treatment to support patients in managing the consequences of the disease [7]. However, 
although the need for psychosocial support is high in patients with SSc [8-10] and increasingly 
recognized by professionals [11], so far the evidence regarding the development and testing 
of psychological interventions is limited and focuses on psycho-education [12-14]. To the best 
of our knowledge, only one intervention using cognitive-behavioural techniques [15] for pain, 
depressive symptoms, and body image disturbance in patients with SSc was developed and 
tested, although the results of the study into its effectiveness study has not been published yet.
In addition to disease symptoms such as fatigue, impairments in physical functioning, stiffness 
of hands, and pain, recent studies found depressive symptoms to be common in patients with 
SSc [16,17]. In a review, 36-65% of the patients were found to be scoring above a cut-off threshold 
for possible depression on self-reported questionnaires, and depressive symptom scores were 
found to be associated with a variety of sociodemographic variables (e.g., unmarried, less 
education), disease-related factors (e.g., pain, breathing problems, gastrointestinal symptoms), 
and psychosocial factors (e.g., personality, coping, social support) across diverse studies [17].
Furthermore, patients have reported that concerns about the future are amongst the 
most important stressors. These concerns include uncertainty, fear of disease progression, 
and physical disability. Furthermore, patients reported unmet information and treatment 
needs in this area [9,10]. Since SSc is a highly unpredictable disease with serious consequences 
in most patients, disease progression is a realistic threat to them. A certain level of fear for 
disease progression is considered functional; it motivates patients, for instance, to take their 
medication, stop smoking or to physical exercise. However, if these concerns about the future 
overwhelm patients, it may have an impact on their current quality of life. In the latter case, 
concerns about the future, although based in reality, become dysfunctional [18]. For this 
dysfunctional fear of disease progression, therapeutic interventions might be indicated, aiming 
at reducing the fear to a functional level.
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In a recent study, the association between depressive symptoms and fear of disease 
progression were assessed [16]. Adjusted for sociodemographic variables and disease 
characteristics, depressive symptoms and fear of progression were found to be robustly 
associated with each other, implying that these factors might need to be targeted in 
psychological therapies together. Furthermore, the independent association of pain and fatigue 
with depressive symptoms, suggest that these psychological therapies should preferably be 
accompanied with physical therapy, occupational therapy and/or specialized nurse care.
To address the need for support regarding depressive symptoms and concerns about the 
future in patients with SSc, we developed an individually based, tailored, face-to-face cognitive-
behavioural intervention targeting these issues, embedded in an interdisciplinary care program. 
Cognitive-behavioural therapy has shown to be effective in the treatment of depressive 
symptoms across various chronic diseases, including rheumatic diseases [e.g., 19-21]. Also, 
it has been reported that cognitive-behavioural group therapy is effective in reducing fear of 
progression in patients with cancer [18]. However, positive effects of the latter intervention were 
not confirmed in a group of patients with chronic arthritis [22], possibly due to different disease 
characteristics of arthritis compared with cancer. Therefore, the development of an intervention 
that specifically targets depressive symptoms and fear of disease progression in SSc is warranted. 
A single-case study was conducted to preliminary assess the effectiveness of the intervention. 
Single-case designs are increasingly recognized as a valuable alternative to randomized 
controlled trials in studying the feasibility and preliminary effectiveness of interventions, in 
particular for rare diseases like SSc [23,24]. Furthermore, single-case studies provides therapists 
with insight in the course of symptoms over time before, during and after treatment [25]. 
The following case study is presented as an illustration of the development and content of an 
individually, tailored cognitive-behavioural protocol for the treatment of depressive symptoms 
and fear of progression in patients with SSc, and a preliminary study into its effectiveness.
InTeRvenTIon
Development 
An individually, tailored intervention protocol was developed with the overall aim to decrease 
levels of depression and fear of disease progression. In general, the intervention was based 
on cognitive-behavioural techniques that have proven to be effective in the treatment of 
depression in chronic diseases [19,20,26]]. Furthermore, literature was searched for existing 
psychological interventions on fear of progression. One treatment protocol was kindly 
provided by its developer [21,22]. Both the depression and fear of progression protocol were 
adapted for use in patients with SSc. For instance, the rare and unpredictable nature of SSc was 
addressed, as well as homework assignments tailored to the experience of living with SSc. 
Although the intervention was provided following a treatment protocol, the therapist 
could choose to emphasize on certain aspects of the intervention (such as behavioural 
components or cognitive components) more than others based on the functional analysis of 
the patients’ main problems.
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structure 
The intervention protocol consists of an intake, followed by a module of 5 sessions targeting 
depressive symptoms and a module of 4 sessions targeting fear of disease progression. 
Relapse prevention and evaluation are targeted in the final session. Thus, the total intervention 
including intake, consisted of 11 face-to-face sessions with a psychologist. 
Because of the complexity of the disease, and the high unmet health care needs also in 
the physical domain [8,11], the psychological intervention was embedded in an interdisciplinary 
care program. In addition to the psychological intervention, the interdisciplinary treatment 
consisted of physical therapy, occupational therapy and specialized nurse care, tailored to 
the patients’ needs and individual treatment goals, following evidence-based guidelines and 
best clinical practice. Physical therapists educate patients on the importance of exercising 
and relaxation, and instruct them how to perform exercises. Occupational therapists instruct 
patients how to prevent contractures of the hands and mouth, and educate patients about joint 
protection and the use of aids and devices. A specialized nurse educates the patients about 
medication and skin care.
Intake 
The patient for the present study was selected from the longitudinal cohort study “Psychological 
factors in scleroderma”, of which details are described elsewhere [16]. Additional to the in- and 
exclusion criteria of the cohort study, inclusion criteria for the intervention were: 1) a score ≥ 16 
on the Center for Epidemiologic Studies- Depression (CES-D) [27] at two consecutive measures 
(6 months), 2) a score ≥ 34 on the Fear of Progression-Questionnaire Short Form (FoP-Q-SF) 
[28,29], and 3) a one-way travel time of ≤ 60 minutes to our hospital.
Since patients were invited based on their questionnaire scores, an interdisciplinary intake 
was provided to check for eligibility of the intervention. It was checked whether there were 
indeed clinically significant symptoms of depression related to SSc, and whether there was a 
dysfunctional level of fear of disease progression, for which treatment was indicated.
The psychologist and specialized nurse conducted a psychosocial intake together. They 
provided information about the intervention, assessed the case history, assessed the aims, 
goals, and patients’ expectancies of the treatment. The physical and occupational therapist 
conducted an intake together to make an inventory of physical health care demands. A 
rheumatologist checked for contra indications for the treatment programme (e.g. major organ 
failure). Following the intake, an interdisciplinary decision was made to determine whether the 
intervention was eligible, and the frequency and duration of other interventions additional 
to the psychological intervention. Then, the psychologist and researcher discussed their 
treatment plan with the patient. 
Case description
Patient A. is a female, aged 53 years, who lived alone but was in a relationship. She was 
diagnosed with diffuse SSc for almost 9 years and worked at an office for 30 hours a week. 
Physical problems included impaired hand function and pain and stiffness of joints in the upper- 
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and lower extremities, especially after exercise. Although she used to be an avid sportier, she 
had to stop with that because of her symptoms. 
Patient A. experienced symptoms of depression, notably sadness, feelings of helplessness 
and hopelessness, and diminished interest in activities. At baseline, patient A. had a score of 27 
on the CES-D (Table 1). She experienced problems with acceptance of the disease and showed 
denial of her complaints. She did not talk about her disease to others, and felt she could not live 
the life she wanted to. These coping strategies exhausted her, as is also reflected in her score 
on the Checklist Individual Strength (CIS) [30] (Table 1). Thus, goals for the intervention were to 
increase acceptance of the disease and decrease feelings of depression. Furthermore, Patient 
A. wanted to express her feelings about the disease more often to others.
Concerns about the future were also present regarding both work and personal life. At 
baseline, patient A. had a score of 34 on the FoP-Q-SF (Table 1). Patient A. had a strong believe 
that, when her symptoms increased, it was her own fault, and felt she had done something 
wrong. She tried to change her situation through excessive physical training, which led to an 
increase of her symptoms. For instance, she forced herself to walk at least 100 stairs everyday 
despite her symptoms and had a strong believe this prevented her from progression of the 
disease. Therefore, one of the goals formulated by the therapist was, to give the patient insight 
into which factors related to SSc she could influence, and which not. 
 In addition to the psychological intervention, the nurse care focused on activity pacing 
and energy distribution. The occupational therapist focused on hand exercises, and aids and 
devices to help with daily activities, in particular related to hand function. The physical therapist 
focused on posture, especially during walking. Also, sport activities were explored, including 
hydrotherapy, and relaxation exercises were provided. 
session 1-5: depressive symptoms 
The treatment module on depressive symptoms started with goal setting and assessing the 
experience of the patient with the disease. If applicable, these goals were divided into smaller, 
concrete and attainable goals to facilitate behavioural changes. 
For patient A., one goal formulated was “feeling more relaxed”. Concrete steps how to reach 
this goal were explored. For instance; “taking a break even if the house has not been cleaned 
yet”, and “having a more balanced activities plan”. Other steps focused on cognitive changes, 
such as “being satisfied with the things I have done today” instead of “being unsatisfied what 
I did not achieve”. Talking about her goals was already a new experience for patient A. The 
therapist encouraged her to think ‘out of the box’.
The first homework assignment was, to write a story about “Me and my scleroderma”. This 
assignment was discussed in the second session, and feelings of depression and other emotional 
responses to the disease were validated and normalized by the therapist. Previously used coping 
strategies were explored, and discussed why some of them worked but others did not.
This assignment was very confronting for patient A. She could barely stand to talk about 
herself for 60 minutes, as she felt very uncomfortable being in the center of interest. She felt 
vulnerable to talk about her emotions and cognitions related to the disease. Therefore, the 
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session was shortened to 40 minutes and the assignment was continued in the next session. The 
therapist tried to follow the pace of the patient, and she was asked to give feedback about the 
session afterwards. This gave patient A. a feeling of control in the exposure to her cognitions. 
Sadness and depressive feelings increased during this stage of the treatment. 
Homework consisted of exploring alternative ways of coping with problems. In the third 
session, the therapist provided insight into the patients’ coping strategies and activities.
This assignment gave direction to behavioural changes; patient A. experienced for instance 
that timely breaks were helpful to her, in contrast to doing everything at the same pace. 
After the third session, the homework assignment consisted of a registration of activities 
and mood. Patients with few activities should be motivated to be more active if applicable. 
If this is not indicated, patients could be stimulated to focus on valued activities. Also, the 
concept of cognitive restructuring was introduced in the fourth session. 
For patient A., activation was not indicated. She led a quite active life, both in her work and 
socially. Therefore, the assignment focused on activities that the patient valued and liked to do, 
called the ‘pearls’ of her life. 
The homework assignment after session 4 was, to focus on these valued activities (‘pearls’) 
and try to implement more valued activities in her daily routine. At the beginning of each 
following session, starting with the fifth session, positive changes in activities were encouraged 
and obstacles for not being able to perform valued activities were assessed. 
Patient A. was increasingly able to name the ‘pearls’ in her life. Furthermore, at this stage, 
she tried to inform her partner about the process she was going through. Although the 
therapist asked patient A. multiple times to bring her partner to a session, she refused because 
she did not want to be a burden for him. Actually, this was a more general cognition; “I do not 
want to be a burden for other people” and “If I complain about my disease, others will think I 
am whining”. Cognitive restructuring focused on these cognitions, and patient A. was able to 
recognise that not telling anything could also be a burden to others. 
At this point of the intervention, patient A. found the treatment emotionally difficult. 
The insight into her cognitions and behaviour increased, but it took longer to implement the 
desired behavioural changes. This led to feelings of frustration and defeatism. In session 5, 
this process was validated and normalised. The desired behavioural changes were divided in 
smaller, attainable goals. For instance, one of the goals was, to communicate more often about 
her needs at work. During the session, this was made more concrete and restricted in time: it 
was discussed to which colleague she wanted to talk first about her disease, and when in the 
upcoming week would probably be an appropriate moment to do so. 
session 6-9: fear of progression 
The homework assignment for session 6 was a reading text on concerns about the future, 
and the registration of situations and thoughts regarding fear of progression. The session 
started with the explanation of functional versus dysfunctional fear. Furthermore, cognitive 
restructuring was practiced, and patient A. was encouraged to fill out thought records at home. 
If there were cognitions about situations that can be solved with a practical solution, this was 
CBT TARGETING DEPRESSION AND FEAR OF PROGRESSION
8
113
encouraged. For instance, if the patient was worried about what might happen with her assets 
when she dies, she was encouraged to make a notarial will. 
Patient A. filled out at least two thought records every week. The exposure to her thoughts 
and concerns about the future was experienced as very confronting and led to an instant 
increase in fear and depressive symptoms. Cognitions were for instance “I am stuck in this job 
I do not like, because of my scleroderma” and “I must not show scleroderma-related problems 
at work, otherwise they will fire me”. Also strong cognitions regarding her own influence on 
disease progression were present, such as “I have to walk 100 stairs everyday to prevent my 
lungs to be affected by the disease”.
In sessions 7 and 8, cognitive restructuring was expanded, and the patient was encouraged 
to make behavioural changes accordingly. Important to note is that the therapist should be 
aware that concerns about the future could be realistic, resulting from the progressive nature 
of SSc. Thus, the aim is to reduce this fear to a functional, manageable level, not to resolve fears 
completely. For this purpose, it can be helpful to assess the worst case scenario together with 
the patient and explore what is needed to regain confidence that she can handle this situation if 
it might become truth in the future, or whether it is helpful to worry about it at this point in time. 
Patient A. experienced through the process of cognitive restructuring, that she was not a 
victim of her disease, but that she could make her own choices. Instead of thinking “I am stuck 
in this job I do not like, because of my scleroderma”, she reformulated the cognition “I choose 
to stay in this job, since financial certainty is important to me”. She was more open about her 
disease at work, and was able to discuss with her employer what she needed to be able to 
function at work. Her fear that she would be dismissed because of this, had reduced. 
It was also easier for her to communicate to her partner about her wishes and needs. In case 
of stress, she tried to actively solve the situation that caused it, instead of linger on it. About 
her disease, she said “I am not sick but have a condition, and it does not have to be a drama”. 
Furthermore, she stopped with her excessive physical training. For instance, instead of 
taking the stairs, she used the elevator more often, and said that it had become easier for her 
to ‘permit’ it to herself. 
In the last session of the fear of disease progression module, patient A. was asked to think 
about the most important values in life, and about ways her behaviour should change to 
emphasize these values more. In addition, the toolbox model was emphasized, and patient A. 
was asked to think about the ‘tools’ that she had learned during therapy and described them in 
the homework assignment. 
These exercises were again very confronting to Patient A., but helped her to give direction 
to her life. One of the values for Patient A. was, “to make other people happy”. To put more 
emphasis on this value in her life, she intended to orientate on volunteer work.
session 10: relapse prevention 
In the final session, the therapist and patient evaluated the intervention and developed a relapse 
prevention plan, including signs of possible relapse, risk factors for relapse and resources to 
prevent or resolve relapse of symptoms of depression and/or fear of progression.
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The ‘tool’ that Patient. A. found most helpful, were the thought records. She continued to 
complete these records after the intervention. Furthermore, she was eager to continue her 
increased communication skills both at work and in her private life. In general, she had learned 
to take better care of her body, through the use of aids and devices, but also in terms of taking 
the elevator more often or stop cycling to work in winter. 
Patient evaluation
After the intervention, Patient A. evaluated the intervention as very valuable and helpful, and 
graded the intervention an 8 out of 10 points. She described that she gained more insight into 
her own thoughts and behaviour. Although it had been very confronting to her, and emotionally 
challenging, she felt herself supported by the therapist through this process. 
She said that after the intervention she takes better care of her body. For instance, she 
bought heated gloves to keep her hands warm and prevent herself from getting a Raynauds’ 
attack. In general, she was more able to adjust her behaviour to her physical needs, for instance 
stopped forcing herself to walk 100 stairs everyday despite her symptoms. 
The communication with her partner and friends about her disease and physical limitations 
had improved substantially. This was also true at work, where her employer complimented her 
with her increased communication skills. 
In the final session of the intervention, patient A. told that she had gained confidence that she 
had enough tools to continue working on her psychological process without the therapists’ help. 
PReLIMInaRy effeCTIveness 
Method 
The preliminary effectiveness of the intervention was studied using a single-case design. In this 
design, patients complete questionnaires at multiple occasions during a baseline phase (A), 
treatment phase (B) and follow-up phase (A’). In our study, 50 measurements were completed 
in 24 weeks, starting after the intake. To increase internal validity, the starting point of the 
intervention was randomized between the 8th and 16th measurement occasion (4 to 8 weeks) 
[31]. The study was approved by the medical ethics board (CMO 2009/231; ABR NL28603.091.09).
Diary measures 
Twice a week, a short questionnaire consisting of 8 visual analogue scales (VAS, ranging 
from 0-100) was completed. Pain and fatigue were measured using straightforward questions. 
For the measurement of depression, fear of progression and appearance self esteem, the 
two questions with the highest factor loading were extracted from validated questionnaires 
measuring depression (CES-D), fear of progression (FoP-Q-SF), and appearance self-esteem 
(State Self Esteem Scale; SSES) [32], respectively. These items were determined in a cohort 
study including 215 patients with SSc, which is described elsewhere [16]. Depressive symptoms 
(sadness and depressed feeling) and fear of progression (disease progression and fear that 
medication damages the body) were the primary outcome measures.
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Questionnaires 
In addition to the VAS measures, validated questionnaires on depressive symptoms (CES-D), 
fear of progression (FoP-Q-SF), general anxiety (shortened version of the Dutch Spielberger 
State Trait Anxiety Inventory; STAI) [33,34], coping (Coping Inventory Stressful Situations; CISS) 
[35], cognitions (Illness Cognition Questionnaire; ICQ) [36], fear of negative evaluation (Fear 
of Negative Evaluation; FNE) [37], fatigue (Checklist Individual Strength; CIS8r), and physical 
functioning (Scleroderma Health Assessment Questionnaire; SHAQ) [38,39], were completed 
before the intake, after the intervention and at 6 months follow-up. 
statistical analysis 
For each treatment phase, the autocorrelation between the diary measures was assessed using 
the lag one method. In case of significant autocorrelation, a moving-average transformation 
was performed, taking the previous and following data points into account [40]. For the two 
depression measures, means were calculated at each assessment point, because of the overlap 
in the items’ contents. Using the 2SD-band method [40], data were visualized and inspected. 
If two or more successive data points in phase B or A’ fell outside the band, results were 
considered to be statistically significant. Statistical analyses were conducted using Stata/IC 10.1 
software (StataCorp LP, College Station, TX).
ResULTs
Diary measures 
Figure 1 depicts the combined VAS scores for depressive symptoms over time, as well as the 
two fear of progression measures. Visual inspection and the 2-SD band interpretation does not 
show changes in the depression measures. For fear of progression, after an initial increase just 
before the intervention phase, a small decrease is visible, although not confirmed by the 2SD 
band-interpretation. The figure depicting the VAS on fear that treatment damages the body 
shows a small but significant decrease. For the secondary outcome measures on pain and 
fatigue, no significant changes are observed. 
Questionnaires
The questionnaire scores on the pre-, post- and follow-up measures are displayed in Table 1. 
Compared to pre-treatment, the depression score decreased on the post treatment measure (11.1%) 
and follow-up measure (-22.2%). At follow-up, the score is below the cut-off threshold for probable 
depression (CES-D ≥ 19), but still above the cut-off threshold for possible depression (CES-D ≥ 16). 
Fear of progression scores also decreased post-treatment (20.6%). Of the secondary outcomes, the 
largest changes were a decrease in helplessness (-44.4%) and fatigue (-46.0%) at follow-up. 
DIsCUssIon
The current case study illustrated the implementation and preliminary effectiveness of an 
individually tailored intervention targeting depressive symptoms and fear of disease progression 
CBT TARGETING DEPRESSION AND FEAR OF PROGRESSION
8
116
Figure 1: VAS measures for depression 
(combined, A) and fear of progression (B 
and C) with 2-SD band graph for baseline, 
intervention and post-intervention phases. 
Scores on the range from 0 to 100; higher 
scores indicate more depression and fear of 
progression, respectively.
A
C
B
in a patient with SSc. Although the diary measures showed no clear effect of the intervention, 
the post- and follow-up measures showed substantial changes on questionnaire scores. Scores 
on the primary outcome measures depression and fear of progression decreased, although the 
score for depression was still above the cut-off for possible depression at follow-up. The most 
remarkable changes in questionnaire scores were the decrease in fatigue and helplessness. 
Since the psychological intervention was integrated in an interdisciplinary treatment setting, 
these changes might be attributable to the other interventions as well. Studies including more 
patients are warranted to further examine the effectiveness of the intervention. 
It might be challenging for therapists to decide for which patients treatment of fear of disease 
progression is indicated. Since SSc is a progressive disease, fears might be realistic. Also, an 
avoidant coping strategy might be functional and helpful to cope with the uncertainty about the 
future, and might not need any interventions from therapists. In our opinion, fear of progression 
is dysfunctional and needs treatment if a patients‘ current quality of life is substantially impaired 
because of the fear of progression, for instance through excessive worrying, sleeplessness or 
social withdrawal, treatment might be indicated. Also, if a patients’ behaviour is potentially 
harmful treatment might be indicated, as with Patient A. for whom the forced manner in which 
she physically exercised led to exhausting and an increase in symptoms, or if a patient withdraws 
from appropriate health care, for instance through avoidance of medical examinations.
Treating fear of progression in a chronic disease might be challenging for a therapist as 
well. One particular aspect of fear of progression, notably fear of death, could be considered as 
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a universal fact that also relates to the therapists’ own vulnerability. As a therapist treating FoP, 
avoidance of this topic, or getting overwhelmed by your own emotions might be important 
pitfalls, and are not helpful for the patients’ treatment. Furthermore, the intervention as 
described turned out to be very confronting to the patient, and led to an instant increase in 
emotions, that were very intense. However, after the confrontation, these emotions decreased 
and a balance in emotions was regained. For therapists, it is important to validate and normalise 
this process to the patient, instead of being worried about this increase of emotions [41]. 
Table 1: Pre- post and follow-up mean scores 
outcome variable Range Pre-treatment
Post-treatment  
(% change)
follow-up  
(% change)
Depression (CES-D)* 0-60 27 24 (-11.1%) 21 (-22.2%)
Fear of progression (FoP-Q-SF)* 12-60 34 27 (-20.6%) 27 (-20.6%)
Coping (CIss)
 Emotion focused 16-80 59 53 (-10.2%) 51 (-13.6%)
 Problem focused 16-80 59 67 (+13.6%) 57 (-3.4%)
 Avoidance 16-80 46 40 (-13.0%) 46 (0.0%)
Cognitions (ICQ)
 Acceptance 6-24 14 16 (+14.3%) 18 (+28.6%)
 Helplessness 6-24 18 15 (-16.7%) 10 (-44.4%)
Anxiety (STAI short form) 10-40 29 26 (-10.3%) 24 (-17.2%)
Fear of negative evaluation (FNE) 12-60 56 46 (-17.8%) 52 (-7.1%)
Physical functioning (HAQ-DI) 0-3 0.75 0.88 (+17.3%) 0.63 (-16.0%) 
Fatigue (CIS8r) 8-56 50 32 (-36%) 27 (-46.0%)
* Primary outcome measures
Figure 2: VAS measures for pain (A) and fatigue (B) with 2-SD band graph for baseline, intervention and post-
intervention phases. Scores on the range from 0 to 100; higher scores indicate more pain and fatigue, respectively.
A B
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The intervention as described in the present study includes complicated processes, which might 
need more time to change than the follow-up time of the present study, in particular for the diary 
measures. The relatively short (10 sessions) intervention is however very suitable to start up this 
process, in particular in hospital (secondary care) settings. For some patients, the intervention might 
be too short and referral to a primary care clinic after these sessions might be indicated.  
The results of the preliminary study into the effectiveness of the intervention are difficult 
to interpret. The diary measures showed no clear patterns of changes whereas the pre-post 
design using standardized questionnaires revealed positive changes in the primary and some 
of the secondary outcomes, notably fatigue and helplessness, after the intervention and at 
follow-up. This discrepancy in results might be due to the nature of the instruments used. Visual 
analogue scales are usually used to assess the current state of an outcome (e.g., pain, health, 
fatigue), while questionnaire scores are considered a relatively stable measure of outcomes 
[42]. In addition, a study in patients in the immediate postoperative period showed, that the 
repeatability of a VAS on pain was low, with an individual imprecision of ±20mm [43]. It remains 
to be elucidated whether the variability of the diary measures in the present study reflected real 
fluctuations in symptoms, or whether it is due to the measurements used. 
We believe this intervention is an example and starting point for treatment of fear of disease 
progression in other chronic somatic diseases also. These might include other rheumatic 
diseases as well as for instance diabetes or multiple sclerosis, in which fear of progression was 
also found to be an important stressor [44,45]. Although the effectiveness of the intervention 
should be established in future studies, elements of the intervention can be integrated in 
psychological care in medical health settings. 
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sUMMaRy anD GeneRaL DIsCUssIon
9
This thesis focused on psychological well-being in patients with systemic sclerosis (SSc). The 
studies described in this thesis were designed with the overarching aim to improve the assessment 
of health-related patient-reported outcomes (HR-PROs; Part I), and to develop and test non-
pharmacological interventions for patients with SSc (Part II). In this final chapter, the results of the 
studies described in this thesis are summarized and discussed, focusing on the limitations of the 
presented studies, implications for clinical practice and future directions for research.
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sUMMaRy
Part I: assessment
For all studies of Part I, the baseline data of a longitudinal cohort study were used. In this cohort 
study, 215 patients were included. All patients had a definitive diagnosis of SSc according to 
the preliminary American College of Rheumatology classification criteria and were under 
treatment of the Rheumatology departments of the Sint Maartenskliniek or Radboud University 
Medical Center Nijmegen, the Netherlands. The participants completed sets of physical and 
psychological questionnaires every 6 months over 3 years. Furthermore, a number of disease 
characteristics were assessed by a rheumatologist (e.g., modified Rodnan Skin Score (mRSS)) at 
baseline. Exclusion criteria for participation in the cohort were a life expectancy of less than a 
year (because of the burden of the study), acute serious complications (e.g., acute renal crisis), 
severe psychiatric comorbidity (e.g., severe substance abuse, psychosis or dementia), other 
serious comorbidities (e.g., cancer) and insufficient knowledge of the Dutch language. The 
attending rheumatologist assessed whether a patient met one or more of the exclusion criteria 
based on clinical experience, using a checklist stating the exclusion criteria. The baseline data 
were collected between June 2008 and February 2010. 
In Chapter 2, the prevalence of depressive symptoms and its associated sociodemographic, 
disease-related and psychosocial factors were studied. In our sample, one-third of the patients 
scored above a cut-off threshold for possible depression (CES-D ≥ 16), and 25% scored above the 
threshold for probable depression (CES-D ≥ 19), which was comparable with the prevalences that 
were found in previous studies. Furthermore, results of the study revealed that factors associated 
with depressive symptoms were mainly in the psychosocial domain. In addition to more 
fatigue and pain, less satisfaction with social support, and more emotion-focused coping and 
helplessness were also significantly associated with more depressive symptoms. Moreover, higher 
fear of progression was associated with more depressive symptoms and a marginally significant 
association was found with lower appearance self-esteem. These results suggested that, in 
addition to assessment of disease characteristics, attention should be given also to psychosocial 
factors found to be associated with depressive symptoms. Furthermore, for the development and 
testing of psychological interventions, fear of progression could be an important target.
In order to improve patient-centered care, accurate measurement of outcomes important 
to patients is crucial. Since fear of progression was found to be highly associated with depressive 
symptoms and might be a possible target for interventions, we validated the Dutch version of 
the Fear of Progression Questionnaire- Short Form (FoP-Q-SF) as described in Chapter 3. The 
FoP-Q-SF was originally developed in Germany to assess fear of disease progression in patients 
with diabetes, breast cancer and rheumatoid arthritis. Based on the standards described by 
the Consensus-based Standards for the selection of health status Measurement Instruments 
(COSMIN) checklist, we assessed floor-and ceiling effects, internal consistency and factor 
structure, and examined the construct validity by testing 12 hypotheses on correlations 
of the FoP-Q-SF with other questionnaires. No floor- or ceiling effects were found, and the 
original one-factor structure was confirmed in our sample. Cronbach’s alpha was satisfactory. 
SUMMARY AND GENERAL DISCUSSION
9
125
Moreover, since most of our a priori hypotheses (> 75%) were confirmed, the FoP-Q-SF could 
be considered a valid measure of the construct in SSc. As hypothesized, high correlations 
were found between FoP-Q-SF scores and general measures of anxiety, depressive symptoms, 
and mental health and small to moderate correlations with physical functioning and pain. The 
results of the study demonstrated that the FoP-Q-SF is a useful and valid instrument for the 
measurement of fear of disease progression in patients with SSc. Since fear of progression was 
found to be one of the most important stressors in SSc in previous studies, a valid measure is a 
prerequisite for building up knowledge regarding this stressor. For instance, the FoP-Q-SF can 
be used as an outcome measure in intervention studies targeting fear of disease progression. 
In SSc, initiatives to improve health care often requires multi-center and international 
collaborations, because of the rare nature of the disease. Thus, results obtained with HR-PRO 
measures are often pooled across nations and languages. Less often, however, the cross-
linguistic and cross-cultural measurement equivalence of HR-PRO measures has been assessed. 
Measurement equivalence means, that individuals from different groups with similar levels of 
an outcome of interest (e.g., fatigue), should obtain equal scores on the measure and respond 
similarly to individual items of the measure. In Chapter 4, the cross-linguistic measurement 
equivalence of the Center for Epidemiologic Studies Depression (CES-D) scale was examined 
between English-speaking Canadian (N = 922) and Dutch (N = 213) SSc patients utilizing the 
Multiple-Indicator Multiple-Cause (MIMIC). Small-magnitude differential items functioning 
(DIF) was found for 4 of 20 items on the CES-D. The English-speaking Canadian sample endorsed 
more feeling-related symptoms (item 3, “blues” and item 4, “good”), whereas the Dutch sample 
endorsed more somatic/retarded activity symptoms (item 7, “effort” and item 20, “get going”). 
It is possible that this is related to cultural differences in how symptoms are experienced or 
expressed. It is also possible, however, that these differences may be related to translation. 
However, the overall estimate in depression latent scores between English and Dutch was not 
influenced substantively by DIF. Thus, although there were several CES-D items with evidence of 
minor DIF between the English and Dutch sample, there was no evidence that these differences 
influenced overall scores. Therefore, CES-D scores from English-speaking Canadian and Dutch 
SSc patients can be compared and pooled without concern that measurement differences may 
substantively influence results. 
In addition to HR-PROs reflecting narrow constructs like fear of progression or depression, 
HR-PRO measures could also reflect complex constructs, such as health-related quality of 
life. The EQ-5D and SF-6D are self-administered utility measures, designed to assess value of 
health in a single summary measure with a value of 0 for a health state equivalent to death 
and 1 for perfect health. Utility measures cover different domains of health related quality of 
life that might be influenced by (chronic) diseases, for instance pain, physical limitations, and 
mental health, and are increasingly used in economic evaluations of treatments and policy-
making. Although the EQ-5D and SF-6D are frequently used and considered as well-established 
measures of utility, the interchangeability of the two measures generally is low. This decreases 
the comparability of (cost-) effectiveness studies tremendously, and might lead to different 
resource allocation decisions. Therefore, in Chapter 5, we assessed agreement, compared the 
SUMMARY AND GENERAL DISCUSSION
9
126
validity and estimated minimal important differences (MID), effect sizes (ES) and standardized 
response means (SRM) of the EQ-5D and SF-6D utility measures in patients with SSc. For this 
purpose, in addition to the baseline measure (N = 211), also the one-year follow up (N = 154) 
measure of our cohort was used. The moderate agreement we found in our sample, especially 
for lower scores (including about 10% of the sample), implies that caution is needed when 
interpreting and comparing results that are obtained with the EQ-5D and SF-6D, especially for 
patients with low utility scores. Furthermore, we found that the responsiveness (SRM and ES) 
of the SF-6D was structurally larger than for the EQ-5D, especially for the improved subgroups. 
This might indicate that, since treatment induced health gains in SSc are usually small, the 
SF-6D should be preferred over the EQ-5D to assess treatment outcomes in SSc, although the 
EQ-5D was better regarding its construct validity compared with the SF-6D.
In conclusion, in Part I, we found that factors associated with depressive symptoms were, in 
addition to pain and fatigue, mostly in the psychological domain, and included fear of disease 
progression. An instrument to measure fear of disease progression, the Dutch FoP-Q-SF was 
found to be valid in patients with SSc, and helps building up knowledge regarding this stressor 
in SSc. Another HR-PRO measure that is often used in SSc is the CES-D, an instrument to assess 
depressive symptoms. Results of our study assessing whether CES-D scores were influenced by 
translational or cultural differences between English-speaking Canadian and Dutch patients with 
SSc revealed, that the total CES-D score was not substantially influenced by this. Thus, CES-D 
scores from these samples can be compared and pooled without concern that measurement 
differences may substantively influence results. Finally, we compared two generally accepted 
utility measures, notably the EQ-5D and SF-6D, and concluded that the SF-6D might be preferred 
over the EQ-5D to assess treatment outcomes, because of its larger responsiveness. 
Part II: Treatment
Part II of this thesis focused on the treatment of patients with SSc. Systemic sclerosis is a complex 
disease, with many different consequences for patients. Disease symptoms in patients with SSc 
often needs multidisciplinary treatment. However, knowledge on health care utilization of patients 
is scarce and was not yet comprehensively assessed in any European country. Furthermore, since 
patients have described high health care needs amongst various areas in previous studies, the 
development and testing of interventions targeting these needs is warranted. 
In Chapter 6, health care utilization and patients’ perspectives on the quality of health care 
were examined. Patients with SSc, recruited by the Dutch patient organization (NVLE) completed 
an anonymous survey assessing health care utilization, quality of care and quality of life in a 
cross-sectional design (N=198). According to the results of this study, 95% of the patients had 
contact with at least one medical specialist in the last 12 months, and two-third contacted at least 
one health professional (HP). The median numbers of different disciplines contacted since the 
onset of SSc and in the last 12 months were 8 and 4, respectively. The median numbers of visits to 
medical specialists and HPs during the last year were 7 and 7.5, respectively. Having a partner and 
reduced physical health status were significantly associated with more visits to medical specialists 
and HPs. Surprisingly, patients with less fatigue contacted more disciplines, as well as patients 
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with higher pain scores. A higher number of disciplines involved in the care was significantly 
associated with less satisfaction with cooperation and alignment of care. These results showed, 
that health care utilization in Dutch patients with SSc is substantial, as is reflected in both the high 
number of visits and the number of different disciplines involved in the care of patients. Patients’ 
rating of alignment of care was lower if more disciplines were involved in their care, leaving room 
for improvement through, for instance, appointing a case-manager in the management of SSc. 
Patients diagnosed with SSc have reported a high need for education and support in previous 
studies. To address these needs, a short, group-based psycho-educational programme for 
patients with SSc was developed and evaluated. Chapter 7 describes the content and pre-post 
assessment of this programme. Patients could be included in the programme if they had a 
diagnosis of SSc for more than one year. The programme consisted of the following broad topics: 
goal setting and evaluation (social worker), education about disease characteristics, diagnosis 
and treatment (rheumatologist), education about joint protection and energy conservation 
(occupational therapist), discussing psychosocial aspects of the disease (psychologist) and 
education about the benefits of exercise (physical therapist). Furthermore, an introduction 
lesson of Tai Chi was provided to give patients the opportunity to practice and experience this 
form of low intensity exercise. Participants (N = 41) completed questionnaires on physical and 
psychological functioning before, 6 weeks and 6 months after the intervention, and were asked 
to evaluate the content of the programme by questionnaire. Patients reported less helplessness 
after the intervention, and higher acceptance of their limitations. However, no difference in 
depressed mood and physical functioning was observed. Patients reported high satisfaction 
with the content of the programme. Thus, despite the limited changes in psychological and 
physical functioning, this psycho-educational programme addressed patients’ needs reported 
in previous studies. Therefore, we concluded that our psycho-educational programme 
contributes to the improvement of care for patients with SSc. 
Because of the limited changes found on depressive symptoms in the psycho-educational 
programme study, a more intensive, individually tailored intervention was developed 
for patients with SSc and depressive symptoms. Chapter 8, a case study is presented as 
an illustration of the development, components, and delivery of this intervention and a 
preliminary study into its effectiveness. An intervention protocol consisting of an intake and 
10 face-to-face sessions with a psychologist was developed based on cognitive-behavioural 
principles. Because of the complexity of symptoms and complaints due to systemic sclerosis, 
the psychological intervention was embedded in an interdisciplinary care program also 
consisting of physical therapy, occupational therapy, and specialized nurse care. A case study 
was conducted including a 53 years old female with a diagnosis of systemic sclerosis for 9 
years. Diary measures utilizing visual analogue scales for depression, fear of progression, 
fatigue and pain were completed twice a week and validated questionnaires on depression 
(CES-D), fear of progression (FoP-Q-SF) were completed pre- post and at follow-up. The 
diary measures showed no clear effect of the intervention. The post- and follow-up measures 
showed substantial changes decreases in depression and fear of progression. The secondary 
outcomes fatigue and helplessness showed the most remarkable changes. Our intervention 
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is an example and starting point for the treatment of depressive symptoms and fear of disease 
progression in systemic sclerosis and other progressive chronic somatic diseases. Elements of 
the presented intervention can be integrated in psychological care in medical health settings. 
The effectiveness of the intervention should be established in future studies.
In summary, in Part II, the assessment of health care use of Dutch patients with SSc 
revealed that, in general, multiple disciplines are involved in the care of patients, and that the 
number of visits to health care providers is substantial. Despite the involvement of multiple 
disciplines, patients have reported the need for more information in previous studies, and the 
development of evidence-based non-pharmacological interventions seem warranted. Therefore, 
a multidisciplinary psycho-educational intervention was developed and tested in a pre-post 
design. Results revealed that patients reported less helplessness after the intervention, and higher 
acceptance of their limitations. In addition, we developed an individually tailored intervention for 
an important subgroup of patients, namely patients with depressive symptoms and high fear of 
disease progression. This intervention was illustrated with a case study, and since only one patient 
was included and results are mixed, a conclusion for its effectiveness would be premature. 
MeThoDoLoGICaL IssUes
There are limitations related to the patient samples and the study designs that should be 
considered in interpreting the results of the studies described in this thesis. 
Part I: assessment
For the studies described in Chapters 2, 3, 4 and 5, all included patients were recruited from 
two hospitals in Nijmegen. The Rheumatology departments of the Sint Maartenskliniek and 
Radboud University Medical Center Nijmegen, the Netherlands, are both specialized in the 
treatment of SSc. This might have an influence on the generalizability of our results. Due to 
referral bias, patients in specialized hospitals might differ from patients under treatment of 
non-specialized hospitals for instance in terms of their medical treatment, the accessibility of 
care, or the severity of the disease. A recent study, in fact, has shown that significant differences 
in disease presentation of patients with SSc exist between centres, even between centres of 
close geographical proximity [1]. As yet, however, it remains unclear whether patients’ disease 
characteristics under treatment of specialized clinics for SSc differ from other hospitals, and 
how this might have influenced our results and the generalizability of our findings. 
Furthermore, in Chapter 2, a cross-sectional design was utilized. Although longitudinal data 
are currently being collected in our centres, the study in Chapter 2 only included the baseline 
data of this study. Therefore, the relationships assessed in this study could not be used to 
identify which factors predict the development of depressive symptoms over time. 
Part II: Treatment
In Chapter 6, only members of the patient organization (NVLE) were included. This sample 
might not be reflective of the whole patient population. Members of a patient organization 
potentially differ from non-members, for instance regarding their information- and treatment 
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seeking behaviour, acceptance of the disease or social network. Furthermore, the diagnosis of 
the included patients was self-reported and we were unable to verify this diagnosis. However, 
patients in our study were comparable with regard to demographic and disease characteristics 
to another large and well-described Dutch sample [2]. Thus, although it was a strength that 
patients from all regions in the Netherlands were included, the sample recruitment might limit 
the generalizability of our results.
Furthermore, health care utilization in Chapter 6 was assessed using retrospective questionnaires. 
Recall-bias potentially have influenced our results. According to the literature [3,4], self-reported 
physician visits in the last year were less precise than computerized provider records and biased due 
to underreporting. Underreporting is likely to increase as the number of visits increases. Thus, health 
care use in SSc might be somewhat higher than described in our study. To reduce recall-bias, the 
use of historical medical records, for instance collected by health insurance companies, might be an 
alternative. Also, collecting the data in a prospective design in which patients fill out diary measures 
on their health care visits might reduce the risk of recall bias [5]. 
In Chapter 7, the pre-post assessment of a psycho-educational treatment programme is 
presented. In total, 41 patients were included in the analysis. There was, however, no control 
group. As a consequence, the observed changes cannot be attributed to the intervention with 
absolute certainty. The lack of a control group makes it difficult to interpret and understand 
the observed changes. We recommend that in future intervention studies in patients with SSc, 
a control group should be included. 
A similar limitation relates to the individual intervention described in Chapter 8. This case 
study was presented as an illustration of the development, components, and delivery of this 
intervention and a preliminary study into its effectiveness. Since only 1 patient was included, 
the conclusions that can be drawn from this study are restricted and external validity is limited. 
Randomized single-case studies are often considered a valuable alternative to randomized 
controlled trials in rare diseases, in which a randomized controlled trials with adequate power is 
hard to conduct [6]. However, results obtained with these study designs should be interpreted 
with great caution, and the limitations of the design should be taken into account. 
IMPLICaTIons foR CLInICaL PRaCTICe
Part I: assessment
The high prevalence of depressive symptoms that we found in our study described in Chapter 2, 
and the finding that the associated factors were mainly in the psychological domain, implies 
that in clinical practice attention should be given also to the psychosocial consequences of 
the disease. There is mixed evidence whether physical functioning and disease characteristics 
are associated with psychological well-being, suggesting that it might not be possible to 
identify patients at risk of psychosocial complaints based solely on their physical health status. 
Therefore, it might seem useful to screen patients on psychological well-being, for instance 
through the use of validated questionnaires. However, to date the additional value of routine 
screening has not been assessed in patients with SSc, nor has it been proven in other patient 
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populations [7,8]. Screening of depressive symptoms is only useful to the degree that it leads 
to improved outcomes above and beyond existing care. There is currently no direct evidence 
that screening for depression and subsequent treatment leads to improved outcomes in 
patients with SSc. Thus, recommendations for depression screening among patients with SSc 
at this point would be premature. Taking into account the current evidence, we would suggest 
that, instead of routinely asking patients to fill out a depression questionnaire, health care 
providers should pay attention to psychosocial well-being in the standard medical anamnesis, if 
appropriate given the purpose of the visit [9]. Health care providers should be alert to possible 
depression and refer patients to a specialized nurse, social worker or psychologist for further 
assessment and interventions when psychosocial complaints are present.
Part II: Treatment
According to the results of the study described in Chapter 6, patients with SSc utilized health 
care substantially, and multiple disciplines were involved in the care of patients. In general, 
patients were satisfied with the care they had received. However, patients with more disciplines 
involved in their care were less satisfied with the alignment of their care. This implies that, in 
particular for those patients with a more complex disease, attention should be given also to the 
alignment of care provided by the different disciplines. A large number of health care providers 
involved could result in overlap of treatment or contradictory advices, leading to inadequate 
care and a higher disease burden for the patient [10,11]. To optimize alignment of care it might 
be useful to appoint a case manager such as a nurse specialist, to coordinate the care in patients 
with SSc who experience problems with the alignment of their treatments. 
The pre-post assessment of the psycho-educational programme as described in 
Chapter 7, showed significant improvements in the level of helplessness and more acceptance 
of limitations. Furthermore, participants were very satisfied with the programme that was 
initially designed to address patients’ needs regarding information about the disease and its 
treatment options. According to the results of the study, the programme contributes to the 
improvement of care for patients with SSc. On the other hand, the programme as presented 
was quite intense and alternative, less intensive forms might also be suitable to address these 
patients’ needs. Especially for information provision, internet-based programmes are very 
well suited [12]. Taking into account these considerations, we would suggest that health care 
providers, in cooperation with patient organizations if possible, ensure that patients have 
access to reliable information regarding their disease and its treatment options, for instance 
through the use of the internet or information flyers. Furthermore, we would suggest that 
patients are made aware of available non-pharmacological interventions that might contribute 
to the acceptance of their limitations and enhance self-management skills. 
MovInG foRwaRD: fUTURe DIReCTIons
This thesis aimed to contribute to the gap of knowledge on psychological well-being in SSc. 
Although efforts to improve psychological well-being in SSc are increasingly being made, as yet 
there is still room to move forward in this area, both in research and clinical practice.
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Part I: assessment
Various studies have examined the relationship of demographic, disease, and psychosocial 
factors with depressive symptoms using cross-sectional designs. Results of these studies have 
provided us with insight into the interrelationships of these factors, and potential targets that 
should receive attention from clinicians. However, large-sample longitudinal studies are needed 
to be able to examine how patients cope with disease-related stressors and which patients are 
potentially at higher risk for developing psychosocial complaints. Evidence in other chronic 
diseases showed, that there is considerable variability in adjustment to a chronic illness [13]. Since 
SSc is a progressive disease with serious consequences in most patients, quality of life might also 
decrease as the disease progresses. On the other hand, one could argue that patients might find 
ways to cope with their disease and learn to adapt. Cohort studies are needed to assess disease 
progression concurrent with depressive symptoms to clarify the trajectory of depression in SSc 
and the interface between mood and disease progression. If more insight is obtained into the 
course of quality life and its determinants, patients at risk for psychological problems could be 
identified in an early stage and (preventive) interventions could be provided to them. 
So far, studies in patients with SSc have used HR-PRO measures to asses depressive symptoms. 
Patients that score above a certain cut-off threshold are usually considered to have a possible 
or probable clinical depression. However, it is yet unknown how many patients suffer from a 
clinical depressive disorder. Studies that use “gold standard” structured clinical interviews are 
needed to understand the percentage of patients currently suffering from a clinical depression 
[14]. These patients might require a more intensive psychological intervention than patients 
with subclinical levels of depression, possibly in combination with anti-depressant drugs. 
In Chapters 2, 3 and 8 of this thesis, we focused on fear of disease progression in patients 
with SSc. We translated and validated the Fear of Progression Questionnaire- Short Form 
(Chapter 3) and used it to examine the association with depressive symptoms, which was 
found to be high (Chapter 2). Taking the results of these studies into account, we developed 
an individually tailored intervention for patients with depressive symptoms and high fear of 
progression (Chapter 8). The FoP-Q-SF provides a good basic to build up knowledge regarding 
fear of progression in SSc, for instance in the comparison of the levels of fear of progression 
with other patient populations. Possibly, however, the FoP-Q-SF does not capture all aspects of 
fear of progression relevant to patients with SSc. For instance, the FoP-Q-SF does not include 
questions on specific consequences of SSc, such as internal organ involvement. We believe that 
in future studies, the experience of fear of disease progression in patients should be studied in 
more depth, using qualitative research designs. This will provide us with more insight into the 
experience of fear of progression of patients with SSc, and whether these are captured by the 
generic questionnaire we validated in Chapter 3. Possibly, an additional questionnaire should 
be developed to capture disease-specific aspects of fear of progression.
Part II: Treatment
Not all potential stressors of patients with SSc were taken into account in the presented studies. For 
instance, sexual dysfunction, pruritis, and accessing health care are reported as important stressors 
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for patients [15]. In addition, patients have reported concerns about their appearance as an important 
stressor, related to changes in the appearance of face and hands. Also, the majority of the patients 
across countries [16,17] have reported fatigue as their most frequently experienced symptom, that 
has an impact on daily life in almost all patients. In other studies [18,19], impaired hand function was 
found to be the most important determinant of limitations in physical functioning. However, as of 
now, research into these domains are scarce, and there are little or no tested interventions targeting 
these stressors in SSc. Development and testing of these interventions might further improve health 
care for patients with SSc, and are therefore warranted.
Finally, when conducting the two intervention studies (Chapter 7 and 8) we experienced that 
for some patients, physical limitations and fatigue were preventing them from participating in 
the interventions. Even in a relative small country as the Netherlands, about half of the patients 
in our cohort study had a travelling time to the hospital of more than one hour (unpublished 
observations). In more widespread countries such as Canada or Australia, patients might have 
even more problems accessing specialized care. Therefore, in order to improve the accessibility 
of care in the Netherlands and across other countries, the development of internet- or 
phone-based therapies might be a valuable alternative to face-to-face therapies. In fact, an 
international project to develop and test these kinds of interventions was recently initiated and 
funded for the upcoming 5 years (2012-2017) [20]. Other initiatives to improve the accessibility 
of health care of patients, include the stimulation of knowledge transfer between health care 
providers, through uniting them in (international) networks [21,22]. Increased knowledge 
transfer between health care providers probably leads to expanded accessibility to specialized 
health care closer to the patients’ living area. 
In summary, the studies described in this thesis contributed to the gap of knowledge regarding 
psychological well-being in patients with SSc. In the upcoming years, preferably collaborative 
initiatives should be established to further optimize the assessment and treatment in this area. 
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saMenvaTTInG  
(DUTCh sUMMaRy)

InLeIDInG
Systemische sclerose (SSc) oftewel sclerodermie, is een zeldzame, chronische aandoening van 
het bindweefsel. De naam sclerodermie is afgeleid van de Griekse woorden skleros (hard) en 
derma (huid), en reflecteert het meest kenmerkende symptoom van de ziekte; fibrose van 
de huid door een overmatige productie en afzet van bindweefsel, voornamelijk collageen, 
waardoor verharding en verstrakking van de huid ontstaat. Naast de huid, kan ook het 
bindweefsel van inwendige organen toenemen, wat kan leiden tot verminderde functie van 
de longen, hart, nieren en maag-darm stelsel. Het fenomeen van Raynaud komt bij 95% van 
de patiënten voor, en kan leiden tot weefselschade in de vingers en tenen, met zweren als 
gevolg van de verminderde doorbloeding. Systemische sclerose wordt onderscheiden in 2 
klinische subtypes: gelimiteerde SSc waarbij de huidaantasting beperkt is tot de onderarmen 
en – benen, en diffuse SSc, waarbij ook de bovenarmen en – benen en de romp is aangedaan.
Met een geschatte prevalentie van 8.9 patiënten per 100.000 volwassenen in Nederland en 
een geschatte incidentie van 0.77 patiënten per 100.000 komt SSc minder voor dan de meeste 
andere reumatische aandoeningen. In totaal leven in Nederland naar schatting ongeveer 1200 
patiënten met SSc. Vrouwen krijgen 4-5 maal vaker SSc dan mannen, en de ziekte ontstaat 
meestal tussen het 30e en 50e levensjaar. Hoewel de gevolgen van SSc erg variëren tussen 
patiënten, is de levensverwachting over het algemeen verkort, met een mediaan van 11 jaar 
vanaf het stellen van de diagnose. Met name de betrokkenheid van inwendige organen, in het 
bijzonder het hart en de longen, is voorspellend voor een kortere levensverwachting. 
Systemische sclerose leidt vaak tot beperkingen in het fysieke functioneren, vermoeidheid 
en pijn. Met name patiënten met beperkingen in de handfunctie ervaren veel problemen met 
dagelijkse bezigheden, zoals het huishouden, persoonlijke verzorging en werk. Naast deze 
beperkingen in het fysieke functioneren, ervaren patiënten ook psychologische problemen. 
Een systematisch literatuuronderzoek liet zien, dat depressieve klachten bij 36-65% van de 
patiënten voorkomen. Daarnaast veroorzaken veranderingen in het uiterlijk in de sociaal 
belangrijke lichaamsdelen (het gezicht en de handen) ontevredenheid over het uiterlijk bij 
veel patiënten. Een diagnose van SSc kan ook leiden tot onzekerheid over de toekomst en 
angst voor ziekteprogressie. Deze angst kan functioneel zijn in de zin dat het patiënten helpt 
voor zichzelf te zorgen, bijvoorbeeld door medicatie te gebruiken of te stoppen met roken. Als 
deze angst echter te groot wordt, kan er sprake zijn van disfunctionele angst voor progressie, 
wat tot uiting kan komen in bijvoorbeeld overmatig piekeren, slapeloosheid en het vermijden 
van sociale contacten. Disfunctionele angst voor progressie beïnvloedt de kwaliteit van leven 
waardoor psychologische begeleiding geïndiceerd kan zijn. 
Momenteel is SSc niet te genezen, en behandeling is met name gericht op het beperken van 
de symptomen van de ziekte. Het verbeteren van de kwaliteit van leven is daarom een belangrijk 
behandeldoel bij SSc, waarbij niet-medicamenteuze behandelingen zoals psychologische 
interventies een rol kunnen spelen. Onderzoek is echter nodig om inzicht te krijgen in 
psychologische gevolgen van SSc, zoals het omgaan met een veranderd uiterlijk en angst voor 
ziekteprogressie. Om patiëntgerichte zorg te verbeteren, is het daarnaast van groot belang dat 
er accurate meetinstrumenten bestaan om uitkomsten van belang voor patiënten te meten. 
SAMENVATTING (DUTCH SUMMARY)
139
 De studies in dit proefschrift richtten zich op het psychologische welbevinden van patiënten 
met SSc en zijn uitgevoerd met de volgende overkoepelende doelen: 1) het onderzoeken 
van de meeteigenschappen van patiëntgerapporteerde uitkomstmaten (patient-reported 
outcome measures, PROs) bij patiënten met SSc (Deel I); 2) het ontwikkelen en testen van niet-
medicamenteuze behandelingen voor patiënten met SSc (Deel II). 
saMenvaTTInG
Deel 1: Meten
In deel 1 werd allereerst de prevalentie van depressieve klachten en factoren welke daarmee 
samenhangen onderzocht. Vervolgens werd ingegaan op verschillende klinimetrische 
eigenschappen van instrumenten om angst voor progressie, depressieve klachten en kwaliteit 
van leven te meten. 
De gegevens die gebruikt zijn voor de studies in deel 1, zijn ontleend aan de baseline meting 
van een longitudinale cohort studie waaraan 215 patiënten deelnamen. Deze patiënten waren 
door een reumatoloog gediagnosticeerd met SSc volgens de preliminaire classificatie criteria 
opgesteld door de American College of Rheumatology in 1980 en waren allen onder behandeling 
in de Sint Maartenskliniek Nijmegen of het Universitair Medisch Centrum St Radboud Nijmegen, 
Nederland. Voor de cohortstudie vulden deelnemers gedurende 3 jaar iedere 6 maanden een 
set vragenlijsten in, welke bestond uit vragen over het fysieke en psychologische functioneren. 
Daarnaast werd bij inclusie een aantal ziekte kenmerken geregistreerd door de reumatoloog, 
zoals bijvoorbeeld de mate van huidbetrokkenheid (modified Rodnan Skin Score, mRSS). Exclusie 
criteria voor deelname aan de cohort studie waren een te verwachten levensverwachting van 
minder dan een jaar (vanwege de belasting van de studie), acute ernstige complicaties (bijv. 
acuut nierfalen), ernstige psychiatrische comorbiditeit (bijv. psychose of dementie), overige 
ernstige comorbiditeiten (bijv. kanker) en onvoldoende kennis van de Nederlandse taal. Op 
basis van klinische ervaring bepaalde de behandelend reumatoloog of er sprake was van één 
of meerdere exclusiecriteria met behulp van een checklist. De data van de baseline meting zijn 
verzameld in de periode juni 2008 tot februari 2010.
In hoofdstuk 2 werd het voorkomen van depressieve klachten onderzocht en de associatie 
van depressieve klachten met demografische, ziektegerelateerde en psychosociale factoren. 
Van de patiënten in onze studie scoorde een derde boven het afkappunt voor een mogelijke 
depressieve stoornis, en 25% scoorde boven het afkappunt voor een waarschijnlijke depressieve 
stoornis. Deze percentages komen overeen met eerder gerapporteerde prevalenties bij 
patiënten met SSc. In deze studie werd voorts gevonden dat factoren die geassocieerd waren 
met depressieve klachten, naast meer pijn en vermoeidheid, met name in het psychosociale 
domein lagen. Minder tevredenheid met sociale steun, meer emotiegerichte coping en 
hulpeloosheid waren onafhankelijk van elkaar geassocieerd met meer depressieve klachten. 
Daarnaast had een lagere waardering van het uiterlijk een marginaal significante associatie 
met meer depressieve klachten. Na vermoeidheid, bleek een grotere angst voor progressie de 
sterkste associatie te hebben met depressieve klachten. Deze resultaten impliceren dat naast de 
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medische gevolgen van SSc, ook aandacht gegeven moet worden aan psychosociale factoren 
welke geassocieerd zijn met depressieve klachten. Daarnaast kan angst voor progressie een 
belangrijk speerpunt zijn in de ontwikkeling en evaluatie van psychologische interventies.
In de studie in hoofdstuk 3 werd de Nederlandse versie van de Fear of Progression 
Questionnaire-Short Form (FoP-Q-SF) gevalideerd. De originele FoP-Q-SF is ontwikkeld in 
Duitsland om angst voor progressie van ziekte te meten bij patiënten met diabetes, borstkanker 
en reumatoïde artritis. Op basis van de Consensus-based Standards for the selection of health 
status Measurement Instruments (COSMIN) checklist, hebben we vloer- en plafondeffecten, 
interne consistentie en factorstructuur onderzocht. Daarnaast werd de constructvaliditeit 
onderzocht door het toetsen van 12 a priori opgestelde hypotheses over correlaties van de 
FoP-Q-SF scores met andere vragenlijsten die fysieke of psychologische concepten meten. 
Er werden geen vloer- en plafondeffecten gevonden en de originele 1-factor structuur werd 
bevestigd in onze patiëntengroep. Cronbach’s alfa was voldoende groot. Omdat het merendeel 
van onze hypotheses (>75%) werd bevestigd, was er bewijs voor de constructvaliditeit van de 
FoP-Q-SF. Zoals verwacht werden hoge correlaties gevonden tussen de FoP-Q-SF scores en 
mate van angst, depressieve symptomen en mentaal welbevinden. Kleine tot middelgrote 
correlaties werden gevonden met fysiek functioneren en pijn. De resultaten van deze studie 
tonen aan, dat de FoP-Q-SF een bruikbaar en valide instrument is om angst voor progressie 
te meten in patiënten met SSc. In eerdere studies is aangetoond dat angst voor progressie 
een belangrijke stressor is voor patiënten met SSc. Een valide meetinstrument voor angst voor 
progressie is een voorwaarde voor het opbouwen van meer kennis over deze stressor. De 
FoP-Q-SF zou bijvoorbeeld gebruikt kunnen worden als een uitkomstmaat in interventiestudies 
die zich richten op angst voor progressie. 
Vanwege het zeldzame karakter van SSc is voor initiatieven ter verbetering van de zorg vaak 
(internationale) samenwerking nodig. Dit betekent, dat data afkomstig uit verschillende landen 
en in verschillende talen samengevoegd worden. De crosslinguïstische of crossculturele meet-
equivalentie van deze uitkomstmaten is echter meestal niet onderzocht. Meet-equivalentie 
betekent, dat individuen van verschillende groepen met hetzelfde niveau van een uitkomstmaat 
(bijv. vermoeidheid), ook gelijke scores behalen op de vragenlijst. In hoofdstuk 4 werd een studie 
beschreven waarin de meet-equivalentie van de Center for Epidemiologic Studies Depression 
(CES-D) onderzocht werd tussen Engelstalige Canadese patiënten (N=922) en Nederlandse 
patiënten (N=213) met SSc. Hiervoor werd het Multiple-Indicator Multiple-Cause (MIMIC) model 
gebruikt. Voor 4 van de 20 items van de CES-D werden kleine verschillen tussen de groepen 
gevonden. De Engelstalige Canadese patiënten scoorden hoger op gevoelsgerelateerde 
items (item 3, “blues” en item 4, “good”) terwijl de Nederlandse patienten meer somatische 
symptomen rapporteerden (item 7, “effort” en item 20 “get going”). Het gevonden verschil 
kan veroorzaakt worden door culturele verschillen in de manier waarop symptomen worden 
ervaren of geuit, of door verschillen tussen de items vanwege de vertaling van de vragenlijst. 
Hoewel er enkele items van de CES-D verschilden tussen de Engelstalige Canadese patiënten 
en de Nederlandse patiënten met SSc, was er geen bewijs dat dit de totaalscores van de CES-D 
substantieel beïnvloedde. Daarom kunnen de CES-D scores van Engelstalige Canadese patiënten 
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en Nederlandse patiënten met SSc in het vervolg vergeleken en samengevoegd worden, zonder 
dat ongelijkheid in de meetinstrumenten substantiële invloed heeft op de resultaten. 
Naast meetinstrumenten die een relatief nauw construct reflecteren, zoals angst voor 
progressie of depressieve klachten, zijn er ook meetinstrumenten die meer complexe 
constructen reflecteren, zoals gezondheidsgerelateerde kwaliteit van leven. De utiliteitsmaten 
EQ-5D en SF-6D bijvoorbeeld, zijn ontworpen om de waarde van het leven samen te 
vatten in een score met een range van 0 (equivalent aan de dood) tot 1 (perfect gezond). 
Utiliteitsmaten omvatten verschillende domeinen van kwaliteit van leven die door (chronische) 
aandoeningen beïnvloed kunnen worden, zoals pijn, fysieke beperkingen en mentale 
gezondheid. Utiliteitsmaten worden in toenemende mate gebruikt bij economische evaluaties 
en beleidsvorming. Hoewel de EQ-5D en SF-6D vaak gebruikte en algemeen geaccepteerde 
maten van utiliteit zijn, is de uitwisselbaarheid van de twee maten in het algemeen laag. Dit 
vermindert de vergelijkbaarheid van (kosten-) effectiviteitstudie welke zijn uitgevoerd zijn met 
deze instrumenten. Dit kan leiden tot verschillende beslissingen op het gebied van toewijzing 
van (financiële) middelen en beleidsbepaling. In hoofdstuk 5 werd daarom de overeenkomst 
tussen de EQ-5D en SF-6D onderzocht bij patiënten met SSc. Daarnaast werden de minimal 
important differences (MIDs), effect sizes (ES) en standardized response means (SRM) geschat 
en vergeleken tussen de twee maten, evenals de constructvaliditeit. Hiervoor werden naast 
de baseline meting van de cohort studie (N=211) ook de resultaten van de 1-jaars follow-up 
gebruikt (N=154). De middelgrote overeenstemming tussen de EQ-5D en SF-6D die we in onze 
studie vonden, in het bijzonder voor lagere scores (ongeveer 10% van de patiënten), impliceert 
dat voorzichtigheid geboden is wanneer resultaten die met de EQ-5D en SF-6D gevonden zijn 
geïnterpreteerd of vergeleken worden. Verder werd gevonden dat de responsiviteit (SRM en 
ES) van de SF-6D groter was dan de EQ-5D, met name voor de verbeterde subgroepen. Omdat 
verbeteringen in gezondheid bij SSc over het algemeen klein zijn, impliceren deze resultaten 
dat de SF-6D aanbevolen wordt over de EQ-5D om uitkomsten van behandeling te meten.
Concluderend toonden de studies in deel I aan, dat factoren welke samenhingen met 
depressieve klachten, naast pijn en vermoeidheid, vooral in het psychosociale domein lagen, 
waaronder angst voor progressie. Een instrument om angst voor progressie te meten, de 
Nederlandse FoP-Q-SF bleek valide en bruikbaar te zijn voor patiënten met SSc, en helpt zo 
meer kennis op te bouwen over deze stressor. Een ander instrument dat vaak wordt gebruikt 
in onderzoek bij patiënten met SSc is de CES-D, een vragenlijst die depressieve symptomen 
meet. De resultaten van onze studie waarin onderzocht werd of de CES-D scores beïnvloed 
werden door vertalingen of culturele verschillen tussen Engelstalige Canadese en Nederlands 
patiënten met SSc lieten zien, dat de CES-D totaal score hierdoor niet substantieel beïnvloed 
werd. Dus, de CES-D scores van Engelstalige Canadese patiënten en Nederlandse patiënten 
met SSc kunnen in het vervolg vergeleken en samengevoegd worden, zonder dat ongelijkheid 
in de meetinstrumenten invloed heeft op de resultaten. Tenslotte vergeleken we twee vaak 
gebruikte en geaccepteerde utiliteitsmaten, de EQ-5D en SF-6D. Deze studie liet zien, dat de 
SF-6D een grotere responsiviteit heeft dan de EQ-5D, waardoor deze aanbevolen wordt als 
uitkomstmaat voor het evalueren van de effectiviteit van behandelingen.
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Deel II: behandeling 
De studies in deel II van deze thesis richtten zich op de behandeling van patiënten met SSc. Systemische 
sclerose is een complexe ziekte, met veel verschillende consequenties voor patiënten, waarvoor 
vaak multidisciplinaire behandeling nodig is. Naast diverse medische specialisten zijn ook vaak 
health professionals (HPs) zoals een fysiotherapeut, ergotherapeut of verpleegkundige betrokken 
bij de zorg. Echter, de kennis over zorggebruik van patiënten is schaars en was nog niet uitgebreid in 
kaart gebracht in Europese landen. Daarnaast is in diverse studies gevonden, dat patiënten behoefte 
hebben aan informatie over hun ziekte en de behandelmogelijkheden. Daarom is de ontwikkeling en 
evaluatie van interventies die ingaan op deze behoeften genoodzaakt. 
In hoofdstuk 6 werd de mate van zorggebruik en de kwaliteit van deze zorg vanuit het 
patiëntenperspectief onderzocht. Leden met SSc van de Nationale Vereniging voor lupus, 
APS, sclerodermie en MCTD (NVLE) werd gevraagd een anonieme vragenlijst in te vullen over 
zorggebruik, kwaliteit van zorg en kwaliteit van leven. Aan deze cross-sectionele studie namen 
198 patiënten met SSc deel, waarvan 95% aangaf tenminste één medisch specialist bezocht 
te hebben in het afgelopen jaar, en tweederde tenminste één health professional (HP). De 
mediaan van het aantal verschillende disciplines waarmee patiënten contact hadden gehad 
was 8 sinds de diagnose SSc, en 4 in het laatste jaar. De mediaan van het aantal bezoeken aan 
medisch specialisten gedurende de afgelopen 12 maanden was 7, en 7.5 voor HPs. Patiënten met 
een partner of een slechtere fysieke gezondheid, bezochten vaker een zorgverlener. Opvallend 
was, dat patiënten die minder vermoeidheid rapporteerden, meer verschillende disciplines 
bezochten, evenals patiënten met meer pijn. Een groter aantal disciplines betrokken bij de zorg, 
was geassocieerd met een lagere tevredenheid met samenwerking en afstemming van zorg. 
De resultaten van deze studie toonden aan, dat zorggebruik van Nederlandse patiënten met 
SSc substantieel is. Dit blijkt zowel uit het aantal disciplines als het aantal bezoeken. Patiënten 
beoordelen de afstemming van de zorg lager als er meer disciplines betrokken zijn. Hier ligt 
mogelijk ruimte voor verbetering, bijvoorbeeld door het toewijzen van een case manager die 
helpt de zorg van disciplines op elkaar af te stemmen.
Ondanks de verschillende disciplines die betrokken zijn bij de zorg voor patiënten met SSc 
rapporteerden patiënten in eerdere studies behoefte te hebben aan informatie en begeleiding 
ten aanzien van hun ziekte en behandeling. Om aan deze behoefte te voldoen, werd een korte 
psycho-educatieve groepsinterventie ontwikkeld en geëvalueerd, zoals in hoofdstuk 7 werd 
beschreven. Patiënten konden deelnemen aan de interventie als ze meer dan een jaar geleden 
gediagnosticeerd waren met SSc. De interventie bestond uit de volgende onderwerpen: 
doelstelling en evaluatie (maatschappelijk werkende), informatie over ziektekenmerken, 
diagnosestelling en behandeling (reumatoloog), informatie over gewrichtsbescherming en 
energieverdeling (ergotherapeut), psychologische aspecten van de ziekte (psycholoog), 
en educatie over fysieke activiteit (fysiotherapeut). Daarnaast werd er een introductieles 
gegeven in Tai Chi, om patiënten kennis te laten maken met deze vorm van laag intensieve 
training. In totaal vulden 41 deelnemers voorafgaand, 6 weken en 6 maanden na de interventie 
vragenlijsten in over hun fysieke en psychologische functioneren. Daarnaast werd hen gevraagd 
een evaluatieformulier in te vullen over de inhoud van de behandeling. Na de interventie 
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rapporteerden de deelnemers minder hulpeloosheid en een grotere acceptatie van hun 
beperkingen. Er werd geen significant verschil gevonden in de mate van depressieve klachten en 
fysiek functioneren. De deelnemers gaven voorts aan erg tevreden te zijn met de inhoud van het 
programma. Dus, ondanks de beperkte veranderingen in fysiek en psychologisch functioneren, 
kwam deze behandeling tegemoet aan de behoefte van patiënten zoals gerapporteerd in 
eerdere studies, en draagt daarmee bij aan het verbeteren van de zorg voor patiënten met SSc.
Omdat er geen veranderingen in depressieve klachten werd gevonden bij de psycho-
educatie groepsinterventie, werd een intensievere, individueel op maatgemaakte behandeling 
ontwikkeld voor een subgroep van patiënten met SSc en depressieve klachten. In hoofdstuk 8 
werd aan de hand van een case studie de ontwikkeling en inhoud van het interventieprotocol 
beschreven. Daarnaast werd een eerste aanzet gedaan tot het evalueren van de effectiviteit 
van deze interventie. De interventie bestond, naast een intake, uit 10 sessies met een 
psycholoog. Vanwege de complexiteit van de symptomen van patiënten met SSc, was deze 
psychologische behandeling ingebed in een interdisciplinaire behandeling, die verder bestond 
uit fysiotherapy, ergotherapie en verpleegkundige zorg. Een case studie werd uitgevoerd bij 
een patiënte van 53 jaar, die sinds 9 jaar gediagnosticeerd was met SSc. Om de effectiviteit te 
onderzoeken werden een tweemaal per week visual analogue scales (VAS) werden ingevuld om 
depressie, angst voor progressie, vermoeidheid en pijn te meten. Daarnaast werd voorafgaand, 
na afloop en 6 maanden na afloop van de behandeling vragenlijsten ingevuld. Met behulp van 
de VAS werd geen duidelijk effect van de behandeling aangetoond. De vragenlijsten lieten 
wel een substantiële verbetering zien in depressieve klachten en angst voor porgressie. De 
grootste daling in scores werd gevonden op de secundaire uitkomstmaten hulpeloosheid en 
vermoeidheid. De interventie is een voorbeeld en mogelijk startpunt voor de behandeling van 
depressieve klachten en angst voor progressie bij patiënten met SSc en andere progressieve 
chronische aandoeningen. Elementen van de behandeling kunnen geïntegreerd worden in 
de psychologische behandeling van patiënten met chronisch-somatische aandoeningen. De 
effectiviteit van de interventie dient verder onderzocht te worden in toekomstige studies. 
Samenvattend kan worden gesteld dat in deel II aangetoond is dat over het algemeen 
verschillende disciplines betrokken zijn bij de zorg van patiënten met SSc en dat ook het 
aantal bezoeken aan medisch specialisten en HPs aanzienlijk is. Ondanks deze betrokkenheid 
van verschillende disciplines laten eerdere studies zien, dat patiënten behoefte hebben aan 
meer informatie en begeleiding omtrent hun ziekte en behandelmogelijkheden, en blijkt de 
ontwikkeling en evaluatie van niet-medicamenteuze interventies wenselijk. Om aan deze 
behoefte te voldoen, is een multidisciplinair psycho-educatie programma ontwikkeld en 
geëvalueerd in een design met voor- en nameting. De resultaten toonden aan, dat deelnemers 
minder hulpeloosheid rapporteerden en meer acceptatie van de beperkingen na afloop van 
de interventie. Naast deze psycho-educatieve interventie, hebben we een individueel op maat 
gemaakte interventie ontwikkeld voor een subgroep van patiënten, namelijk patiënten met 
depressieve klachten en een hoge angst voor progressie. Deze interventie is geïllustreerd aan 
de hand van een case studie. Omdat slechts één patiënt werd geïncludeerd kunnen nog geen 
uitspraken gedaan worden over effectiviteit van de behandeling. 
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Met de studies in deze thesis is een bijdrage geleverd aan de geringe kennis die bestond 
over het psychologische welbevinden van patiënten met SSc. In de komende jaren zal, bij 
voorkeur door middel van (internationale) samenwerkingsverbanden, dit gebied verder 
ontwikkeld worden om de zorg voor patiënten met SSc te optimaliseren.
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“Moving forward”, daar hebben veel mensen aan bijgedragen die ik graag wil bedanken. Op de 
eerste plaats alle patiënten met systemische sclerose (sclerodermie) die hebben meegewerkt 
aan de verschillende studies. Zonder jullie openheid en doorzettingsvermogen was dit 
proefschrift er niet geweest. In het bijzonder wil ik de NVLE bedanken voor de betrokkenheid 
bij de verschillende projecten, met name Marja, Joep, Jessica, Wendy†, en de Commissie 
sclerodermie/MCTD. Jullie open en kritische houding heb ik steeds erg gewaardeerd en ik 
hoop dat we in de toekomst samen verder kunnen bouwen aan onderzoek en interventies om 
de zorg voor mensen met sclerodermie te verbeteren.
Dr. van Lankveld, Wim, je was een van de eersten die het belang inzag van psychosociaal 
onderzoek en interventies voor patiënten met systemische sclerose, en hebt na gedegen voorwerk 
ervoor gezorgd dat ik mijn promotietraject kon starten. Ik weet dat je dit onderzoek altijd een 
warm hart hebt toegedragen, en wil je bedanken voor je vertrouwen en onze samenwerking.
Prof. dr. Becker, my promotor and mentor. Eni, it was your passion for psychological 
research that inspired me to start a career in research in 2005. I am grateful for the opportunities 
that you have given me, and your mentoring and supervision throughout the years. Your clear 
thinking, knowledge and experience have shaped me as a researcher, and I hope that we will 
continue to work together.
Mijn co-promotoren Dr. CHM van den Ende en Dr. FHJ van den Hoogen. Els, als dagelijks 
begeleider en hoofd van het onderzoeksbureau heb ook jij velen uren besteed aan de totstandkoming 
van dit proefschrift. Dank voor je onaflatende toewijding en advies, en ook voor je persoonlijke 
betrokkenheid en steun tijdens mijn herstel en werkhervatting. Ik ben blij dat er nog veel lopende 
projecten zijn, waarin we elkaar regelmatig tegenkomen! Frank, je passie om de zorg voor patiënten 
met systemische sclerose te verbeteren is aanstekelijk en inspirerend. Dank voor alle kansen die je 
me, als co-promotor en directeur van het Reumacentrum, hebt gegeven. Naast inhoudelijk advies, 
kon ik ook altijd rekenen op je bemoedigende woorden; “Keep on smiling!”
Dr. M Jeurissen en Dr. MC Vonk, dank voor jullie actieve bijdrage aan de werving van patiënten 
en de artikelen in mijn proefschrift. Maurice en Madelon, ik waardeer het dat jullie het belang van 
psychosociaal onderzoek inzien en hieraan jullie medewerking hebben gegeven. Hetzelfde geldt 
voor de vele co-auteurs met wie ik heb mogen samenwerken, en die met hun inbreng en kritische 
feedback de studies in dit proefschrift hebben verbeterd, en de manuscriptcommissie. 
Met mijn directe collega’s heb ik de afgelopen jaren meer tijd doorgebracht dan met vele 
anderen. Joke, Agnes, Thomas, Hanneke, Linda W, Aniek, Sara en Nienke, bedankt voor alle 
gezellige lunches, nuttige bijeenkomsten en andere binnenloopmomenten. Dicky, dank voor 
al je hulp en praktische ondersteuning. Aatke, Gijs, Karen, Karin, Elien, Noortje, Victor, Bart, 
Alfons, Ester, en alle onderzoekers van Research wil ik bedanken voor hun betrokkenheid en 
input door de jaren heen. Het management team van de afdeling Reumatologie van de Sint 
Maartenskliniek wil ik bedanken dat ze het onderzoek en alles wat daarbij komt kijken mogelijk 
heeft maakt. Mirelle, jij hoort ook in bovenstaand rijtje thuis, maar eigenlijk beschouw ik je nog 
meer als een goede vriendin. Je begrijpt als geen ander dat een promotietraject hoogte- en 
dieptepunten kan hebben, en hebt daarbij aan een half woord genoeg. Maar ook naast het 
werk stond je steeds voor me klaar met een luisterend oor, allerlei praktikaliteiten, of gewoon 
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voor de gezelligheid. Onze “buitenmomentjes” waren heel erg waardevol, en ik mis het nu 
we niet meer samen werken. Ik ben blij dat je mijn paranimf bent.
Andere collega’s die ik bij naam wil noemen zijn Toon, Hanneke en Helma. Een kruisbestuiving 
tussen de klinische praktijk en onderzoek is nodig, maar met jullie te werken was daarnaast 
ook ontzettend fijn en leerzaam. Hetzelfde geldt voor alle andere betrokken collega’s van het 
Ambulant Reumacentrum, en de reumaconsulenten. De verschillende disciplines hebben me met 
enthousiasme laten zien wat hun vak inhoudt en hoe dit kan bijdragen aan de zorg voor patiënten 
met een chronische ziekte. Dank voor het verbreden van mijn kennis en jullie inzet bij de projecten. 
I have had the pleasure of working with many people throughout the years, including the 
Department of Clinical Psychology of the Radboud University Nijmegen. Although my office was at a 
physical distance most of the time, I have always felt part of your group. Thank you for all your input 
and the fun we have had at writing weeks, my workdays at the uni, and on many other occasions.
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